- Published One-Month Case Study and the Brahma Rasayana Avaleha Pathway
- Meningioma Ayurvedic Treatment Without Surgery
- How Common Is Meningioma in the USA, UK, Canada, and Australia?
- Can Meningioma Ayurvedic Treatment Be Curative?
- Meningioma Ayurvedic Treatment at the Root
- Meningioma Ayurvedic Treatment With Brahma Rasayana
- Brahma Rasayana Avaleha (Main Medicine)
- Why Market Avaleha May Fail in Meningioma Treatment
- Measuring Meningioma Treatment Response
- Meningioma Ayurvedic Treatment by Tumour Location
- Meningioma Ayurvedic Treatment: Causes
- Clinical Features(Symptoms)
- Other Common and Rare Disorders Associated With Meningioma
- Meningioma Ayurvedic Treatment by Grade
- How Fast Does Meningioma Grow?
- Diagnostic Evaluation
- Latest Meningioma Ayurvedic Treatment Research
- Modern Treatment Side Effects
- Diet for Meningioma Ayurvedic Treatment
- Meningioma Ayurvedic Treatment Duration
- Modern Management vs Ayurvedic Root-Cause Approach
- Who Is the Ideal Candidate for Ayurvedic Treatment?
- Online Meningioma Ayurvedic Treatment
- Frequently Asked Questions (FAQs)
- Start Meningioma Ayurvedic Treatment
- References
Published One-Month Case Study and the Brahma Rasayana Avaleha Pathway
Meningioma Ayurvedic treatment can be planned with curative intent when the objective is to achieve measurable improvement in the lesion, reduce its effect on nearby neurological structures, restore the patient’s functional health, and verify progress through comparative imaging. A published Ayurvedic case is especially relevant because it documented a massive parasellar meningioma, defined the treatment period as one month, and used contrast-enhanced brain CT before and after treatment to assess the result rather than relying only on subjective symptom relief [1]. OpenAlex
What the Published Ayurvedic Meningioma Case Documented
The case was reported in 2022 by Divya Kajaria and Kundan Sushilkumar Wasnik from the All India Institute of Ayurveda, New Delhi. It was published as a peer-reviewed case report in the Journal of Integrative Medicine and Public Health, Volume 1, Issue 2, pages 71–77 [1].

The lesion was located in the left parasellar region, the anatomically complex area beside the pituitary gland. The tumour extended medially and superiorly, displaced the pituitary stalk, and indented the left orbital nerve as described by the authors [1]. These findings are clinically important because a parasellar meningioma may affect structures involved in vision, eye movement, pituitary regulation, facial sensation, and nearby cerebral circulation.
The structural findings also explain why patients with a parasellar lesion commonly want answers to more than one question. They need to know whether the treatment can influence the actual tumour, whether pressure on neighbouring structures can improve, whether vision and neurological function can be protected, how quickly a response may become evident, and which test will confirm that the treatment is working.
Contrast-enhanced brain CT was used as both the diagnostic and outcome-assessment tool in the published case. This means that the treatment response was not reported only through changes in headache, sleep, fatigue, appetite, dizziness, or general wellbeing. The authors used repeat imaging to evaluate the condition after the Ayurvedic programme [1]. OpenAlex
One-Month Ayurvedic Treatment and the Reported Outcome
The principal Ayurvedic interventions described in the case were Virechana and Nasya. Virechana is physician-supervised therapeutic purgation selected according to the patient’s strength, digestive capacity, bowel pattern, Dosha involvement, and ability to tolerate purification. Nasya is the controlled administration of a prescribed Ayurvedic medicine through the nasal route for disorders involving the head and related structures.
The complete treatment period was one month. After treatment, contrast-enhanced CT was used to determine the outcome, and the authors reported that the massive parasellar meningioma had been treated successfully. The title of the published report described the case as a parasellar massive meningioma “cured” through Virechana and Nasya [1].
This case is significant because the Ayurvedic intervention was directed toward the underlying lesion and not presented merely as supportive care for symptoms. The treatment period was defined, the anatomical findings were documented before treatment, and the outcome was assessed radiologically after completion of the programme.
The case also demonstrates an essential principle of authentic Ayurveda: the diagnosis may be the same, but the treatment route is not automatically identical for every patient. Virechana and Nasya were selected for the clinical presentation described in that report. Their use in one successful patient does not make them compulsory prerequisites for every person diagnosed with meningioma.
Why This Case Does Not Make Travel or Panchakarma Compulsory
The published case represents a procedure-based Ayurvedic pathway. A different patient may be treated through a physician-designed oral Rasayana pathway when the patient is medically stable, can take medicine reliably, has access to local imaging and clinical evaluation, and does not require a procedure-based programme.
Ayurveda selects treatment according to the patient’s Prakriti, current Dosha disturbance, digestive capacity, functional strength, symptoms, tumour location, previous treatment, current medicines, and overall clinical condition. A patient with good digestive strength who lives overseas and remains neurologically stable may be suitable for continuous oral Rasayana treatment from home. Another patient with marked metabolic disturbance, unsuitable digestion, or a specifically indicated purification requirement may be advised to undergo supervised procedures.
The logical conclusion from the published case is therefore not that every patient must travel for Virechana and Nasya. The case establishes that a structured Ayurvedic programme can be directed toward meningioma and assessed through imaging. The route used to deliver that treatment may be procedure-based or oral, depending on the patient.
For a suitable international patient, consultation, MRI review, formulation planning, medicine preparation, Day 15 assessment, Day 30 assessment, and subsequent report comparison can be organised remotely. MRI, CT, visual-field testing, optical coherence tomography, neurological examination, and blood investigations can be completed in the patient’s own country and submitted for review.
Brahma Rasayana Avaleha as the Home-Based Oral Treatment Model
Brahma Rasayana Avaleha provides the oral Rasayana foundation for patients selected for home-based treatment. Avaleha is a concentrated semi-solid Ayurvedic formulation designed for consistent daily administration. It permits decoction herbs, herbal pastes, nourishing media, Medhya Rasayana ingredients, and carefully selected case-specific components to be combined in a patient-specific treatment programme.
The classical foundation of Brahma Rasayana is found in Charaka Samhita, Chikitsa Sthana, Rasayana Adhyaya, Abhayamalakiya Rasayana Pada, Chapter 1, Quarter 1, verses 41–57. The formulation is built around Haritaki, Amalaki, groups of Panchamula, and multiple Rasayana and Medhya substances. Charaka concludes the first Brahma Rasayana description with the following verse [2]:
रसायनमिदं ब्राह्ममायुष्कामः प्रयोजयेत्।
दीर्घमायुर्वयश्चाग्र्यं कामांश्चेष्टान् समश्नुते॥५७॥
rasāyanam idaṁ brāhmam āyuṣkāmaḥ prayojayet |
dīrgham āyur vayaś cāgryaṁ kāmāṁś ceṣṭān samaśnute ||57||
A person desiring longevity should use this Brahma Rasayana; through it, one attains long life, excellent vitality, and the desired therapeutic benefits [2]. Charak Samhita
The classical passage establishes Brahma Rasayana as a comprehensive restorative formulation intended to promote strength, vitality, cognition, tissue nourishment, and resistance to disease. The classical text does not use the modern diagnostic word “meningioma.” For a patient with meningioma, the physician therefore adapts the Rasayana framework according to the modern imaging diagnosis, neurological findings, tumour location, digestive capacity, and individual Ayurvedic assessment.
The personalised Brahma Rasayana Avaleha is not prescribed as an ordinary memory tonic or general health supplement. It is designed as the principal Ayurvedic treatment for the selected patient. The formulation may combine Medhya Rasayana herbs for cognition and neurological function, Deepana-Pachana herbs for digestion and metabolic transformation, ingredients selected for Kapha-Meda regulation and abnormal tissue accumulation, nourishing Rasayana herbs for strength and recovery, and physician-selected herbo-mineral components where clinically appropriate.
The exact formulation must change according to the patient. A person with headache, eye pressure, visual fatigue, poor appetite, constipation, disturbed sleep, and weakness requires a different balance of ingredients from a patient whose main problems are seizures, cognitive slowing, postoperative fatigue, or recurrent disease. The dose, Anupana, timing, diet, and treatment duration are finalised only after reviewing these differences.
For a medically stable patient, Brahma Rasayana Avaleha may constitute the complete Ayurvedic programme without routine admission. A reference 30-day course may be prescribed in divided daily doses, while the actual batch quantity and dosage are adjusted according to digestion, body weight, strength, age, current medicines, and the concentration of the personalised formulation.
Human Research Supporting the Brahma Rasayana Foundation
Modern human research provides additional support for the systemic Rasayana role of Brahma Rasayana. In a clinical pilot study involving cancer patients receiving chemotherapy together with radiotherapy, Brahma Rasayana accelerated recovery of the blood-forming system. Total leukocytes recovered more rapidly, and neutrophils and lymphocytes were significantly improved in the Rasayana-treated patients [3].
The reported lowest total white-blood-cell count was 3,633 ± 120 in the Brahma Rasayana group compared with 2,954 ± 305 in the untreated group. The lowest neutrophil count was 2,830 ± 964 in the treated group compared with 1,791 ± 922 in the untreated group. Consecutive days of leukopenia, neutropenia, and lymphopenia were also significantly reduced [3].
The study additionally reported reduced serum lipid peroxidation, indicating lower treatment-associated oxidative stress. These findings support the use of Brahma Rasayana as a formulation capable of improving systemic resilience, tissue recovery, and physiological tolerance during serious illness [3]. PubMed
For a patient with meningioma, these systemic actions form one part of the treatment rationale. The lesion-specific outcome is assessed separately through comparative MRI or CT, while neurological recovery is assessed through vision, seizures, headache, cognition, balance, strength, sleep, appetite, energy, and daily functioning.
The evidence pathway is therefore coherent. The published one-month meningioma case demonstrates that Ayurveda has been applied with lesion-directed curative intent and evaluated through post-treatment imaging. The classical Brahma Rasayana source provides the foundation for sustained oral Rasayana therapy. Human research supports its effects on recovery capacity, blood-cell protection, and oxidative-stress regulation. The personalised Avaleha model then converts these principles into a continuous home-based programme for patients who do not require inpatient procedures.
What the Patient Can Expect During the First 30 Days
Before oral treatment begins, the patient’s baseline must be documented. This includes the latest contrast MRI or CT findings, previous scan comparison, exact tumour location, available dimensions, oedema, mass effect, involvement of the pituitary or visual structures, neurological symptoms, current medicines, and ordinary functional capacity.
The Day 15 review assesses early changes in headache frequency, pain intensity, dizziness, eye pressure, visual comfort, sleep, appetite, bowel function, energy, concentration, balance, seizure frequency, limb symptoms, and ability to work or perform normal daily activities. It also determines whether the dose, timing, Anupana, diet, or composition should be modified.
The Day 30 review compares the patient’s condition with both baseline and Day 15. Improvement should be documented through actual measurements, such as fewer headache days per week, reduced pain scores, longer comfortable reading or working time, improved sleep duration, reduced rescue-medicine use, more stable walking, or improved ability to complete daily tasks.
Clinical improvement and radiological response are recorded separately. A patient may notice better sleep, appetite, energy, headache control, or concentration before structural change is assessed. MRI remains the preferred imaging method for most meningiomas and is used to compare tumour dimensions, enhancement, surrounding oedema, mass effect, and relationship with nearby neurological structures [4]. PubMed Central (PMC)
Where the lesion is close to the optic pathway, follow-up should also compare visual acuity, colour vision, automated visual fields, optic-disc findings, and optical coherence tomography. Where seizures, weakness, memory problems, or speech changes are present, these functions should be recorded from the beginning and reviewed at every consultation.
The patient can complete these investigations locally without relocating for the entire treatment period. The reports and images are then reviewed together with the clinical response so that the continuing Brahma Rasayana Avaleha programme remains personalised, measurable, and directed toward both neurological recovery and the underlying meningioma.
Meningioma Ayurvedic Treatment Without Surgery

Meningioma Ayurvedic treatment without surgery may be considered for selected patients when the tumour is clinically stable, neurological function is preserved, and the patient can complete regular MRI and medical follow-up. The Ayurvedic programme is centred on personalised oral Rasayana, correction of the patient’s metabolic and constitutional disturbances, continuous symptom assessment, and objective comparison of the lesion over time.
The phrase “without surgery” does not describe one fixed situation. It may refer to a newly detected meningioma being monitored through serial MRI, a residual lesion remaining after earlier surgery, a recurrent tumour requiring further assessment, or a lesion located near structures where immediate removal has not been selected. Some small, asymptomatic, or slow-growing meningiomas are managed initially through observation rather than immediate intervention [4].
Ayurvedic treatment can begin during this monitoring period when the patient is medically stable. The therapeutic objective is to influence the disease process through sustained Rasayana treatment while documenting changes in tumour size, oedema, pressure effects, neurological symptoms, visual function, and daily activity. The treatment plan is individualised rather than determined by tumour size alone.
How Suitability for Oral Rasayana Is Decided
The decision begins with a detailed review of the tumour rather than a general prescription based only on the word “meningioma.” The physician evaluates its exact location, available dimensions, enhancement pattern, surrounding oedema, mass effect, involvement of cranial nerves or blood vessels, previous growth rate, and relationship with the brain, pituitary region, optic pathway, or spinal cord.
Symptoms are interpreted in relation to the lesion’s location. A parasellar or optic-pathway meningioma may affect vision, eye movement, colour perception, visual fields, or hormonal function. A frontal meningioma may present with reduced concentration, memory changes, altered judgement, loss of motivation, or personality change. A convexity or parasagittal lesion may be associated with seizures, limb weakness, numbness, or difficulty walking.
The Ayurvedic assessment examines Prakriti, the patient’s constitutional pattern, together with current Dosha disturbance, Agni, bowel function, appetite, sleep, strength, energy, cognition, and previous treatment burden. These findings determine whether the patient can tolerate a concentrated Avaleha, whether digestion must be corrected first, and which therapeutic groups should receive priority in the formulation.
Age, body weight, liver and kidney function, diabetes, hypertension, seizure medicines, corticosteroids, anticoagulants, hormonal medicines, and previous surgery or radiotherapy also influence the prescription. Two patients with similarly sized meningiomas may therefore receive different formulations, doses, Anupana, and treatment durations.
A patient whose lesion is radiologically suspected but has not been surgically sampled should not automatically be assigned a WHO grade. Imaging can strongly suggest meningioma, but definitive grading generally depends on histopathological examination of tumour tissue [4]. The Ayurvedic treatment plan should therefore retain the precise wording used in the medical records, such as radiologically suspected meningioma, residual meningioma, or pathology-confirmed Grade 1, Grade 2, or Grade 3 disease.
Oral Rasayana as the Principal Ayurvedic Treatment
For a suitable patient, Brahma Rasayana Avaleha may be prescribed as the principal Ayurvedic treatment rather than as an occasional supplement. The formulation is administered continuously at home, allowing the treatment to act through a sustained daily regimen instead of depending on repeated inpatient procedures.
The personalised Avaleha may include Medhya Rasayana herbs for cognition, memory, sleep, and neurological function; Deepana-Pachana ingredients for digestion and metabolic transformation; herbs selected for Kapha-Meda regulation and abnormal tissue accumulation; nourishing Rasayana substances for strength and recovery; and carefully chosen herbo-mineral components where appropriate.
The therapeutic reasoning is based on the patient’s complete disease pattern. Agni is addressed because impaired digestion and transformation can reduce medicine tolerance and disturb tissue nourishment. Kapha and Medas are considered where the clinical pattern shows excessive density, accumulation, heaviness, or slow persistent growth. Vata is evaluated where seizures, pain, dizziness, tremor, weakness, sensory change, speech disturbance, or irregular neurological function are present.
Majja Dhatu is considered in relation to neurological nourishment and function without treating it as an exact anatomical equivalent of the meninges or brain. Ojas is addressed through the patient’s resilience, recovery capacity, strength, appetite, sleep, and ability to maintain normal activity during prolonged treatment.
The classical Brahma Rasayana framework provides the restorative foundation, while the final prescription is modified according to the tumour’s location, the patient’s symptoms, digestion, strength, previous treatment, and present medicines [2]. Human research on Brahma Rasayana has also demonstrated effects on physiological recovery and oxidative stress during intensive cancer treatment, supporting its broader Rasayana role in serious illness [3].
The exact formulation should not be copied from another patient. A person with visual pressure, headache, constipation, and poor sleep requires a different therapeutic balance from a patient whose principal concerns are seizures, cognitive slowing, postoperative weakness, or recurrence after radiotherapy.
Monitoring the First 30 Days
The treatment begins with a dated baseline. Headache frequency, pain intensity, dizziness, vision, seizures, sleep, appetite, bowel function, energy, concentration, walking capacity, limb symptoms, rescue-medicine use, and ability to perform ordinary activities are recorded before the first dose.
At approximately 15 days, the physician compares the patient’s current condition with the baseline. Early changes may include fewer headache episodes, reduced eye pressure, better sleep, improved digestion, increased energy, clearer concentration, reduced dizziness, or greater tolerance of reading, walking, work, or household activity.
The same measurement method is maintained throughout treatment. A headache recorded on a zero-to-ten scale should be reassessed on the same scale. Comfortable reading or working time should be recorded in hours. Seizures should be documented by number, duration, pattern, and recovery time. This makes the response clinically meaningful and reduces dependence on vague descriptions.
The Day 15 review also determines whether the formulation requires adjustment. The dose may be changed when digestion is weak, appetite is reduced, heaviness develops, bowel function changes, sleep becomes disturbed, or the patient’s neurological symptoms require a different balance of ingredients.
At 30 days, the physician evaluates whether the initial improvement has continued and whether the patient’s daily function has become more stable. The first month also helps determine whether the same core formulation should continue, whether the dose should be modified, and whether the next treatment period should emphasise neurological recovery, visual protection, seizure control, digestion, strength, or tumour-directed Rasayana.
Clinical improvement during the first month is recorded separately from radiological response. Better sleep, appetite, energy, or headache control indicates meaningful recovery, but the effect on the lesion must be assessed through comparative imaging.
Confirming the Deeper Response
MRI is used to compare tumour dimensions, enhancement, surrounding oedema, mass effect, involvement of adjacent nerves or blood vessels, and changes in pressure on nearby neurological structures [4]. The follow-up scan should be reviewed beside the baseline study rather than interpreted as an isolated report.
Where the lesion involves the optic pathway, visual acuity, colour vision, automated visual fields, optic-disc findings, and optical coherence tomography provide additional evidence of functional response. Where cognition, speech, weakness, balance, or seizures are affected, these functions should be measured repeatedly alongside the imaging findings.
The timing of repeat MRI depends on the tumour’s location, previous growth, current symptoms, pathology where available, and the patient’s clinical response. The scan can be completed locally and shared for comparison, allowing the entire Rasayana programme to continue from home.
A curative-intent outcome is documented through the combined pattern of radiological change, neurological recovery, symptom reduction, restored daily function, and sustained follow-up. Tumour regression, reduction in oedema, reduced mass effect, or durable stability should be stated only when confirmed by comparative imaging and the corresponding clinical findings.
How Common Is Meningioma in the USA, UK, Canada, and Australia?

Meningioma is the most frequently diagnosed primary brain tumor in adults across Western countries. Its incidence has increased over the past two decades, largely due to widespread MRI use and an aging population.
United States
In the United States, meningiomas account for about 39 percent of all primary brain and central nervous system tumors. The annual incidence is approximately 8 to 10 cases per 100,000 people. They are more common in women, with a female-to-male ratio of nearly 2:1. The risk rises significantly after the age of 50, and many tumors are discovered incidentally during imaging for unrelated conditions.
United Kingdom
In the UK, meningioma represents the most common non-malignant brain tumor. The incidence is estimated at around 7 to 8 per 100,000 people per year. Similar to the US, it is seen more frequently in women and older adults. Improved neuroimaging access through the NHS has led to increased detection of small, asymptomatic tumors.
Canada
Canadian cancer registry data show patterns very similar to the United States. Meningiomas make up the largest proportion of primary brain tumors, with an incidence of roughly 7 to 9 per 100,000 population annually. Many are diagnosed during scans performed for headaches, trauma evaluation, or neurological symptoms.
Australia
In Australia, meningioma is also the most commonly reported benign brain tumor. The incidence ranges between 6 and 8 per 100,000 people per year. As in other Western countries, it is more common in women and in individuals over 50 years of age. The widespread availability of advanced imaging has contributed to earlier and more frequent diagnosis.
Key Global Patterns
Across all four countries, the epidemiology shows consistent features:
- It is the most common primary brain tumor in adults
- It occurs more often in women
- Incidence increases with age
- Many cases are detected incidentally
- Most tumors are WHO Grade I and slow growing
Meningioma is the most common primary brain tumor in adults in the USA, UK, Canada, and Australia, with an incidence of about 6 to 10 cases per 100,000 people each year. It occurs more often in women, increases after age 50, and is frequently detected incidentally during MRI scans.
From an Ayurvedic perspective, this rising prevalence reflects long-standing metabolic imbalance, chronic stress, hormonal disruption, and accumulation of Aama affecting Majja Dhatu. Early detection provides a valuable window for interventions aimed at reversing the underlying pathology and preventing progression.
Can Meningioma Ayurvedic Treatment Be Curative?

Yes, meningioma Ayurvedic treatment can be planned with curative intent in selected patients. The objective is to influence the underlying disease process, reduce the tumour’s pressure on nearby neurological structures, restore affected functions, prevent further progression, and achieve a measurable clinical and radiological response. A published Ayurvedic meningioma case documented a one-month treatment programme followed by contrast-enhanced CT assessment and reported a successful outcome, demonstrating that Ayurvedic treatment may be directed toward the lesion itself rather than restricted to temporary symptom relief [1].
Curative intent is different from simply controlling headache, dizziness, disturbed sleep, poor appetite, fatigue, eye pressure, or anxiety. These symptoms remain important because they reflect the patient’s functional recovery, but the deeper therapeutic goal is assessed through changes in tumour dimensions, surrounding oedema, mass effect, neurological function, visual findings, seizure burden, and long-term stability.
What Curative Intent Means
A curative-intent Ayurvedic programme aims to produce the greatest possible reversal of the disease process while preserving neurological function and restoring normal daily life. Depending on the patient’s condition, this may appear as radiological regression, disappearance of previously visible abnormal tissue, reduction in oedema, release of pressure on a nerve or brain structure, sustained arrest of tumour growth, or durable clinical recovery with stable follow-up imaging.
The intended outcome must be defined before treatment begins. A patient with an optic-pathway meningioma may require preservation or improvement of vision as a principal goal. A patient with a frontal lesion may require recovery of concentration, memory, judgement, or behaviour. A patient with a parasagittal lesion may require reduction in seizures and recovery of limb strength or walking ability.
The physician therefore establishes a baseline that includes imaging findings, neurological symptoms, visual function, seizure history, headache frequency, sleep, appetite, bowel function, energy, cognition, mobility, and ability to perform ordinary activities. These measurements allow the curative response to be assessed progressively rather than inferred from a general feeling of improvement.
How Ayurveda Addresses the Disease Process
Ayurveda evaluates the patient’s internal disease terrain together with the anatomical diagnosis. The modern diagnosis of meningioma remains based on imaging and, where available, histopathology. Ayurvedic assessment then examines the disturbances that may sustain abnormal tissue formation, impaired tissue metabolism, neurological dysfunction, reduced resilience, and delayed recovery.
Agni represents the functional capacity responsible for digestion, assimilation, and metabolic transformation. When Agni is disturbed, the patient may develop poor appetite, heaviness, constipation, acidity, irregular bowel function, fatigue, and reduced tolerance of medicine. Correcting these disturbances improves the patient’s ability to receive and respond to sustained Rasayana treatment.
Kapha and Medas are considered when the clinical pattern shows excessive density, accumulation, heaviness, slow persistent growth, or impaired tissue clearance. Vata is assessed when the patient experiences seizures, pain, dizziness, weakness, numbness, tremor, altered speech, disturbed coordination, or irregular neurological function.
Majja Dhatu is considered in relation to neurological nourishment, sensory function, cognition, and recovery. It is not treated as an exact anatomical equivalent of the brain or meninges, but its functional assessment helps guide the selection of Medhya and Majja-supporting Rasayana medicines.
Ojas reflects the patient’s resilience, vitality, stability, recovery capacity, and ability to withstand prolonged disease. Poor sleep, weight loss, reduced appetite, persistent fatigue, anxiety, recurrent symptoms, and slow recovery may indicate that Ojas-supporting treatment should receive greater emphasis.
The formulation is therefore designed to address both the lesion-directed objective and the patient’s wider functional condition. This is why two patients with the same tumour location may receive different combinations, doses, Anupana, dietary instructions, and treatment durations.
Brahma Rasayana Avaleha in the Curative Programme
Brahma Rasayana Avaleha provides the oral foundation for a sustained home-based treatment programme. The classical Brahma Rasayana described in Charaka Samhita, Chikitsa Sthana, Rasayana Adhyaya, Abhayamalakiya Rasayana Pada, is intended to promote longevity, strength, vitality, cognitive function, tissue nourishment, and resistance to disease [2].
For a patient with meningioma, the classical framework is personalised rather than copied unchanged. The final Avaleha may combine Medhya Rasayana herbs for cognition, memory, sleep, and neurological function; Deepana-Pachana ingredients for digestion and metabolic correction; ingredients selected for Kapha-Meda regulation and abnormal tissue accumulation; nourishing herbs for strength and recovery; and case-specific herbo-mineral components where appropriate.
The Avaleha is administered continuously in divided daily doses so that treatment does not depend on occasional procedures. The dose, timing, Anupana, food instructions, and treatment duration are adjusted according to the patient’s age, body weight, digestive capacity, neurological condition, current medicines, previous treatment, and response during follow-up.
Human research on Brahma Rasayana has shown accelerated recovery of leukocytes, neutrophils, and lymphocytes and reduced oxidative stress in patients receiving chemotherapy and radiotherapy [3]. These findings support its role in systemic resilience, tissue recovery, and physiological protection during serious illness. In meningioma treatment, these Rasayana actions are integrated with lesion-directed formulation design and objective imaging follow-up.
Clinical Recovery During Treatment
The first signs of response may occur in symptoms and daily function. The patient may experience fewer headaches, reduced eye pressure, improved sleep, better appetite, more regular bowel movements, increased energy, clearer concentration, reduced dizziness, improved walking confidence, or greater ability to read, work, study, and participate in household activity.
These changes are recorded at the 15-day review using the same measurements established before treatment. Headache is compared by days per week and intensity. Sleep is compared by total hours and number of awakenings. Energy is assessed through walking, work, study, or household capacity. Visual comfort is assessed through reading tolerance, screen tolerance, light sensitivity, and eye pressure.
The 30-day review determines whether the early response has continued and whether functional recovery has become more stable. The formulation may then be continued, strengthened, or modified according to the patient’s remaining symptoms, digestion, strength, neurological findings, and treatment tolerance.
A reduction in symptom burden is clinically meaningful because it shows improvement in the patient’s functional state. The deeper curative response is then determined by correlating these changes with neurological examination, visual assessment, seizure records, and comparative imaging.
Radiological Confirmation
MRI is used to assess the effect of treatment on the underlying meningioma. The baseline and follow-up scans are compared for tumour dimensions, estimated volume, enhancement pattern, surrounding oedema, mass effect, compression of nearby brain structures, cranial-nerve involvement, vascular relationships, and changes in adjacent tissues [4].
The entire scan comparison is considered rather than relying on one isolated diameter. A reduction in one measurement may have limited significance unless it is accompanied by a consistent change in other dimensions, oedema, mass effect, neurological findings, or the radiologist’s overall conclusion.
For tumours involving the optic pathway, radiological assessment is combined with visual acuity, colour vision, visual fields, optic-disc examination, and optical coherence tomography. A patient may experience reduced pressure or pain before measurable visual recovery occurs, while another patient may show stabilisation of visual function before a clear size reduction is documented.
For tumours associated with seizures, weakness, sensory loss, balance problems, speech difficulty, or cognitive change, the MRI findings are correlated with seizure frequency, strength, gait, coordination, speech, memory, and daily independence.
Radiological regression, reduced oedema, decreased mass effect, and improved neurological function provide objective evidence that the curative-intent programme is influencing the underlying disease process. Durable stability on serial imaging may also represent a meaningful treatment outcome when accompanied by sustained clinical recovery.
Long-Term Curative Assessment
The response is followed beyond the first month because tumour behaviour, neurological recovery, and tissue restoration may continue over a longer period. The patient’s symptoms, function, imaging, visual findings, and medicine tolerance are reviewed at defined intervals.
A complete curative assessment considers whether the tumour has regressed or remained durably controlled, whether neurological functions have recovered, whether the patient has returned to normal activity, whether seizures or visual symptoms have reduced, and whether the improvement remains stable after continued follow-up.
The treatment duration is therefore determined by the lesion’s size, location, previous growth, grade where known, neurological involvement, earlier surgery or radiation, digestive capacity, strength, and response to the first treatment cycles. The Brahma Rasayana Avaleha programme is adjusted progressively so that each phase continues to address the patient’s current therapeutic needs.
Meningioma Ayurvedic Treatment at the Root

Meningioma Ayurvedic treatment at the root begins by retaining the anatomical diagnosis established through MRI, neurological assessment, and histopathology where available, while identifying the patient’s individual Samprapti, or disease-development pathway. The Ayurvedic assessment examines how Dosha disturbance, abnormal tissue organisation, impaired metabolic transformation, functional obstruction, neurological depletion, and reduced recovery capacity are interacting in that particular patient. Tumour location, grade, growth, oedema, and pressure on nearby structures remain defined through modern investigations, while Ayurveda determines how treatment should be personalised [4].
Ayurveda does not treat every meningioma as the same disease pattern. A slow-growing convexity lesion associated with heaviness and mild headache may require a different therapeutic emphasis from an optic-pathway lesion producing visual decline, a frontal lesion affecting memory and behaviour, or a parasagittal lesion associated with seizures and limb weakness. The formulation must therefore address both the mass-forming process and the specific neurological functions placed at risk.
Classical Correlation With Arbuda
The modern diagnosis of meningioma should not automatically be renamed Arbuda. Meningioma is an anatomically and histologically defined tumour arising from cells associated with the meninges, whereas Arbuda is a broader classical Ayurvedic description of a deep, persistent, mass-forming disorder. The correlation is clinically useful for treatment reasoning, but it is not an exact one-to-one diagnostic equivalence.
Sushruta Samhita, Nidana Sthana, Chapter 11, verse 14 describes the possible biological foundations of an Arbuda [5]:
कुर्वन्ति मांसोपचयं तु शोफं तमर्बुदं शास्त्रविदो वदन्ति।
वातेन पित्तेन कफेन चापि रक्तेन मांसेन च मेदसा च॥१४॥
kurvanti māṃsopacayaṃ tu śophaṃ tam arbudaṃ śāstravido vadanti |
vātena pittena kaphena cāpi raktena māṃsena ca medasā ca ||14||
“The learned describe as Arbuda a swelling formed through excessive tissue accumulation. It may arise through the involvement of Vata, Pitta, Kapha, Rakta, Mamsa, or Medas.”
This verse establishes that a persistent mass is not attributed to one universal Dosha. Vata, Pitta, Kapha, Rakta, Mamsa, and Medas may contribute in different proportions. The patient’s symptoms, tumour behaviour, constitutional pattern, previous treatment, digestion, strength, and neurological involvement are therefore assessed before deciding which pathway is dominant.
A second classical passage explains why an Arbuda may remain organised and persistent. Sushruta Samhita, Nidana Sthana, Chapter 11, verse 21 states [5]:
न पाकमायान्ति कफाधिकत्वान्मेदोबहुत्वाच्च विशेषतस्तु।
दोषस्थिरत्वाद्ग्रथनाच्च तेषां सर्वार्बुदान्येव निसर्गतस्तु॥२१॥
na pākam āyānti kaphādhikatvān medobahutvāc ca viśeṣatas tu |
doṣasthiratvād grathanāc ca teṣāṃ sarvārbudāny eva nisargatas tu ||21||
“Arbuda does not ordinarily undergo suppuration because of the predominance of Kapha, abundance of Medas, stability of the disturbed Doshas, and the compact binding together of its constituents.”
The description of stability, cohesion, deep organisation, and slow persistence provides an Ayurvedic framework for understanding why some masses remain established for prolonged periods. It does not determine the modern tumour grade or predict growth by itself. Those features are assessed through serial imaging and pathology, while the classical model guides the therapeutic strategy.
Kapha, Medas, and Persistent Tissue Accumulation
Kapha becomes clinically relevant when the disease pattern shows stability, density, heaviness, slow progression, excessive tissue accumulation, or resistance to normal tissue clearance. Medas is considered when abnormal nourishment and accumulation contribute to the persistence of the pathological tissue environment.
Mamsa is evaluated because the classical description of Arbuda involves excessive or disorganised tissue growth. This does not mean that meningioma originates from muscle tissue. Mamsa is used here as a functional Ayurvedic concept related to structural tissue formation and abnormal tissue consolidation.
When Kapha, Medas, and Mamsa involvement predominates, treatment must do more than nourish the patient. Excessively heavy or purely strengthening medicines may increase digestive burden when they are not balanced with ingredients that regulate accumulation, maintain metabolic activity, and support functional clearance.
The personalised Brahma Rasayana Avaleha therefore combines restorative Rasayana action with patient-specific ingredients selected to regulate Kapha-Meda accumulation, support normal tissue metabolism, and prevent the formulation from becoming excessively heavy for the patient’s Agni. The balance differs according to appetite, bowel function, body composition, fatigue, oedema, and medicine tolerance.
Vata and Neurological Function
Vata involvement becomes prominent when the patient develops seizures, dizziness, pain, weakness, numbness, tremor, altered coordination, disturbed speech, loss of balance, insomnia, or irregular neurological function. These manifestations may arise because the tumour or surrounding oedema affects the brain, cranial nerves, spinal cord, or nearby blood vessels.
Treatment must distinguish between symptoms caused by direct structural pressure and functional disturbance occurring around the lesion. A patient with optic-nerve compression requires serial visual testing and imaging, while the Ayurvedic prescription addresses pain, neurological irritation, sleep, digestion, and tissue recovery. A patient with seizures requires careful seizure documentation while the Rasayana programme is designed to stabilise Vata without creating excessive sedation or digestive heaviness.
Unchecked Vata can also interfere with sleep, appetite, bowel regularity, concentration, and treatment adherence. Stabilising Vata therefore supports both neurological recovery and the patient’s ability to continue the complete therapeutic programme consistently.
Medhya Rasayana ingredients are selected when memory, concentration, emotional regulation, speech, or sleep are affected. Majja-supporting ingredients are selected when weakness, sensory disturbance, neurological fatigue, or prolonged recovery is prominent. These actions are integrated into the tumour-directed formulation rather than prescribed as an unrelated brain tonic.
Pitta and Rakta Involvement
Pitta and Rakta become more relevant when the patient presents with burning pain, inflammatory features, marked irritability, disturbed sleep, redness, heat intolerance, visual irritation, or treatment-related inflammatory symptoms. Their involvement may also influence how the patient tolerates concentrated herbs, mineral ingredients, ghee, honey, and heating digestive medicines.
A patient with strong Pitta features may require a formulation that maintains tumour-directed and digestive action without aggravating heat, acidity, irritability, or sleep disturbance. Cooling and stabilising Rasayana ingredients may therefore be combined with carefully measured metabolic and channel-supporting medicines.
Rakta assessment is especially relevant when imaging or clinical findings involve vascular structures, congestion, oedema, or altered microcirculation. This Ayurvedic interpretation does not replace neuroradiological assessment of blood-vessel involvement. It guides the selection of medicines intended to support healthy circulation and tissue balance while the anatomical findings continue to be monitored objectively.
Aama and Srotorodha
Aama refers to incompletely transformed metabolic material that, in Ayurvedic pathology, can interfere with normal tissue nourishment and functional regulation. Its clinical assessment is based on findings such as poor appetite, coated tongue, abdominal heaviness, bloating, irregular bowel movements, fatigue after meals, nausea, mental dullness, and reduced tolerance of medicines.
Srotorodha means functional obstruction within the body’s channels of transport and communication. In a patient with meningioma, this concept may be considered when there is oedema, heaviness, impaired circulation, sluggish digestion, restricted tissue exchange, or disturbed neurological transmission. It should not be interpreted as a literal substitute for a blocked artery, compressed nerve, or radiological mass effect.
When Aama and Srotorodha are prominent, intensive nourishing treatment may be introduced gradually. Deepana-Pachana therapy is used to improve metabolic readiness, while bowel regularity and food tolerance are corrected so that the patient can assimilate the Rasayana formulation effectively.
As digestion and tolerance improve, the Brahma Rasayana Avaleha can be strengthened according to the patient’s response. This staged approach allows the medicine to remain sufficiently nourishing for recovery while retaining the metabolic and tissue-regulating actions required for a persistent mass-forming condition.
Personalising Brahma Rasayana Avaleha
The final prescription is based on the dominant Samprapti rather than on the tumour name alone. A Kapha-Meda-dominant presentation requires greater emphasis on abnormal tissue accumulation and metabolic regulation. A Vata-dominant presentation requires stronger neurological stabilisation, sleep support, and restoration of sensory or motor function. Pitta-Rakta involvement requires control of inflammatory heat, irritability, and tissue sensitivity.
The formulation must also account for the patient’s Bala, previous surgery or radiation, current medicines, weight, appetite, bowel function, sleep, liver and kidney status, and ability to tolerate long-term oral treatment. These factors determine the relative proportions of nourishing, metabolic, neurological, circulatory, and lesion-directed ingredients.
Brahma Rasayana Avaleha supports the curative-intent programme through three coordinated actions: regulating the pathological tissue environment, protecting and restoring neurological function, and rebuilding the strength required for sustained recovery. Clinical improvement is tracked through symptoms and daily function, while the deeper response is assessed through serial MRI, neurological findings, visual testing where relevant, and long-term stability.
Meningioma Ayurvedic Treatment With Brahma Rasayana

Meningioma Ayurvedic treatment with Brahma Rasayana Avaleha is designed as a sustained oral programme that addresses the tumour-related tissue environment, protects neurological function, improves treatment tolerance, and restores the patient’s strength over successive treatment cycles. The formulation is personalised according to tumour location, symptoms, digestion, constitutional pattern, previous treatment, current medicines, and the measurable clinical objectives established before therapy begins.
Classical Foundation
The classical foundation of Brahma Rasayana is described in Charaka Samhita, Chikitsa Sthana, Rasayana Adhyaya, Abhayamalakiya Rasayana Pada, Chapter 1, Quarter 1, verses 41–57. A second Brahma Rasayana preparation follows in verses 58–61 [2].
The classical formulation combines Rasayana, Medhya, nourishing, digestive, and restorative substances to promote longevity, cognitive clarity, physical strength, tissue stability, and resistance to disease [2]. These therapeutic principles make Brahma Rasayana relevant when a patient requires prolonged neurological recovery, sustained oral treatment, improved resilience, and careful restoration after chronic illness or previous intervention.
The classical text does not identify meningioma as a modern anatomical diagnosis. The physician therefore retains the MRI or histopathological diagnosis and applies the Rasayana principles according to the individual clinical presentation. The classical foundation remains intact, while the contemporary formulation is modified to address the tumour’s location, pressure effects, neurological symptoms, digestive capacity, and associated health conditions.
Personalised Formulation Design
The personalised Brahma Rasayana Avaleha is not prepared as one fixed formula for every meningioma patient. The proportions and additional ingredients are selected after reviewing the patient’s Prakriti, current Dosha imbalance, Agni, bowel function, sleep, energy, neurological findings, imaging, previous treatment, and current prescriptions.
A patient with frontal-lobe involvement may require greater emphasis on memory, concentration, behaviour, speech, and cognitive endurance. A patient with optic-pathway involvement may require stronger support for visual comfort, neurological stability, microcirculation, and recovery from pressure-related symptoms. A patient with seizures, weakness, or sensory disturbance may require a formulation with greater Vata-stabilising and Majja-nourishing actions.
Digestive findings influence the formulation from the beginning. When appetite is weak, heaviness is present, or bowel movements are irregular, the Avaleha must contain sufficient Deepana-Pachana support to improve digestion and metabolic transformation. When the patient is depleted, underweight, fatigued, or recovering after surgery or radiation, the nourishing component requires greater emphasis without making the formulation too heavy for the patient’s Agni.
The tumour-related component is selected according to the dominant tissue pattern. Kapha-Meda involvement requires ingredients that regulate excessive accumulation and support normal tissue metabolism. Vata involvement requires neurological stabilisation and restoration of coordinated function. Pitta-Rakta involvement requires careful regulation of inflammatory heat, vascular sensitivity, visual irritation, and medicine tolerance.
Rasayana and Medhya Ingredients
Amalaki may form part of the Rasayana base because of its traditional role in tissue nourishment, vitality, Pitta balance, and long-term rejuvenation. Haritaki may be included to support Vata regulation, bowel regularity, digestion, and the proper elimination of metabolic waste. Guduchi may be selected for its Rasayana, metabolic, inflammatory-regulating, and tissue-protective roles.
Brahmi and Shankhapushpi may be incorporated when concentration, memory, sleep, emotional steadiness, or cognitive endurance are affected. Jatamansi may be considered where sleep disturbance, mental restlessness, neurological irritability, or emotional instability accompanies the condition.
Ashwagandha may be selected when weakness, fatigue, disturbed sleep, reduced stamina, or Vata aggravation is prominent. Shatavari and Yashtimadhu may be incorporated when the patient requires greater nourishment, mucosal protection, Pitta regulation, or improved tolerance of a concentrated formulation.
Manjistha may be selected when Rakta involvement, inflammatory congestion, or microcirculatory disturbance requires attention. Gokshura and Punarnava may be considered when fluid balance, oedema, urinary function, or tissue congestion are part of the clinical presentation.
The final selection depends on the complete case rather than the diagnosis alone. An ingredient included for one patient may be reduced, replaced, or omitted in another patient according to digestion, blood pressure, blood sugar, hormonal status, liver function, kidney function, current medicines, and previous reactions.
Lesion-Directed Therapeutic Groups
The lesion-directed component is intended to regulate the pathological tissue environment while preserving healthy neurological structures. Ingredients traditionally used in persistent Granthi-Arbuda patterns may be considered when the clinical presentation shows deep, firm, slow, or recurrent tissue accumulation.
Kanchanara, Varuna, Guggulu, or other physician-selected substances may be incorporated according to the patient’s constitution, Agni, bowel function, inflammatory state, and ability to tolerate metabolically active medicines. These ingredients are not added automatically or in identical quantities for every patient.
The formulation must maintain balance between Lekhana and Brimhana actions. Lekhana refers to therapeutic reduction of excessive or pathological accumulation, while Brimhana refers to nourishment and rebuilding. Excessive reduction may weaken a depleted patient, while excessive nourishment may aggravate heaviness, poor digestion, or Kapha-Meda accumulation. The personalised Avaleha combines both actions according to the patient’s strength and disease pattern.
Medhya and Majja-supporting ingredients protect cognitive and neurological function during the lesion-directed programme. This is particularly important where the meningioma affects vision, hearing, speech, memory, coordination, sensation, limb strength, or seizure threshold.
Herbo-Mineral Rasayana Components
Case-specific herbo-mineral ingredients may be incorporated when the physician determines that the patient requires a more concentrated Rasayana action. Swarna Bhasma may be considered for Ojas, vitality, neurological resilience, and long-term tissue restoration. Heerak Bhasma may be selected in carefully assessed tumour-related formulations where a highly refined Rasayana component is clinically justified.
Abhraka Bhasma may be considered for strength, respiratory and metabolic resilience, tissue restoration, and prolonged convalescence. Rajata Bhasma may be selected where neurological irritability, disturbed sleep, mental agitation, or Pitta-Vata involvement requires additional regulation. Mukta-based preparations may be considered where Pitta, visual irritation, disturbed sleep, or emotional instability is prominent.
The quantity of each component is calculated for the complete batch and adjusted according to age, strength, digestive capacity, treatment duration, current medicines, and laboratory findings. These substances are administered only after appropriate purification, preparation, identification, and quality assessment.
The complete formulation should have traceable batch identity, controlled preparation, uniform incorporation of powdered ingredients, and appropriate testing where required. The prescription is reviewed during follow-up so that the dose and composition continue to match the patient’s evolving condition.
Avaleha Preparation and Administration
The Avaleha form permits decoction-derived constituents, herbal pastes, Rasayana substances, lipid media, honey, and selected fine powders to be incorporated into one concentrated oral medicine. This allows several therapeutic objectives to be addressed through a consistent daily dose.
The decoction component is prepared from the harder and water-soluble herbs and reduced to the required concentration. The sweet medium is then processed to the correct Avaleha consistency. Herbal pastes and ghee are incorporated at the appropriate stage, while honey and heat-sensitive substances are added after cooling. Fine herbo-mineral components are integrated uniformly after the preparation is removed from direct heat.
The exact dosage depends on the concentration and the patient’s digestive capacity. A personalised programme may use divided doses after meals, accompanied by the prescribed Anupana. The medicine should be taken at approximately the same times each day so that the treatment remains continuous and the response can be interpreted accurately.
The Anupana may be selected according to the dominant therapeutic need. Warm water may be used where digestion and Kapha regulation require support. Milk or another nourishing vehicle may be considered where depletion and Vata-Pitta imbalance predominate. Ghee may be used in carefully selected neurological and Rasayana contexts when digestion permits. The vehicle is modified if appetite, bowel function, sleep, heaviness, or tolerance changes during treatment.
First Treatment Cycle
The first 30-day cycle establishes how the patient digests, tolerates, and responds to the formulation. Baseline findings are recorded before treatment so that Day 15 and Day 30 changes can be compared with the same symptoms and functional measurements.
At Day 15, the physician evaluates headache, dizziness, visual comfort, sleep, appetite, bowel function, energy, concentration, seizure burden, limb symptoms, and daily activity. The dose, timing, Anupana, diet, or ingredient balance may be adjusted according to the early response.
At Day 30, the physician determines whether the clinical improvement is continuing, whether neurological function is stabilising, and whether the same core formulation should be maintained for the next cycle. Persistent symptoms are used to refine the next batch rather than automatically repeating the identical medicine.
Human research on Brahma Rasayana has demonstrated accelerated recovery of total leukocytes, neutrophils, and lymphocytes, together with reduced oxidative stress in patients undergoing intensive cancer treatment [3]. These findings support its role in systemic resilience, tissue recovery, and physiological protection during prolonged therapeutic programmes.
The lesion-directed response is assessed through comparative MRI or CT at the clinically appropriate interval. Tumour dimensions, enhancement, oedema, mass effect, pressure on nearby structures, and associated neurological findings are reviewed alongside the patient’s functional recovery [4].
Continued Brahma Rasayana Avaleha treatment is adjusted according to the relationship between clinical improvement and objective imaging. A patient showing progressive symptom relief, restored function, improved digestion, stable neurological findings, and favourable imaging can continue with a formulation that consolidates the response while strengthening long-term tissue stability.
Brahma Rasayana Avaleha (Main Medicine)
Brahma Rasayana Avaleha is a physician-designed 30-day formulation inspired by the classical Brahma Rasayana descriptions in Charaka Samhita, Chikitsa Sthana, Rasayana Adhyaya, Abhayamalakiya Rasayana Pada, verses 41–57 and 58–61, together with classical Granthi-Arbuda, Medhya Rasayana, and Rasa Shastra principles [2,5,6].
The classical Rasayana foundation is strengthened with herbs selected for neurological protection, abnormal tissue regulation, oedema, inflammation, digestion, energy, sleep, cognition, and recovery. The formulation is prepared as a concentrated Avaleha so that the patient can take the complete Ayurvedic programme orally from home.
Thirty-Day Treatment at a Glance
| Treatment detail | Patient information |
|---|---|
| Finished medicine | Brahma Rasayana Avaleha |
| Final quantity | 900 g |
| Duration | 30 days |
| Daily dosage | 15 g twice daily |
| Total daily quantity | 30 g |
| Total number of doses | 60 doses |
| Timing | After breakfast and after the evening meal |
| Form | Concentrated semi-solid Avaleha |
| Follow-up | Clinical review after approximately 15 and 30 days |
| Monitoring | Symptoms, neurological function, vision where relevant, and comparative imaging |
The ingredient weights below are pharmacy-input quantities. Decoction herbs are boiled, filtered, and concentrated; therefore, their entire raw weight does not remain in the finished medicine. The final preparation is adjusted to a finished net weight of 900 g.
Classical Rasayana Decoction Herbs
These herbs form the principal nourishing, metabolic, neurological, and tissue-regulating decoction.
| Ingredient | Botanical identity or form | Quantity | Why it is included |
|---|---|---|---|
| Amalaki | Phyllanthus emblica, fruit | 120 g | Principal Rasayana fruit for tissue protection, antioxidant defence, Pitta balance, recovery, and long-term vitality |
| Haritaki | Terminalia chebula, fruit pericarp | 40 g | Supports Vata regulation, bowel function, digestion, tissue clearance, and Rasayana action |
| Bibhitaki | Terminalia bellirica, fruit pericarp | 20 g | Supports Kapha regulation, metabolic clearance, and balanced tissue nourishment |
| Guduchi | Tinospora cordifolia, stem | 40 g | Immune-metabolic Rasayana used for inflammatory regulation, tissue resilience, and treatment tolerance |
| Kanchanara | Bauhinia variegata, bark | 20 g | Traditionally used in persistent Granthi and abnormal tissue-accumulation patterns |
| Varuna | Crataeva nurvala, bark | 15 g | Supports tissue metabolism, channel regulation, and management of deep-seated accumulation |
| Manjistha | Rubia cordifolia, root | 15 g | Supports Rakta balance, microcirculation, inflammatory regulation, and tissue clearance |
| Ashwagandha | Withania somnifera, root | 30 g | Supports strength, sleep, neurological endurance, Vata balance, and recovery from fatigue |
| Draksha | Vitis vinifera, dried fruit | 20 g | Provides restorative nourishment and supports weakness, dryness, appetite, and treatment tolerance |
| Punarnava | Boerhavia diffusa, root | 10 g | Supports fluid balance, oedema regulation, microcirculation, and metabolic clearance |
| Gokshura | Tribulus terrestris, fruit or root | 10 g | Supports fluid balance, tissue nourishment, strength, and urinary function |
| Bala | Sida cordifolia, root | 10 g | Supports neurological strength, muscle function, Vata balance, and physical recovery |
| Shatavari | Asparagus racemosus, root | 15 g | Nourishing Rasayana for tissue restoration, Pitta-Vata balance, and treatment tolerance |
| Jivanti | Leptadenia reticulata, whole plant | 5 g | Supports vitality, tissue nourishment, vision-related Rasayana care, and recovery |
| Eranda root | Ricinus communis, root | 5 g | Supports Vata regulation and movement through functional channels |
| Bilva | Aegle marmelos, root | 5 g | Supports digestion, bowel stability, and classical root-group Rasayana action |
| Agnimantha | Premna integrifolia, root | 5 g | Supports Agni, Vata-Kapha balance, and tissue-channel regulation |
| Shyonaka | Oroxylum indicum, root bark | 5 g | Included within the classical root complex for inflammatory and tissue support |
| Patala | Stereospermum suaveolens, root | 5 g | Supports the classical restorative and inflammatory-regulating root complex |
| Gambhari | Gmelina arborea, root | 5 g | Nourishing classical root used for Vata-Pitta balance and tissue recovery |
| Shalaparni | Desmodium gangeticum, root | 5 g | Supports strength, Vata balance, and neurological recovery |
| Prishniparni | Uraria picta, root | 5 g | Supports tissue restoration, strength, and inflammatory balance |
| Brihati | Solanum indicum, root | 5 g | Supports Kapha-Vata regulation and functional channel clearance |
| Kantakari | Solanum xanthocarpum, root | 5 g | Supports Kapha regulation and movement through obstructed functional channels |
| Mudgaparni | Vigna trilobata, whole plant | 5 g | Supports nourishment, strength, and recovery |
| Mashaparni | Teramnus labialis, whole plant | 5 g | Supports Brimhana, tissue nourishment, and Vata balance |
Medhya and Neurological Herbs
These herbs are added as fine powders or concentrated extracts after the decoction has been reduced. Their purpose is to protect cognition, sleep, sensory function, emotional stability, and neurological endurance.
| Ingredient | Botanical identity or form | Quantity | Why it is included |
|---|---|---|---|
| Brahmi | Bacopa monnieri, whole plant | 20 g | Medhya Rasayana for memory, concentration, cognitive endurance, and neurological protection |
| Mandukaparni | Centella asiatica, whole plant | 10 g | Supports cognition, microcirculation, neurological repair, and mental clarity |
| Shankhapushpi | Convolvulus pluricaulis, whole plant | 15 g | Supports concentration, sleep, emotional calm, and mental stamina |
| Jatamansi | Nardostachys jatamansi, rhizome | 10 g | Supports sleep, Vata-Pitta regulation, emotional stability, and neurological calm |
| Vacha | Acorus calamus, rhizome | 3 g | Used in carefully controlled quantity for Medhya action, speech, cognition, and Srotas regulation |
| Yashtimadhu | Glycyrrhiza glabra, root | 10 g | Supports Pitta balance, neurological nourishment, mucosal protection, and medicine tolerance |
| Pippali | Piper longum, fruit | 5 g | Supports bioavailability, Agni, metabolic transformation, and tissue penetration |
| Musta | Cyperus rotundus, rhizome | 5 g | Supports digestion, appetite, inflammatory balance, and treatment tolerance |
| Vidanga | Embelia ribes, fruit | 5 g | Supports Deepana-Pachana, metabolic clearance, and regulation of accumulated Aama |
| Chandana | Santalum album, heartwood | 5 g | Supports cooling Pitta balance, mental calm, and heat-related discomfort |
| Aguru | Aquilaria agallocha, heartwood | 2 g | Aromatic ingredient used for Vata-Kapha regulation and functional channel support |
| Nagakesara | Mesua ferrea, stamens | 5 g | Supports Rakta-Pitta balance, digestive stability, and formulation aroma |
| Ela | Elettaria cardamomum, seed | 3 g | Improves aroma, digestion, palatability, and medicine tolerance |
| Tvak | Cinnamomum verum, bark | 3 g | Supports circulation, digestion, metabolism, and uniform Avaleha assimilation |
Tumour-Directed and Metabolic Additions
These ingredients strengthen the personalised formulation beyond the classical nourishing base. They are selected for abnormal tissue regulation, inflammatory control, oedema, angiogenesis-related pathways, liver support, and metabolic clearance.
| Ingredient | Form | Quantity | Role in the formulation |
|---|---|---|---|
| Haridra | Standardised Curcuma longa extract | 15 g | Supports inflammatory regulation, antioxidant defence, apoptosis-related pathways, and tumour-cell signalling |
| Shallaki | Standardised Boswellia serrata extract | 20 g | Supports inflammatory control, cerebral oedema management, and boswellic-acid-mediated tumour pathways |
| Shuddha Guggulu | Purified Commiphora mukul resin | 15 g | Supports Kapha-Meda regulation, Lekhana action, metabolism, and abnormal tissue control |
| Daruharidra | Standardised Berberis aristata extract | 10 g | Supports Rakta balance, inflammatory regulation, liver function, and metabolic control |
| Kutki | Standardised Picrorhiza kurroa extract | 10 g | Supports liver function, Pitta-Kapha balance, digestion, and processing of a concentrated formulation |
| Tulsi | Ocimum tenuiflorum, leaf | 10 g | Supports antioxidant defence, stress regulation, immunity, and inflammatory balance |
| Shuddha Shilajit | Purified mineral resin | 5 g | Yogavahi and Rasayana component used for strength, metabolism, tissue delivery, and recovery |
| Wild Cordyceps | Whole authenticated material | 10 g | Supports stamina, energy, recovery, and adaptation during prolonged illness |
| Cordyceps extract | Concentrated extract | 5 g | Provides a concentrated adaptogenic and recovery-support component |
| Wild Ginseng | Root powder or authenticated extract | 5 g | Supports physical endurance, cognition, energy, and treatment-related fatigue |
Physician-Selected Mineral Rasayana
The mineral layer is incorporated only after purification, quality assessment, and individual clinical review. The following quantities represent the complete 900 g pharmacy batch and are not individual single-dose quantities.
| Mineral preparation | Quantity in the complete batch | Purpose within the formulation |
|---|---|---|
| Swarna Bhasma | 2.5 g | Medhya-Ojas Rasayana for neurological resilience, vitality, tissue recovery, and long-term strength |
| Heeraka Bhasma | 2 g | Highly concentrated Rasayana component selected for advanced personalised tumour protocols |
| Abhraka Bhasma Sahasraputi | 600 mg | Supports Majja Dhatu, Prana, deep-tissue recovery, strength, and prolonged Rasayana action |
| Lauha Bhasma | 500 mg | Supports Rakta, energy, strength, and recovery where iron status and digestion permit |
| Godanti Bhasma | 500 mg | Supports Pitta regulation and headache-related discomfort |
| Mukta Shukti Bhasma | 300 mg | Supports Pitta balance, digestive comfort, and tolerance of concentrated medicines |
| Rasa Sindura | 250 mg | Yogavahi component used for formulation integration and deep therapeutic delivery |
| Makaradhwaja | 200 mg | Supports Ojas, vitality, tissue restoration, and convalescence |
| Sphatika Bhasma | 150 mg | Traditional cleansing and Pitta-regulating component |
The mineral quantities are distributed uniformly throughout the entire batch through geometric mixing. They are not added directly to an individual spoonful and are not intended for independent preparation.
Avaleha Base and Final Yield
| Base ingredient | Quantity | Function |
|---|---|---|
| Sharkara or jaggery | 100 g | Creates the Avaleha body, improves palatability, and acts as a binding medium |
| Go-Ghrita | 90 g | Sneha medium for Medhya and lipid-soluble constituents; supports Vata-Pitta balance |
| Sesame oil | 20 g | Supports Vata regulation, neurological nourishment, and lipid-soluble extraction |
| Honey | 100 g | Yogavahi Avaleha medium added only after cooling |
| Concentrated herbal decoction | Quantity obtained after reduction | Carries the water-soluble constituents of the decoction herbs |
| Final finished quantity | 900 g | Provides 60 doses of 15 g for a complete 30-day course |
Patient-Friendly Preparation
The pharmacy first authenticates, cleans, and coarsely powders the decoction herbs. These herbs are soaked in purified water and simmered slowly so that their water-soluble constituents pass into the liquid.
The decoction is filtered to remove fibrous plant material and is then reduced to a concentrated herbal base. Amalaki, Haritaki, Bibhitaki, and the other Rasayana components are incorporated according to their required processing stage.
Sharkara or jaggery is dissolved in the concentrated decoction and cooked over controlled heat. Ghee and sesame oil are added gradually while the mixture is stirred until it reaches the required semi-solid Avaleha consistency.
Brahmi, Mandukaparni, Shankhapushpi, Jatamansi, Pippali, Musta, Vidanga, aromatic herbs, tumour-directed extracts, and other fine botanical ingredients are incorporated uniformly at the appropriate warm stage.
The preparation is removed from heat and allowed to cool. Honey is added only after sufficient cooling. The physician-selected Bhasmas and Rasa preparations are then incorporated through geometric dilution so that each 15 g dose contains a uniform proportion of the complete formulation.
The final medicine is adjusted to a net finished weight of 900 g, tested for consistency and quality, and packed in two 450 g containers. Divided packing reduces repeated exposure of the entire medicine to air and moisture.
Dosage and Administration
| Administration detail | Instructions |
|---|---|
| Morning dose | 15 g after breakfast |
| Evening dose | 15 g after the evening meal |
| Total daily dose | 30 g |
| Duration | 30 days |
| Total medicine required | 900 g |
| Measuring method | Standardised 15 g measuring spoon |
| Anupana | Selected according to Prakriti, Agni, symptoms, and current treatment |
| Storage | Keep tightly closed in a cool, dry place and use only a clean, dry spoon |
The first review is performed after approximately 15 days to assess headache, vision, dizziness, seizures, sleep, appetite, bowel function, energy, concentration, walking capacity, and medicine tolerance. The 30-day review determines whether the same core formulation should continue or whether the next batch requires modification.
Research Relevant to the Formulation
| Ingredient or formulation | Research finding | Relevance to meningioma care |
|---|---|---|
| Complete Brahma Rasayana | Experimental studies reported reduced tumour volume, tumour weight, metastasis, VEGF, MMP-2, MMP-9, endothelial migration, and tube formation [7] | Supports the antiangiogenic and tumour-regulating rationale of the complete Rasayana architecture |
| Brahma Rasayana in human patients | A pilot study reported faster recovery of leukocytes, neutrophils, and lymphocytes and reduced oxidative stress during chemotherapy and radiotherapy [3] | Supports systemic resilience, blood-cell recovery, and treatment tolerance |
| Haridra curcuminoids | Human meningioma-cell studies reported reduced proliferation, migration, invasion, and c-MET–PI3K–Akt–mTOR signalling, with apoptosis and xenograft tumour inhibition [8,9] | Provides direct preclinical relevance to meningioma-cell biology |
| Shallaki boswellic acids | AKBA showed cytotoxic activity in primary human meningioma cultures and inhibited ERK1/2 signalling [10] | Supports direct meningioma-cell and inflammatory-pathway targeting |
| Shallaki for cerebral oedema | A controlled clinical study reported a marked reduction in MRI-measured cerebral oedema in a higher proportion of patients receiving Boswellia than placebo [11] | Relevant where oedema and inflammatory pressure contribute to symptoms |
| Pippali-derived piperlongumine | Primary benign and malignant meningioma-cell research reported cell-cycle arrest, oxidative stress, and caspase-dependent apoptosis [12] | Provides direct preclinical relevance to meningioma-cell growth |
| Guduchi | Experimental research reported reduced angiogenesis, endothelial proliferation, VEGF activity, and inflammatory signalling [13] | Supports vascular and inflammatory regulation around abnormal tissue |
| Punarnava | Punarnavine reduced VEGF, MMP-2, MMP-9, ERK1, and ERK2 in experimental tumour models [14] | Supports oedema, angiogenesis, invasion, and tissue-matrix regulation |
| Shuddha Guggulu | Guggulsterone research reported effects on EGFR, PI3K–Akt, NF-κB, VEGF signalling, tumour burden, and microvessel development [15] | Supports Kapha-Meda regulation and tumour-signalling control |
| Ashwagandha | Withania research reported reduced tumour-cell proliferation and migration with neurological and restorative actions [16] | Supports tumour-pathway regulation, sleep, strength, and neurological recovery |
| Brahmi | Bacopa and bacoside research reported apoptosis, cell-cycle regulation, and reduced tumour-cell survival in experimental models [17] | Combines Medhya support with preclinical tumour-related activity |
| Mandukaparni | Experimental research supports neuroprotection, microcirculation, repair signalling, and cognitive recovery | Relevant to neurological function and recovery around the lesion |
| Amalaki | Experimental studies reported antioxidant, anti-invasive, tumour-promoting-pathway, and apoptosis-related effects [18] | Provides the principal Rasayana and antioxidant foundation |
| Haritaki | Experimental research reported cell-cycle arrest, NF-κB regulation, caspase activation, and growth inhibition [19] | Supports metabolic clearance and tumour-regulating Rasayana action |
| Manjistha | Preclinical studies report antioxidant, inflammatory-regulating, and antiproliferative properties | Supports Rakta balance, microcirculation, and tissue regulation |
| Daruharidra | Berberine-related research reports effects on proliferation, apoptosis, AMPK, and inflammatory signalling | Supports metabolic, hepatic, and tumour-signalling regulation |
| Kutki | Experimental findings support antioxidant, liver-protective, inflammatory-regulating, and immune-modulating actions | Supports safe processing and tolerance of a concentrated long-term formulation |
| Tulsi | Preclinical studies report antioxidant, apoptosis-related, anti-inflammatory, and stress-regulating activity | Supports immune balance, stress adaptation, and tissue protection |
| Shilajit | Research supports mitochondrial function, energy metabolism, antioxidant protection, and delivery of co-administered substances | Supports energy, recovery, and Yogavahi action |
| Cordyceps | Preclinical and limited human research supports fatigue reduction, immune regulation, mitochondrial energy, and recovery | Supports stamina and treatment tolerance during prolonged care |
| Ginseng | Research supports fatigue management, cognitive endurance, immune modulation, and adaptation to physiological stress | Supports energy, cognition, and functional recovery |
The formulation combines lesion-directed herbs with Medhya Rasayana, metabolic correction, oedema support, tissue nourishment, and physician-selected mineral Rasayana. Its response is measured through Day 15 and Day 30 clinical outcomes and through comparative MRI, neurological findings, visual testing where relevant, and long-term functional recovery.
Why Market Avaleha May Fail in Meningioma Treatment
Meningioma Ayurvedic treatment should not be started by purchasing a ready-made Brahma Rasayana Avaleha from the market and taking it without individual assessment. A commercial Rasayana may be prepared as a general rejuvenative product, whereas a meningioma programme requires selection of herbs, extracts, dose, Anupana, diet, monitoring, and where appropriate physician-selected Bhasmas according to the tumour, neurological involvement, Prakriti, Agni, age, strength, associated diseases, and current medicines [2,4,39].
A patient should also never attempt to prepare a meningioma Rasayana Avaleha at home without supervision from a qualified Ayurvedic physician. The classical Brahma Rasayana descriptions involve complex processing, specific proportions, sequential addition of ingredients, assessment of Avaleha Paka, and in some versions the use of mineral preparations. Incorrect identification, purification, heating, dosage, or mixing can change both safety and therapeutic action [2,6].
The Same Avaleha Does Not Suit Every Meningioma
Meningioma is not one uniform disease. A small Grade 1 convexity meningioma, an optic-nerve-sheath lesion threatening vision, a postoperative residual tumour, a recurrent Grade 2 meningioma, and an aggressive Grade 3 tumour represent very different clinical situations [4,23].
A ready-made market product cannot automatically account for tumour location, growth rate, oedema, mass effect, cranial-nerve involvement, seizure burden, visual loss, previous surgery, radiotherapy, molecular findings, or the patient’s current neurological function.
For example, a patient with an optic-pathway meningioma may require greater emphasis on Medhya Rasayana, Pitta-Rakta balance, visual support, microcirculation, and oedema regulation. A patient with seizures and weakness may require stronger Vata regulation, Majja support, sleep stabilisation, and neurological protection. A single commercial formulation cannot be expected to address both patterns equally.
Age Changes the Treatment Requirement
Age strongly affects treatment planning. A 25-year-old patient with strong digestion and good physical reserve may tolerate a concentrated Rasayana differently from a 70-year-old patient with reduced appetite, constipation, muscle loss, hypertension, diabetes, or multiple prescription medicines.
Older patients may require lower introductory doses, greater digestive support, slower escalation, closer liver and kidney monitoring, and stronger attention to sleep, balance, cognition, and fall risk.
Younger patients may tolerate treatment more easily, but age alone does not determine response. Tumour grade, location, duration, constitution, digestion, and previous treatment remain important.
Disease Duration Matters
A recently detected, slowly growing lesion is different from a meningioma that has been present for many years and has gradually produced oedema, seizures, vision loss, neurological weakness, or structural compression.
Long-standing disease may be associated with deeper Dhatu involvement, chronic Vata disturbance, reduced Bala, altered sleep, prolonged medication exposure, and greater functional loss. Such patients may require a longer and more staged Rasayana programme.
A ready-made product cannot adjust itself according to whether the disease has been present for six months or ten years.
Tumour Grade and Biological Behaviour Matter
WHO Grade 1, Grade 2, and Grade 3 meningiomas have different biological behaviour and recurrence risk [23,24].
Grade 1 disease may require emphasis on long-term control, neurological restoration, and stable imaging. Grade 2 disease may require stronger lesion-directed treatment and closer monitoring because recurrence risk is higher. Grade 3 disease requires the most intensive and closely monitored programme.
A general market Avaleha is not formulated according to tumour grade, brain invasion, mitotic activity, TERT-promoter mutation, CDKN2A/B status, NF2 alteration, or other available molecular information.
Tumour Location Changes the Formula
The location of a meningioma often matters as much as its size.
An optic-nerve-sheath meningioma may threaten vision. A parasellar lesion may affect the optic pathway or pituitary region. A frontal meningioma may affect behaviour, judgement, memory, or concentration. A parasagittal tumour may cause seizures or limb weakness. A spinal meningioma may affect walking, sensation, or bladder function.
The Rasayana formulation must therefore be designed around the structures at risk. Market Brahma Rasayana is ordinarily not customised according to whether the treatment priority is vision, cognition, seizure control, motor recovery, pituitary function, or spinal-cord protection.
Other Chronic Diseases Can Alter the Response
Associated medical conditions can substantially change both the formulation and dose.
Diabetes or insulin resistance may require modification of the Avaleha sweet base and closer glucose monitoring. Hypertension and fluid retention may change sodium, fluid, Punarnava, and oedema-management decisions. Liver disease may affect the choice and concentration of extracts, Bhasmas, and other metabolically active medicines.
Kidney disease requires particular caution with concentrated herbal and mineral preparations. Thyroid disease, cardiac disease, autoimmune disorders, anaemia, digestive disease, obesity, chronic constipation, and hormonal disorders can also change the treatment plan.
A patient with meningioma plus diabetes, chronic kidney disease, and hypertension should not receive the same ready-made formulation as a patient of the same age with normal metabolic, renal, and cardiovascular function.
Current Medicines Must Be Reviewed
Many meningioma patients take antiseizure medicines, corticosteroids, anticoagulants, antihypertensives, diabetes medicines, thyroid medicines, pain medicines, hormonal therapies, or postoperative medications.
These medicines influence the Ayurvedic prescription, administration timing, diet, and monitoring plan. Sedation, liver metabolism, glucose levels, bleeding risk, bowel function, appetite, sleep, and neurological symptoms must be considered before concentrated Rasayana treatment is started.
A market product cannot evaluate these interactions before being purchased.
Prakriti and Vikriti Change the Formula
Two patients with the same MRI diagnosis may have completely different Prakriti and Vikriti.
A Vata-predominant patient may present with constipation, insomnia, anxiety, weakness, dizziness, and weight loss. A Kapha-predominant patient may have heaviness, slow digestion, obesity, fluid retention, and excessive sleep. A Pitta-predominant patient may have acidity, burning sensations, inflammatory eye symptoms, irritability, and disturbed sleep.
The Brahma Rasayana base may remain similar, but the proportions of warming, cooling, nourishing, metabolic, neurological, and lesion-directed components must change according to the active pattern [39].
Weak Agni Can Make a Strong Avaleha Ineffective
A potent Rasayana is useful only when the patient can digest and assimilate it.
Weak Agni may present with low appetite, heaviness after meals, bloating, nausea, constipation, loose stools, coated tongue, or fatigue after eating. A rich Avaleha taken in this state may produce more heaviness and reduce adherence instead of producing the intended therapeutic effect.
Some patients therefore require Deepana-Pachana support before or during Brahma Rasayana therapy. Others may need a lower initial dose and gradual escalation.
The same 15 g dose may not be appropriate from the first day for every patient.
Wrong Anupana Can Reduce the Intended Effect
The vehicle taken with the medicine is selected according to the patient’s constitution and treatment objective.
Warm water may suit a Kapha-dominant patient with heaviness and slow digestion. A nourishing vehicle may be selected for a depleted Vata-predominant patient. A Pitta-sensitive patient may require a different approach when acidity or heat is prominent.
Using the wrong Anupana can increase heaviness, acidity, dryness, heat, or bowel disturbance and may reduce the patient’s ability to continue treatment.
Inappropriate Diet Can Reduce Treatment Response
A patient may take an expensive personalised medicine but continue eating in a way that repeatedly aggravates the same digestive and metabolic disturbance.
Excessive refined sugar, fried food, frequent processed meals, alcohol, irregular eating, prolonged fasting, large late-night meals, or foods unsuitable for the patient’s Prakriti and Agni can interfere with digestion and treatment tolerance.
The diet must also change when the patient has diabetes, steroid-induced hyperglycaemia, obesity, weight loss, constipation, oedema, or poor appetite.
The medicine and diet therefore have to be planned together.
Poor Sleep and Chronic Stress Can Slow Recovery
Sleep is important for neurological recovery, cognition, seizure stability, hormonal regulation, appetite, and treatment tolerance.
A patient sleeping four hours each night, using stimulants heavily, or living with severe chronic stress may experience slower improvement in fatigue, memory, concentration, headache, and neurological resilience.
Ayurvedic treatment therefore addresses sleep, daily routine, mental strain, and Ojas alongside the lesion-directed formulation.
Previous Surgery or Radiotherapy Changes the Requirement
A patient who has never undergone treatment may require a different Rasayana programme from a patient recovering after craniotomy, radiotherapy, radiosurgery, or repeated procedures.
Postoperative patients may have weakness, reduced appetite, cognitive fatigue, constipation, sleep disturbance, seizures, or residual neurological deficits.
Patients after radiotherapy may require stronger attention to fatigue, tissue recovery, oxidative stress, appetite, blood counts, neurological function, and previously irradiated tissues.
A commercial Avaleha cannot automatically adjust to these differences.
Residual and Recurrent Tumours Need Different Planning
Residual tumour after surgery and recurrent meningioma are not equivalent to a newly diagnosed stable lesion.
Recurrence may reflect higher tumour grade, difficult anatomical location, incomplete removal, molecular risk factors, or previous radiation exposure. These patients often require closer MRI monitoring and a stronger lesion-directed component.
Treatment should be designed after reviewing the previous operation, pathology, radiotherapy, recurrence interval, present tumour size, and current symptoms.
Raw-Material Quality Can Change the Medicine
The therapeutic quality of an Avaleha depends on the authenticity, age, storage, harvesting, processing, and potency of its ingredients.
Two products carrying the same formulation name may contain herbs of different botanical identity, geographical source, concentration, phytochemical profile, or storage quality.
Standardised extracts also differ according to active-marker concentration. For example, a generic turmeric powder and a properly standardised curcuminoid extract do not provide the same concentration of active constituents.
The same applies to Boswellia, Ashwagandha, Guduchi, Pippali, Brahmi, and other important components.
Incorrect Bhasma Selection Can Be Unsafe
Swarna Bhasma, Heeraka Bhasma, Abhraka Bhasma, Lauha Bhasma, Mukta preparations, Rasa Sindura, Makaradhwaja, and other mineral medicines should never be added merely because they are considered “powerful.”
Their selection depends on the patient’s Bala, Agni, liver and kidney function, current medicines, age, blood reports, and treatment objective.
Incorrect purification, Marana, particle characteristics, contamination, excessive dose, or inappropriate combination can change both efficacy and safety.
A patient should therefore never buy individual Bhasmas online and mix them into a commercial Avaleha.
Preparation Method Changes Therapeutic Quality
Avaleha preparation is not simply mixing herbal powders with honey and ghee.
The decoction must be extracted and reduced correctly. The sweet medium must reach the appropriate Paka. Ghee and other lipid media must be incorporated at the correct stage. Fine powders must be added at an appropriate temperature. Honey should be introduced only after sufficient cooling.
Bhasmas and heat-sensitive extracts must be distributed uniformly throughout the finished batch. Poor mixing can produce uneven concentration between individual doses.
Incorrect preparation can therefore convert a carefully designed formulation into an inconsistent product.
Storage and Shelf Conditions Matter
Heat, moisture, repeated contamination from wet spoons, prolonged exposure to air, poor-quality containers, or incorrect storage can alter the texture, microbial quality, aroma, and stability of an Avaleha.
The patient should receive a properly packed batch with a defined manufacturing date, storage instructions, and traceable formulation record.
A product kept for prolonged periods under unknown warehouse or retail conditions may differ from a freshly prepared patient-specific batch.
Missing Follow-Up Is a Common Reason for Poor Results
Even a correctly prepared formulation may need modification after the first treatment cycle.
The Day 15 review identifies early response, digestion, sleep, appetite, bowel changes, neurological stability, and tolerance. The Day 30 review determines which therapeutic objectives remain active.
For example, if headache improves but constipation remains severe, the next batch may require stronger Agni and bowel support. If digestion becomes strong but visual symptoms remain, greater emphasis may be placed on Medhya, Majja, Pitta-Rakta, and visual-supportive components.
A ready-made medicine purchased repeatedly from the market cannot evolve according to these changes.
Treatment Gaps Can Delay Progress
Personalised Rasayana is designed for regular administration. Frequent gaps caused by delayed ordering, irregular dosing, travel, poor adherence, or discontinuation whenever symptoms improve can interrupt the intended treatment sequence.
The next batch should therefore be planned before the current supply ends, particularly for international patients who may experience courier or customs delays.
Never Prepare This Medicine Without Ayurvedic Medical Supervision
Brahma Rasayana Avaleha for a patient with meningioma should be prepared only after clinical assessment by a qualified Ayurvedic physician.
The patient should not copy an ingredient list from an article, purchase individual herbs and Bhasmas, calculate mineral quantities independently, or attempt to reproduce the formulation at home.
An ingredient list published for educational purposes cannot account for the patient’s tumour location, grade, age, Agni, Prakriti, liver and kidney function, diabetes, hypertension, seizure medicines, anticoagulants, hormonal treatment, previous surgery, radiotherapy, or current neurological condition.
The correct sequence is medical-report review, Ayurvedic assessment, personalised prescription, professionally controlled preparation, defined dosage, Day 15 review, Day 30 review, and objective follow-up through MRI and relevant neurological or visual investigations.
A market Avaleha may carry the same name, but the name of the formulation does not make it the same treatment. In meningioma care, the therapeutic value comes from correct patient selection, correct ingredients, correct quantities, correct preparation, correct dose, correct Anupana, appropriate diet, continuous administration, and repeated modification according to the patient’s clinical and imaging response.
Measuring Meningioma Treatment Response

Meningioma Ayurvedic treatment should be evaluated through a defined pretreatment baseline, structured clinical reviews, neurological assessment, and comparative imaging. This allows changes in symptoms, daily function, vision, seizure burden, oedema, mass effect, and tumour dimensions to be followed separately while the patient continues the personalised Brahma Rasayana Avaleha programme.
Baseline Before Treatment
The latest contrast-enhanced MRI should be reviewed before the first dose. The report should identify the tumour’s exact anatomical location, three-dimensional measurements, enhancement pattern, surrounding oedema, mass effect, contact with the brain, cranial nerves, blood vessels, venous sinuses, pituitary region, optic pathway, or spinal cord, and any change compared with earlier imaging [4].
Previous MRI or CT studies are clinically valuable because they reveal whether the lesion has remained stable, enlarged slowly, or changed more rapidly. A single scan shows the present anatomy, while serial scans provide information about tumour behaviour and help establish the correct timing for future comparison.
The baseline record should include the date and type of imaging, the scanner findings, the radiologist’s impression, and whether the diagnosis is radiological or confirmed through histopathology. When surgery or biopsy has been performed, the pathology report should record the WHO grade, histological subtype, proliferation findings, brain invasion where present, and available molecular information.
Symptoms must be recorded in measurable terms before treatment begins. Headache should be documented by days per week, average intensity, duration, and rescue-medicine use. Dizziness should be recorded by frequency and its effect on walking or ordinary activity. Sleep should be measured by total hours, awakenings, and morning freshness. Energy should be connected to practical abilities such as working, studying, walking, cooking, reading, or completing household responsibilities.
The same approach applies to neurological symptoms. Seizures should be recorded by number, duration, pattern, warning symptoms, loss of awareness, movements, and recovery time. Weakness, numbness, balance difficulty, speech disturbance, memory change, and reduced concentration should be described according to their effect on independent daily function.
A dated baseline photograph, video of gait, handwriting sample, reading tolerance, work capacity, or caregiver observation may provide additional functional evidence when the tumour affects movement, speech, coordination, cognition, or behaviour. These records help identify gradual recovery that may not be fully represented by one symptom score.
Day 15 Clinical Review
The Day 15 review evaluates early response to Brahma Rasayana Avaleha and confirms that the medicine is being digested and tolerated correctly. The patient’s present condition is compared with the baseline using the same symptom and functional measurements.
Headache improvement may appear as fewer headache days, lower peak intensity, shorter episodes, or reduced reliance on rescue medicine. A patient with eye pressure or visual discomfort may report improved reading tolerance, less pain behind the eye, reduced light sensitivity, or greater comfort during screen use.
Digestive response is assessed through appetite, food tolerance, abdominal heaviness, acidity, nausea, bloating, and bowel regularity. These findings help determine whether Agni is supporting the concentrated Avaleha or whether the dose, timing, Anupana, or digestive component requires adjustment.
Sleep and energy provide additional information about systemic recovery. More restorative sleep, improved morning freshness, reduced daytime fatigue, and increased participation in ordinary activity indicate that the patient is tolerating the programme and beginning to regain functional strength.
Neurological symptoms are assessed with particular attention to any change in seizure frequency, limb function, balance, speech, memory, concentration, visual function, or hearing. Stable neurological function with early symptomatic improvement supports continuation of the programme, while the formulation can be refined according to the functions that still require attention.
The Day 15 review primarily measures clinical and functional response. Imaging is arranged earlier when symptoms or neurological findings require immediate anatomical reassessment. In a stable patient, the Rasayana programme continues while the agreed interval for comparative imaging is maintained.
Day 30 Clinical Review
The Day 30 review compares the patient’s condition with both baseline and Day 15. This establishes whether the early response has continued, whether improvements are becoming more consistent, and whether the next treatment cycle should retain or modify the original formulation.
A meaningful first-month response may include a reduction in headache frequency, improved visual comfort, fewer dizziness episodes, better sleep, increased appetite, regular bowel function, improved concentration, reduced fatigue, more confident walking, fewer seizures, or a return to work, study, household activity, or independent self-care.
The result should be stated through exact changes. A patient whose headache reduced from seven days per week to two days per week has a measurable outcome. A patient whose comfortable reading time increased from thirty minutes to three hours has a functional outcome. A patient whose sleep increased from four interrupted hours to seven restorative hours has a documented recovery parameter.
Symptoms that remain present are also reviewed because they guide the next formulation. Persistent constipation may require stronger Agni and bowel support. Continued insomnia may require greater Vata-Pitta regulation. Ongoing visual fatigue may require additional Medhya and eye-supportive Rasayana. Residual weakness may require stronger Brimhana and Majja-nourishing components.
The second 30-day batch may therefore retain the core Brahma Rasayana foundation while changing the relative emphasis of lesion-directed, neurological, digestive, restorative, or mineral ingredients. This allows the medicine to evolve with the patient’s changing condition rather than repeating an unchanged formulation throughout the entire course.
Comparative MRI Assessment
MRI is the principal imaging method for monitoring most intracranial meningiomas because it demonstrates the lesion’s size, enhancement, relationship with surrounding tissues, oedema, and pressure on neighbouring neurological structures [4].
The follow-up MRI should be compared directly with the pretreatment study. Where possible, similar contrast administration, slice thickness, anatomical planes, and imaging sequences should be used so that small differences are less likely to reflect technical variation.
The comparison should assess all three tumour dimensions rather than relying on one diameter. Volumetric analysis can provide additional value when the lesion has an irregular shape, extends around the optic nerve or cavernous sinus, involves a venous sinus, or cannot be represented accurately by one linear measurement.
The radiological review should examine whether enhancement has changed, whether oedema has reduced, whether mass effect has improved, whether compressed brain structures have regained space, and whether the relationship with the optic pathway, pituitary stalk, brainstem, spinal cord, cranial nerves, or major blood vessels has changed.
Bone involvement should also be reviewed in skull-base meningiomas. CT may provide additional information about calcification, hyperostosis, erosion, or other bony changes when these findings are important for monitoring the lesion.
A favourable treatment response may be expressed as reduction in tumour dimensions or volume, reduced oedema, decreased mass effect, improved separation from a compressed structure, or durable radiological stability accompanied by neurological and functional recovery. Each outcome should be stated with the exact baseline and follow-up dates.
Vision and Optic Pathway Monitoring
Meningiomas involving the optic nerve sheath, optic canal, sphenoid wing, tuberculum sellae, parasellar region, cavernous sinus, or nearby visual pathways require specialised visual monitoring in addition to MRI.
Visual acuity should be measured separately in each eye. Automated visual fields help identify changes in peripheral or central vision. Colour-vision testing may detect optic-nerve dysfunction that is not fully reflected by ordinary visual-acuity testing.
Optical coherence tomography measures the retinal nerve fibre layer and ganglion-cell complex. Serial OCT findings can help document structural changes in the visual pathway when interpreted together with visual acuity, visual fields, colour vision, optic-disc appearance, and MRI.
Eye movement, double vision, eyelid position, eye prominence, pupil response, and facial sensation may also require assessment when the tumour affects the cavernous sinus, orbital apex, sphenoid wing, or cranial nerves controlling eye movement.
The patient should record practical visual function between formal examinations. Reading duration, screen tolerance, night vision, colour perception, eye pressure, light sensitivity, and the ability to perform detailed work provide meaningful evidence of how the condition affects daily life.
Seizure and Neurological Monitoring
Patients with seizure-associated meningioma should maintain a dated seizure record throughout treatment. The record should include focal symptoms, altered awareness, unusual fear, déjà vu, smell or taste sensations, limb movements, convulsions, loss of consciousness, duration, and recovery time.
A reduction in seizure frequency, duration, or post-seizure fatigue can represent meaningful neurological improvement. Existing antiseizure medicines should be recorded accurately so that any change in seizure burden can be interpreted in the correct treatment context.
Motor function can be monitored through grip strength, ability to rise from a chair, walking distance, stair climbing, balance, coordination, and independence in dressing or bathing. Speech and cognitive function may be followed through word finding, memory, attention, reading, writing, calculation, and the ability to complete work or study tasks.
Caregiver observations are especially valuable when the tumour affects personality, judgement, motivation, emotional regulation, or awareness of symptoms. Family members may identify gradual improvement in communication, initiative, memory, patience, or participation before the patient recognises the change independently.
Long-Term Follow-Up
The first month establishes treatment tolerance and early clinical direction, while long-term follow-up determines whether the response remains durable. Serial MRI, neurological assessment, visual testing where relevant, symptom records, and functional outcomes are reviewed together.
Follow-up intervals depend on tumour grade, location, previous growth, symptoms, treatment history, and current response. Grade 1 disease is generally monitored less frequently than Grade 2 or Grade 3 disease, while lesions affecting vision, the brainstem, spinal cord, major vessels, or rapidly changing neurological functions require closer assessment [4].
A complete long-term outcome records the latest imaging date, present tumour dimensions, oedema, mass effect, neurological function, visual status, seizure burden, daily independence, treatment duration, current dosage, and whether the patient has resumed normal work, education, travel, or family activity.
The Brahma Rasayana Avaleha programme is continued, modified, reduced, or consolidated according to the combined clinical and imaging response. This allows the curative-intent treatment to remain focused on both measurable control of the meningioma and restoration of the patient’s neurological and functional health.
Meningioma Ayurvedic Treatment by Tumour Location

Meningioma Ayurvedic treatment must be adapted to the tumour’s location because the same-sized lesion can produce very different symptoms depending on which brain region, cranial nerve, blood vessel, pituitary structure, optic pathway, or spinal segment is affected. MRI findings define the anatomy, while neurological symptoms, vision, cognition, balance, strength, speech, seizures, sleep, digestion, and functional independence determine the priorities of the personalised Brahma Rasayana Avaleha programme [4].
Tumour location also influences how improvement should be measured. A patient with an optic-pathway meningioma requires visual monitoring, while a patient with a frontal lesion may need repeated assessment of memory, judgement, attention, and behaviour. A patient with a parasagittal lesion may require seizure and limb-strength tracking, whereas a spinal meningioma requires assessment of walking, sensation, and bladder or bowel function.
Frontal Meningioma
A frontal meningioma may initially produce subtle changes rather than severe pain. The patient may develop reduced concentration, poor short-term memory, difficulty planning work, slowed decision-making, emotional instability, loss of motivation, inappropriate behaviour, altered personality, speech difficulty, or weakness affecting the opposite side of the body.
Family members may recognise the change before the patient does. Reduced initiative, repeated mistakes, forgetfulness, irritability, unusual withdrawal, or inability to manage ordinary responsibilities may be interpreted incorrectly as stress, depression, ageing, or lack of interest.
Treatment monitoring should therefore include attention span, memory, speech, emotional regulation, work capacity, sleep, and the ability to complete multistep tasks. Caregiver observations are valuable because frontal dysfunction can reduce the patient’s awareness of their own difficulties.
The Brahma Rasayana Avaleha may place greater emphasis on Medhya Rasayana, Majja nourishment, Vata stabilisation, restorative sleep, and cognitive endurance. Brahmi, Mandukaparni, Shankhapushpi, Jatamansi, Ashwagandha, Yashtimadhu, and physician-selected mineral Rasayana may be adjusted according to the patient’s digestion, fatigue, behaviour, sleep, and neurological findings.
Convexity and Parasagittal Meningioma
Convexity meningiomas develop along the outer surface of the brain, while parasagittal lesions arise close to the falx and superior sagittal sinus. Symptoms may include headache, seizures, weakness, numbness, altered coordination, speech difficulty, or progressive problems affecting one side of the body [4].
Parasagittal lesions near the motor region may affect leg strength before arm function. The patient may notice dragging of one foot, difficulty climbing stairs, repeated falls, reduced walking distance, or increasing dependence on support. Tumours involving the venous sinus may also be associated with oedema and greater pressure effects.
The baseline assessment should record seizure frequency, limb strength, grip, walking distance, balance, sensory change, speech, headache burden, and independence in dressing, bathing, and household activity. A dated gait video may help document gradual changes during treatment.
The Rasayana programme may require stronger Vata regulation, Majja support, neurological nourishment, and measures directed toward oedema, inflammation, and tissue congestion. Punarnava, Guduchi, Shallaki, Manjistha, Bala, Ashwagandha, Brahmi, and other case-specific ingredients may be balanced with the lesion-directed component according to imaging and clinical response.
Sphenoid-Wing and Optic-Pathway Meningioma
Sphenoid-wing, tuberculum sellae, optic-canal, orbital, and optic-nerve-sheath meningiomas may affect visual function before causing obvious general neurological symptoms. Patients may experience blurred vision, reduced colour perception, double vision, loss of peripheral vision, eye prominence, pain or pressure behind the eye, eyelid changes, headache, or difficulty reading.
Visual decline may progress slowly and can affect one eye more than the other. A patient may compensate unconsciously until the stronger eye is covered or formal visual-field testing reveals a deficit.
Monitoring should include visual acuity in each eye, colour vision, automated visual fields, optic-disc examination, eye movements, pupil response, optical coherence tomography, reading tolerance, screen tolerance, and MRI comparison. Subjective reduction in eye pressure should be documented separately from measurable visual recovery.
The Brahma Rasayana Avaleha may emphasise Medhya Rasayana, Pitta-Rakta balance, microcirculation, Majja nourishment, visual comfort, sleep, and inflammatory regulation. Brahmi, Mandukaparni, Jivanti, Yashtimadhu, Manjistha, Guduchi, Amalaki, Shallaki, Mukta-based preparations, and other selected ingredients may be adjusted according to visual findings, digestion, and medicine tolerance.
Parasellar and Cavernous-Sinus Meningioma
Parasellar and cavernous-sinus meningiomas develop close to the pituitary gland, optic pathways, internal carotid artery, and cranial nerves controlling eye movement and facial sensation. Symptoms may include double vision, eyelid drooping, restricted eye movement, facial numbness, visual loss, headache, eye pressure, hormonal disturbance, or changes related to pituitary compression.
The published Ayurvedic case involved a large left parasellar meningioma that extended medially and superiorly, displaced the pituitary stalk, and indented an orbital neural structure. The response was assessed after one month through contrast-enhanced CT [1].
Patients with this location require assessment of vision, eye movement, facial sensation, headache, and relevant endocrine findings. Menstrual changes, altered thirst, abnormal urination, fatigue, unexplained weight change, or other hormonal symptoms may require pituitary testing according to the imaging findings.
The personalised Rasayana programme may require coordinated Medhya, Majja, Pitta-Rakta, Vata, and metabolic support. Treatment response should be documented through imaging, visual function, cranial-nerve findings, endocrine assessment where indicated, and changes in daily activity.
Olfactory-Groove Meningioma
Olfactory-groove meningiomas arise near the nerves responsible for smell and may grow considerably before causing obvious symptoms. Reduced or absent smell may be accompanied by headache, personality change, memory difficulty, reduced judgement, visual symptoms, or altered behaviour.
Loss of smell may affect appetite, enjoyment of food, safety awareness, and quality of life. Patients may be unable to detect smoke, spoiled food, gas, or other environmental hazards.
The clinical record should include smell function, appetite, weight, headache, concentration, memory, behaviour, visual symptoms, and daily safety. Caregiver observations are particularly useful when frontal-lobe pressure affects judgement or personality.
Treatment may emphasise Medhya Rasayana, neurological recovery, appetite, Agni, smell-related sensory function, Vata regulation, and tissue-directed therapy. Changes in smell should be recorded with the same test or practical method at each review.
Posterior-Fossa Meningioma
Posterior-fossa meningiomas may affect the cerebellum, brainstem, cranial nerves, or pathways responsible for balance, swallowing, hearing, facial movement, and coordination. Symptoms may include dizziness, vertigo, unsteady walking, hearing loss, ringing in the ears, facial weakness, facial pain, difficulty swallowing, slurred speech, nausea, or limb incoordination.
A patient may initially describe the problem as recurrent vertigo, ear disease, cervical discomfort, or general weakness. Progressive imbalance, repeated falls, difficulty using the hands, swallowing changes, or altered speech require careful neurological assessment.
Monitoring should record walking distance, balance, falls, coordination, hearing, facial symptoms, speech, swallowing, nausea, headache, and independence in ordinary activities. Rehabilitation may include balance training, physiotherapy, swallowing assessment, speech therapy, or hearing evaluation according to the affected function.
The Rasayana formulation may place greater emphasis on Vata stabilisation, Majja support, neurological coordination, anti-inflammatory action, strength, digestion, and nausea control. The medicine must remain sufficiently light and digestible when dizziness, poor appetite, or nausea limits oral intake.
Spinal Meningioma
Spinal meningiomas arise from the meninges surrounding the spinal cord and may compress the cord or nearby nerve roots. Symptoms can include back pain, radiating pain, numbness, tingling, stiffness, weakness, altered walking, loss of balance, reduced hand function, or changes in bladder and bowel control.
Symptoms depend on the spinal level involved. Cervical lesions may affect the arms and legs, thoracic lesions commonly affect the trunk and lower limbs, and lower spinal lesions may affect leg function and pelvic control.
The baseline should document pain location, sensory changes, muscle strength, walking distance, stair climbing, balance, bladder function, bowel function, sleep, and independence. Serial neurological assessment and spinal MRI are required to determine whether cord compression is improving, stable, or progressing [4].
The personalised Brahma Rasayana Avaleha may emphasise Vata regulation, Majja and Asthi support, muscle strength, sensory recovery, bowel regulation, inflammation, and oedema. Bala, Ashwagandha, Guduchi, Guggulu, Punarnava, Shallaki, Medhya herbs, and case-specific mineral Rasayana may be selected according to strength, digestion, neurological findings, and imaging.
Symptoms Requiring Immediate Reassessment
A sudden seizure, rapidly worsening vision, new weakness, loss of balance, altered speech, repeated vomiting, increasing drowsiness, confusion, loss of consciousness, difficulty swallowing, or sudden bladder or bowel dysfunction may indicate a significant neurological change. These symptoms require prompt local assessment and updated imaging rather than waiting for the next scheduled Rasayana review.
The Ayurvedic programme is then reassessed using the new findings. The formulation, dosage, monitoring interval, and treatment priorities are adjusted according to the updated neurological and radiological status.
Meningioma Ayurvedic Treatment: Causes

Meningioma Ayurvedic treatment begins by identifying both the recognised biological drivers of the tumour and the patient’s individual Ayurvedic Nidana and Samprapti. Nidana refers to causative and predisposing factors, while Samprapti describes the pathway through which those factors disturb Dosha, tissue metabolism, functional channels, neurological activity, and recovery capacity. Most meningiomas do not arise from one single cause; they develop through a combination of acquired molecular changes, age-related susceptibility, hormonal influences, previous exposures, inherited predisposition, and the internal tissue environment of the patient [4,23].
Sporadic Molecular Causes
Most meningiomas are sporadic, meaning that they develop without an inherited tumour syndrome or an identifiable external event. Cells associated with the meninges gradually acquire molecular changes that alter normal control of cell growth, tissue organisation, repair, and survival.
Alteration of the NF2 gene or loss of chromosome 22q is one of the most frequent molecular pathways. Other meningiomas may develop through alterations involving TRAF7, KLF4, AKT1, PIK3CA, SMO, POLR2A, SUFU, SMARCE1, BAP1, or related pathways. These changes can influence tumour location, microscopic appearance, rate of growth, recurrence risk, and biological behaviour [23,24].
An NF2-altered meningioma is more commonly found along the cerebral convexity, falx, or posterior and lateral skull base. Tumours with AKT1, SMO, TRAF7, KLF4, or PIK3CA alterations are more frequently associated with particular anterior or midline skull-base locations. These molecular patterns help explain why two patients with the same diagnosis may have different symptoms and treatment responses [23,24].
Changes such as a TERT-promoter mutation or homozygous loss of CDKN2A/B are associated with more aggressive biological behaviour. These are usually tumour-acquired findings rather than abnormalities inherited from a parent. They can be identified only through examination of tumour tissue and molecular testing, not through symptoms, MRI, Prakriti, or pulse examination [23,24].
Age contributes to susceptibility because molecular errors and altered cellular repair accumulate over time. Meningioma incidence rises substantially in older adults, although the tumour can also occur in children, adolescents, and young adults when an inherited syndrome, previous radiation exposure, or rare molecular pathway is present [23].
Hormonal Causes
The marked predominance of meningioma among women and the frequent expression of progesterone receptors within tumour tissue indicate that hormonal signalling can influence meningioma development and growth. Hormonal sensitivity differs between tumours and should be assessed through the patient’s medication history, reproductive history, tumour location, pathology, and pattern of growth [4,23].
Pregnancy is not established as a general cause of new meningioma formation. Hormonal, vascular, and fluid changes during pregnancy can, however, accelerate the growth or clinical expression of an existing tumour. A previously silent lesion may become symptomatic through increasing headache, visual change, seizures, cranial-nerve dysfunction, or raised intracranial pressure [23].
Long-term exposure to certain progestogen medicines is a recognised medication-related cause of meningioma in a small proportion of patients. The strongest associations have been reported with high-dose cyproterone acetate, nomegestrol acetate, chlormadinone acetate, injectable medroxyprogesterone acetate, medrogestone, and promegestone. Risk is influenced by the specific medicine, cumulative dose, duration, and route of administration [21,23].
Injectable medroxyprogesterone acetate has shown a stronger association when used over several years. A nationwide French analysis reported an odds ratio of approximately 5.6 for meningioma requiring surgery among women exposed to prolonged injectable medroxyprogesterone. A later Danish study also found a substantially increased association with recent injectable medroxyprogesterone use [21,22].
Desogestrel 75 micrograms was associated with a smaller increase in risk after prolonged continuous exposure, particularly beyond five years. The French study did not identify an increased risk with the levonorgestrel preparations examined, while later Danish data reported associations with some combined contraceptives and higher-dose levonorgestrel intrauterine systems. These differences make the exact medicine, dose, duration, and national formulation clinically relevant [20,22].
Patients should provide the name, dose, route, start date, duration, and indication for contraceptive injections, oral progestogens, intrauterine hormonal systems, fertility medicines, endometriosis treatment, and menopausal hormone therapy. Some progestogen-associated meningiomas stabilise or regress after the implicated medicine is withdrawn, but the response must be confirmed through serial MRI rather than assumed from discontinuation alone [20–22].
The Ayurvedic formulation is adjusted when hormonal exposure, menstrual disturbance, fluid retention, weight change, Pitta-Rakta aggravation, Kapha-Meda accumulation, or impaired liver metabolism forms part of the patient’s presentation. Hormonal medicines should be reviewed in coordination with the prescribing clinician so that contraception, fertility care, menopause, or gynaecological disease remains appropriately managed.
Radiation-Induced Meningioma
Previous ionising radiation to the head is the best-established environmental cause of meningioma. Radiation-induced tumours may occur after treatment for childhood leukaemia, lymphoma, brain tumours, retinoblastoma, scalp disorders, or other head and neck conditions. The risk increases with radiation dose and is particularly important when exposure occurred during childhood [23,25].
Radiation-induced meningioma commonly appears decades after the original exposure. A recent pooled analysis reported a median latency of approximately 23 years, with cases occurring from less than one year to more than six decades after radiation. Higher radiation doses and exposure at a younger age were associated with earlier tumour development [25].
These tumours may be multiple, more frequently higher grade, and more likely to recur than ordinary sporadic meningiomas. A patient who received cranial or scalp radiation many years earlier should provide the original diagnosis, age at exposure, anatomical field, total dose, number of fractions, and available treatment records [25].
From the Ayurvedic perspective, radiation represents an Agantuja or externally originating tissue injury. The external insult may later disturb Pitta and Rakta through heat and tissue damage, Vata through neurological injury and degeneration, and Kapha-Meda through altered repair and persistent tissue organisation. The resulting internal Dosha and Dhatu disturbance is assessed even when the external exposure occurred decades earlier.
Brahma Rasayana Avaleha may then require greater emphasis on tissue restoration, oxidative-stress regulation, Rakta support, Majja nourishment, Ojas, neurological recovery, and long-term surveillance. The previous radiation field and present MRI findings remain central to treatment planning.
Rare Inherited Causes
Most patients with meningioma do not have an inherited syndrome. Genetic evaluation becomes more relevant when meningioma develops at a young age, when several intracranial or spinal tumours are present, when close relatives have related tumours, or when pathology shows a rare clear-cell, rhabdoid, or papillary pattern [23,24].
NF2-related schwannomatosis is the most recognised inherited meningioma predisposition. Affected patients may develop multiple meningiomas, bilateral vestibular schwannomas, spinal tumours, ependymomas, or other nervous-system lesions. Mosaic NF2 alterations can produce a milder or localised pattern even when there is no obvious family history [23].
Inherited SMARCE1 variants predispose to clear-cell meningiomas, which may occur in the brain or spinal canal and can present in children, adolescents, or young adults. Multiple tumours or a clear-cell meningioma at an unusually young age should prompt consideration of familial assessment [23,24].
Germline SMARCB1 variants can produce familial multiple meningiomas, often involving the falx, and may also be associated with schwannomas. The family history may include different tumour types rather than identical meningiomas in every affected relative [23].
BAP1 tumour-predisposition syndrome is a rare inherited condition associated with uveal melanoma, mesothelioma, renal tumours, and certain aggressive rhabdoid or papillary meningiomas. Loss of BAP1 within a meningioma can indicate a higher-risk biological pattern and may justify genetic counselling when the personal or family cancer history is suggestive [23,24].
Inherited alterations involving SUFU or PTCH1 can occur in Gorlin syndrome or rare familial multiple-meningioma families. SUFU-altered tumours may show recurrent or higher-grade behaviour in some patients, while SMO-altered tumours more often arise in the skull base and follow a different molecular pathway [24].
Rare meningioma associations have also been reported in PTEN-related Cowden syndrome, Werner syndrome caused by WRN alterations, and several other uncommon tumour-predisposition conditions. Only a minority of people with these syndromes develop meningioma, so the presence of one syndrome does not mean that the tumour is inevitable [23].
Genetic counselling may be considered when the patient is unusually young, has multiple meningiomas, has both meningiomas and schwannomas, has clear-cell or rhabdoid histology, or has a family history of meningioma, mesothelioma, uveal melanoma, multiple basal-cell cancers, breast cancer, thyroid cancer, or other syndromic tumours.
Rare Treatment-Related Causes
Methotrexate exposure has been associated with an increased meningioma risk in survivors of childhood cancer, although the evidence does not establish a clear dose-dependent causal relationship. A pooled case-control analysis reported higher odds among exposed survivors, but the association may have been influenced by previous cancer type, radiation exposure, treatment selection, or other unmeasured factors [23,28].
This possible association is most relevant to patients who received intrathecal or systemic methotrexate as part of childhood leukaemia or central nervous system cancer treatment. Methotrexate used later in life for rheumatoid arthritis, psoriasis, or another inflammatory disease has not been established as a common independent cause of meningioma.
Patients with a history of childhood cancer should provide both chemotherapy and radiation records. The combination of previous cranial radiation, methotrexate exposure, young age at treatment, and a long latency period may help explain a later meningioma more accurately than any single factor considered alone.
Metabolic and Lifestyle Associations
Excess body weight is associated with a modestly increased meningioma risk, although obesity is not a direct or sufficient cause. A recent meta-analysis of prospective studies found an approximately 11% higher risk among overweight individuals and a 38% higher risk among those with obesity compared with people of normal weight [27].
Possible links include chronic low-grade inflammation, altered insulin and growth-factor signalling, increased aromatisation of hormones in adipose tissue, oxidative stress, and disturbed metabolic regulation. These mechanisms may be particularly relevant when obesity occurs together with hypertension, hormonal disturbance, poor sleep, fatty liver, insulin resistance, or reduced physical activity.
Smoking has not shown a consistent overall association with meningioma. Some analyses have reported a modest association among men but not women, while other prospective data have not confirmed smoking as a major causal factor [23].
A history of breast cancer is associated with a small increase in subsequent meningioma diagnosis, and women with meningioma also show a modestly increased incidence of later breast cancer. Shared hormonal, genetic, treatment-related, and surveillance factors may contribute, but breast cancer itself has not been established as a direct cause of meningioma [29].
Head Injury and Other Rare Associations
A history of head injury is sometimes reported by patients whose meningioma later appears near the injured area. A 2026 meta-analysis found a statistical association between traumatic brain injury and subsequent meningioma diagnosis, but the result was driven mainly by retrospective studies vulnerable to recall and detection bias. Current evidence does not establish that a single head injury directly causes meningioma [26].
Repeated trauma may still be clinically relevant in the patient’s Ayurvedic history because chronic local injury can disturb Vata, Rakta, Mamsa, and tissue repair. The relationship should be assessed through timing, location, severity, repeated injury, imaging, and other risk factors rather than assumed from one remote incident.
Ordinary psychological stress is not established as a direct molecular cause of meningioma. Prolonged stress can nevertheless disturb sleep, appetite, endocrine regulation, digestion, immune balance, treatment adherence, and neurological symptoms. Ayurveda therefore addresses stress as a factor that can aggravate the internal disease terrain and weaken recovery, not as the sole explanation for the tumour.
Ayurvedic Causes
Ayurveda separates disease causes into Nija, arising predominantly from internal Dosha disturbance, and Agantuja, beginning through an external exposure or injury. Charaka explains that external and internal causes can later interact: an external injury can disturb Dosha, while an internal imbalance can alter the body’s response to an external insult. Charaka Samhita, Sutra Sthana, Chapter 20, verses 3–6 describes this relationship [30].
Radiation exposure, tissue-damaging medicines, repeated trauma, toxic exposure, and other external injuries can be clinically interpreted within the Agantuja framework. Hormonal and metabolic disturbances, impaired digestion, Dosha imbalance, abnormal tissue nourishment, and reduced elimination contribute to the Nija component. Many patients show a combined pathway in which an external trigger acts upon a susceptible internal terrain.
Ayurveda does not contain an exact classical diagnosis identical to meningioma. The diagnosis remains defined through MRI, pathology, anatomical location, grade, and molecular findings. The classical description of Arbuda provides a clinical framework for understanding persistent, organised, mass-forming disease, but it should not replace the modern diagnosis.
Sushruta Samhita, Nidana Sthana, Chapter 11, verse 14 states [5]:
कुर्वन्ति मांसोपचयं तु शोफं तमर्बुदं शास्त्रविदो वदन्ति।
वातेन पित्तेन कफेन चापि रक्तेन मांसेन च मेदसा च॥१४॥
kurvanti māṃsopacayaṃ tu śophaṃ tam arbudaṃ śāstravido vadanti |
vātena pittena kaphena cāpi raktena māṃsena ca medasā ca ||14||
“The learned describe as Arbuda a swelling produced through excessive tissue accumulation. It may arise through the involvement of Vata, Pitta, Kapha, Rakta, Mamsa, or Medas.”
This verse shows that persistent tissue growth is not assigned to one universal Dosha. Vata, Pitta, Kapha, Rakta, Mamsa, and Medas may contribute in different proportions. The individual pattern must therefore be identified before the Brahma Rasayana Avaleha is finalised [5].
Sushruta Samhita, Nidana Sthana, Chapter 11, verse 21 explains the persistent and compact nature of Arbuda [5]:
न पाकमायान्ति कफाधिकत्वान्मेदोबहुत्वाच्च विशेषतस्तु।
दोषस्थिरत्वाद्ग्रथनाच्च तेषां सर्वार्बुदान्येव निसर्गतस्तु॥२१॥
na pākam āyānti kaphādhikatvān medobahutvāc ca viśeṣatas tu |
doṣasthiratvād grathanāc ca teṣāṃ sarvārbudāny eva nisargatas tu ||21||
“Arbuda does not ordinarily undergo suppuration because of the predominance of Kapha, abundance of Medas, stability of the disturbed Doshas, and compact binding of its constituents.”
Kapha contributes stability, density, cohesion, heaviness, and persistence. Medas contributes abnormal nourishment, accumulation, and metabolic storage. Mamsa represents structural tissue proliferation and consolidation. Their combined disturbance creates a terrain in which pathological tissue can remain organised rather than resolving through the body’s normal processes.
Vata contributes irregular growth, displacement, pain, seizures, dizziness, weakness, numbness, disturbed speech, altered coordination, insomnia, and impaired neurological communication. Vata disturbance becomes particularly important when the lesion compresses the brain, cranial nerves, spinal cord, or blood vessels.
Pitta contributes altered cellular transformation, inflammatory heat, vascular reactivity, burning discomfort, disturbed sleep, irritability, visual sensitivity, and accelerated tissue activity. Rakta involvement is considered when vascularity, congestion, inflammatory change, bleeding tendency, or altered microcirculation forms part of the presentation.
Agni, Aama, and Srotorodha
Agnimandya means reduced digestive and metabolic capacity. It may present as low appetite, bloating, heaviness after eating, constipation, irregular bowel movements, acidity, coated tongue, post-meal fatigue, poor medicine tolerance, or unstable energy.
When food and metabolic inputs are not transformed efficiently, Ayurveda describes the production of Aama, incompletely processed material that interferes with tissue nutrition and normal physiological regulation. Aama is not interpreted as the tumour itself. It represents an internal metabolic burden that can promote inflammation, heaviness, impaired circulation, poor elimination, and reduced response to treatment.
Srotorodha means functional obstruction within channels responsible for nutrition, circulation, fluid movement, elimination, and neurological communication. In a meningioma patient, it may be clinically correlated with oedema, congestion, metabolic stagnation, impaired tissue exchange, and disturbed neurological function. It is not a literal replacement term for a compressed optic nerve, occluded vessel, or MRI-visible mass.
The sequence of Agnimandya, Aama accumulation, Srotorodha, Dosha localisation, and Dhatu disturbance explains why digestion, bowel function, sleep, metabolism, and tissue nourishment are treated alongside the lesion. A patient who cannot digest the formulation or maintain regular elimination cannot receive the full benefit of a concentrated Rasayana programme.
Hereditary Causes in Ayurveda
Charaka describes inherited susceptibility through the concepts of Bija, Bija-bhaga, and Bija-bhaga-avayava. These refer respectively to the reproductive seed and progressively more specific hereditary components. They provide a classical framework for understanding how a disturbance carried through parental material can affect particular tissues or organs in the offspring.
Charaka Samhita, Sharira Sthana, Chapter 4, verses 30–32 explains that disturbance affecting the whole reproductive seed, a component of that seed, or a more specific subcomponent can produce different patterns of inherited abnormality [31]. These concepts should not be presented as literal ancient names for DNA, chromosomes, or individual genes, but they provide a clinically relevant Ayurvedic model of inherited predisposition.
Rare familial alterations involving NF2, SMARCE1, SMARCB1, BAP1, SUFU, PTEN, or other genes may therefore be considered through both contemporary genetics and the Ayurvedic concept of Bija-related susceptibility. The inherited predisposition creates vulnerability, while Dosha, Agni, tissue condition, external exposures, age, and treatment history influence when and how the disease becomes manifest.
Diet and Daily Habits
Ayurveda evaluates dietary and lifestyle factors according to their cumulative effect on Agni, Kapha, Medas, Mamsa, Rakta, Vata, and Ojas. Heavy, excessively oily, repeatedly reheated, poorly digested, highly processed, or continuously incompatible food patterns can promote Kapha-Meda accumulation and Aama when they exceed the patient’s digestive capacity.
Excessive eating without hunger, eating again before the previous meal has digested, prolonged inactivity, irregular sleep, persistent constipation, and chronic metabolic heaviness can weaken tissue regulation. These factors are assessed as contributors to the internal terrain rather than presented as independent causes capable of producing meningioma in every person.
Sushruta Samhita, Nidana Sthana, Chapter 11 also describes trauma and excessive meat consumption in the specific classical context of Mamsarbuda [5]. This should not be interpreted as proof that eating meat causes meningioma. It indicates that repeated tissue injury and a diet that excessively promotes Mamsa in a susceptible person were recognised as possible contributors to certain persistent mass-forming patterns.
Sleep deprivation, excessive mental exertion, chronic fear, prolonged grief, and irregular daily routine can aggravate Vata and weaken Ojas. These factors may intensify headaches, seizures, cognitive fatigue, appetite disturbance, constipation, and treatment intolerance even when they did not initiate the tumour.
Causal Assessment Before Treatment
The clinical history should record age at diagnosis, family history, multiple tumours, previous cranial radiation, childhood cancer treatment, hormonal medicines, fertility treatment, pregnancy-related growth, head injury, body-weight changes, metabolic disease, and breast, thyroid, skin, nerve-sheath, or mesothelioma-related cancers within the family.
The Ayurvedic assessment examines Prakriti, Agni, Aama, bowel function, Kapha-Meda accumulation, Vata disturbance, Pitta-Rakta involvement, Mamsa and Majja condition, Ojas, sleep, appetite, energy, emotional state, and the patient’s ability to tolerate sustained treatment.
A radiation-associated, hormone-associated, inherited, metabolically driven, or predominantly sporadic meningioma may require a different balance of lesion-directed herbs, Medhya Rasayana, Deepana-Pachana medicines, Kapha-Meda regulation, Rakta support, Majja nourishment, mineral Rasayana, and Ojas restoration within the personalised Brahma Rasayana Avaleha.
Clinical Features(Symptoms)

The clinical manifestations of meningioma are determined by multiple factors such as tumor location, growth pattern, rate of expansion, and interaction with surrounding neural and vascular structures. Because the tumor grows slowly, symptoms often develop gradually and may remain unnoticed until the lesion reaches considerable size. In Ayurveda, these symptoms are understood as progressive expressions of doshic imbalance and impaired flow through the subtle channels or srotas, primarily involving the Majja Dhatu (nervous tissue) and Shiras Srotas (cranial microchannels) [3, 4, 10, 14].
Meningioma symptoms usually fall into three major categories: signs of raised intracranial pressure, focal neurological deficits based on the site of origin, and systemic manifestations due to chronic tissue disturbance [1, 2, 30].
Headache and Raised Intracranial Pressure
Headache is the most common presenting feature and is often dull, persistent, and diffuse. It typically worsens in the early morning or during physical strain due to increased intracranial pressure from venous congestion or compression of pain-sensitive dural structures [1, 30]. The pain may gradually intensify and is often associated with nausea, vomiting, and a feeling of heaviness in the head. Ayurveda describes this state as Shiroruja, or head pain, resulting from obstruction of cranial srotas and vitiation of Vata and Kapha doshas [3, 10, 14]. The accompanying heaviness and lethargy correspond to Aama accumulation in Majja Dhatu and impaired circulation of Prana within the cranial region [4]. In severe cases, papilledema and vision disturbances occur, indicating chronic raised intracranial pressure [9, 30].
Seizures
Seizures develop in nearly one-third of meningioma patients, particularly when the tumor involves the motor cortex, parietal lobes, or parasagittal regions [31, 35]. They may manifest as focal motor jerks, sensory auras, or generalized tonic–clonic convulsions. The pathophysiology involves cortical irritation, local inflammation, and neuronal hyperexcitability secondary to pressure from the expanding mass [30, 31]. In Ayurvedic terminology, these episodes are referred to as Apasmara—a transient loss of awareness and motor control caused by aggravated Vata disturbing the flow of consciousness through the Manovaha Srotas (mental channels) and depletion of Ojas [3, 4, 10]. Such patients may also experience anxiety, dizziness, or disorientation between episodes, reflecting the disturbed harmony of Prana Vata and Sadhaka Pitta within the brain [14, 29].
Visual Disturbances
Visual symptoms are common in meningiomas located near the optic nerve, optic chiasm, or occipital lobe. Patients may complain of blurred vision, loss of visual fields, double vision, or progressive blindness [9, 32]. These findings result from mechanical compression, ischemia, or demyelination of visual pathways. Ayurveda correlates these features with Netra Dosha, Timira (dimming of vision), and Andhya (progressive blindness), which arise from deranged Pitta and Vata doshas acting upon the Drishti Srotas [3, 10, 14]. The pathological process involves depletion of Tejas in Majja Dhatu, leading to impaired neural transmission in ocular circuits. Ayurvedic scholars such as Chakrapani have also described vision loss as a result of Prana Vata imbalance that disrupts ocular perception and mental clarity [38].
Cognitive and Behavioral Changes
Meningiomas involving the frontal lobe frequently lead to personality alterations, poor judgment, irritability, apathy, or emotional instability [30, 31]. The patient may exhibit disinhibition, loss of social restraint, and decreased concentration, often mistaken for psychiatric disorders. Memory impairment and reduced intellectual capacity are frequent when the lesion compresses the limbic system or frontal association areas [39]. Ayurveda refers to this as Smriti Bhramsha—diminution or confusion of memory caused by Majja Kshaya (degeneration of neural tissue) and Ojas depletion, leading to unstable mental faculties [4, 10, 29]. This loss of mental steadiness reflects a disturbed state of Tarpaka Kapha, which normally nourishes the mind, and Prana Vata, which governs thought and perception. Ayurvedic Rasayana herbs such as Brahmi (Bacopa monnieri) and Shankhpushpi (Convolvulus pluricaulis) are traditionally indicated to restore these functions [5, 33].
Cranial Nerve Palsies
Compression of cranial nerves by skull base or sphenoid wing meningiomas leads to a variety of focal deficits. Involvement of the oculomotor, trochlear, or abducens nerves causes double vision and restricted eye movement; trigeminal nerve involvement leads to facial numbness or pain; and vestibulocochlear nerve compression results in hearing loss or tinnitus [9, 31, 32]. The underlying mechanism involves direct nerve compression, ischemic demyelination, or entrapment within tumor margins. Ayurveda recognizes these manifestations as Indriya Upaghata, meaning impairment of sensory or motor organs due to obstruction of Vata flow within the Nadi Srotas [3, 4, 14]. The pain and numbness reflect aggravated Vata, while the associated heaviness and dullness correspond to Kapha stagnation in the nerve channels.
Rare and Location-Specific Manifestations
Olfactory groove meningiomas may present with gradual loss of smell (anosmia), frontal headaches, and sometimes visual deterioration when the tumor extends posteriorly toward the optic nerves [34]. Ayurveda equates loss of olfaction to Ghrana Nasha, a Vata–Pitta disorder within the Indriya Srotas responsible for smell perception [3, 10]. In some cases, personality changes coexist with anosmia, forming a clinical triad unique to this location [34].
Sphenoid wing and cavernous sinus meningiomas produce symptoms such as ptosis, diplopia, facial pain, or sensory loss due to compression of cranial nerves III, IV, V, and VI [9, 31, 32]. Ayurveda explains these as Nayana Sandhi Shula (pain around the eyes) and Drishti Gati Nasha (restricted ocular motion) from deranged Vata causing localized neural rigidity [3, 14].
Posterior fossa and cerebellopontine angle meningiomas can cause imbalance, vertigo, tinnitus, and hearing loss as a result of vestibulocochlear nerve compression [9, 31]. Ayurveda interprets these symptoms as Bhrama (vertigo) and Karna Nada (tinnitus) resulting from disturbed Vata circulation in the auditory pathways [3, 10, 14].
Parasagittal or falcine meningiomas often produce contralateral leg weakness or sensory loss due to compression of motor and sensory cortex areas [35]. Ayurveda describes similar unilateral deficits as Ekanga Stambha or Ekanga Rukshata, which indicate blocked Vata flow within localized neural tracts [4, 10].
Temporal and sphenoid ridge tumors may lead to speech impairment, memory disturbances, and complex partial seizures, reflecting temporal lobe involvement [9, 31, 36]. Ayurveda parallels these findings with Vacha Shakti Hani (loss of speech ability) and Smriti Bhramsha (memory confusion), which arise from Majja Dushti and Ojas depletion [4, 29].
Spinal meningiomas, though less common, cause back pain, limb weakness, sensory loss, and urinary disturbances due to compression of the spinal cord and nerve roots [9, 37]. Ayurveda identifies these symptoms as Greeva–Trika Shoola (axial pain) and Mutra Vega Dharana Janya Vyadhi (urinary difficulty), caused by obstructed Vata in Prishtha and Vankshana Srotas [3, 14].
Systemic and Late-Stage Symptoms
In advanced cases, large meningiomas may impinge upon the hypothalamic or pituitary regions, producing hormonal disturbances such as menstrual irregularities, weight fluctuations, or excessive thirst and urination [9, 32, 40]. Ayurveda views such systemic changes as multi-dhatu involvement, in which pathological Vata and Kapha extend beyond the Majja Dhatu into Rasa and Meda Dhatus, leading to metabolic imbalance and endocrine dysfunction [4, 10, 29].
Other chronic manifestations include insomnia, fatigue, mood instability, or generalized weakness, all of which correlate with progressive Ojas depletion [28, 29, 41]. As the disease advances, symptoms like hemiparesis, speech arrest, or ataxia may appear, indicating extensive neural compression and degeneration [31, 35]. Ayurveda explains this deterioration as severe Vata vitiation within Shiras Srotas, requiring rejuvenative Rasayana and nerve-restorative therapy to stabilize function [5, 29].
Other Common and Rare Disorders Associated With Meningioma

Commonly associated disorders
Peritumoral brain edema
Peritumoral edema is one of the most frequent radiological and clinical findings in meningioma. It develops due to increased vascular permeability and local inflammatory mediators, leading to accumulation of fluid in the surrounding brain tissue. Patients may experience worsening headache, vomiting, blurred vision, seizures, or progressive cognitive slowing. The degree of edema often correlates more with symptoms than the tumor size itself. In Ayurvedic understanding this resembles Kapha accumulation with Srotorodha in the cranial region, producing heaviness, mental dullness, and pressure sensations. Its presence influences surgical planning, recovery time, and the need for long term metabolic and neuroprotective support.
Seizure disorder
Seizures are a common presenting feature, especially in cortical meningiomas located over the convexity or parasagittal region. Chronic compression and irritation of the cerebral cortex alter neuronal electrical activity and lower the seizure threshold. Even after successful tumor removal, some patients continue to require antiepileptic medication because of long standing cortical changes. Recurrent seizures significantly affect quality of life, memory, mood stability, and daily functioning. In Ayurvedic correlation this resembles Apasmara, where aggravated Vata disturbs higher mental faculties and neural coordination. Long term management therefore requires not only structural treatment but also restoration of Majja Dhatu, stabilization of Vata, and enhancement of cognitive resilience.
Focal neurological deficits
Focal deficits occur when the tumor compresses specific functional areas of the brain. Patients may develop progressive weakness of one side of the body, difficulty in speech, loss of fine motor skills, sensory impairment, or visual field defects depending on the tumor location. These symptoms often evolve slowly and may be misinterpreted as age related decline in early stages. Persistent compression can lead to irreversible neuronal damage if intervention is delayed. From an Ayurvedic perspective this reflects Vata vitiation in the Majja and Snayu systems, leading to loss of coordinated movement and sensory function. Early recognition and neuroregenerative support are essential for functional recovery.
Cognitive impairment
Cognitive decline is frequently seen in frontal and temporal lobe meningiomas and may present as poor concentration, reduced decision making ability, personality changes, emotional instability, and memory loss. These changes are often subtle and may be noticed more by family members than by the patient. Chronic intracranial pressure, vascular compromise, and neuronal compression contribute to progressive dysfunction. Even after treatment, cognitive recovery may take months and requires active rehabilitation. In Ayurvedic mapping this corresponds to impairment of higher mental functions due to Majja Dhatu depletion and disturbance of Prana Vata, affecting Medha, Smriti, and Dhi.
Hormonal imbalance
Meningiomas located near the sellar and parasellar regions can influence pituitary function and lead to endocrine disturbances. Patients may present with menstrual irregularities, infertility, thyroid dysfunction, unexplained weight changes, adrenal insufficiency, or reduced libido. Tumor growth during pregnancy and the higher incidence in women suggest a strong hormonal component, particularly progesterone receptor expression in many meningiomas. These metabolic and reproductive changes indicate involvement beyond the nervous system. In Ayurvedic understanding this reflects disturbance of the neuroendocrine axis, depletion of Ojas, and impaired tissue nourishment affecting the entire hormonal network.
Chronic headache syndrome
Long standing headache is one of the most persistent complaints in meningioma patients. It is typically described as a dull, pressure like pain that worsens in the morning or with bending forward. Causes include dural irritation, peritumoral edema, altered cerebrospinal fluid dynamics, and post treatment neural sensitization. In some individuals the headache continues even after tumor removal, becoming a chronic pain disorder that affects sleep, mood, and productivity. Ayurvedically this is correlated with Shiroruja arising from Vata–Kapha imbalance in the cranial channels, requiring both local and systemic therapeutic measures for sustained relief.
Genetic and syndromic associations
Neurofibromatosis type 2
Neurofibromatosis type 2 is the most important genetic condition linked with multiple meningiomas. These patients often develop bilateral vestibular schwannomas, spinal tumors, and other intracranial neoplasms at a younger age than sporadic cases. The tumors tend to be multiple, recurrent, and biologically more active, requiring lifelong surveillance and repeated interventions. Hearing loss, imbalance, and visual disturbances are common associated features. The presence of this syndrome changes prognosis and treatment planning significantly. From an Ayurvedic viewpoint it indicates a deep seated constitutional imbalance affecting multiple Dhatus and Srotas, requiring long term Rasayana based systemic management rather than a purely local approach.
Multiple meningioma syndrome
Some patients develop two or more meningiomas without fulfilling the diagnostic criteria for neurofibromatosis. These tumors may appear at different times and locations within the cranial cavity. Management becomes complex because treatment of one lesion does not prevent the development of another. Long term imaging follow up is mandatory. This pattern suggests an underlying systemic predisposition rather than a single localized pathology. Ayurvedically this reflects persistent Dosha imbalance with widespread Srotodushti and Majja Dhatu involvement, emphasizing the need for metabolic correction and terrain based therapy.
Vascular and structural complications
Venous sinus invasion
Parasagittal and falcine meningiomas may invade major dural venous sinuses, particularly the superior sagittal sinus. This leads to impaired venous drainage, raised intracranial pressure, and increased surgical difficulty. Complete removal may not be possible without risking major neurological deficits. Patients may present with progressive headache, papilledema, or motor weakness. The involvement of major vascular channels indicates a more aggressive biological behavior and requires careful multidisciplinary planning. In Ayurvedic interpretation this resembles severe Srotorodha in the principal cranial channels affecting circulation and tissue nutrition.
Hydrocephalus
Large meningiomas or those located near cerebrospinal fluid pathways may obstruct normal CSF flow and produce hydrocephalus. Patients develop gait disturbance, urinary urgency or incontinence, slowing of mental activity, and reduced alertness. These symptoms are often reversible if treated early but may become permanent if neglected. The condition reflects mechanical obstruction along with impaired neural function. Ayurvedically this correlates with Kapha accumulation and Vata obstruction in the cranial pathways, leading to impaired movement, heaviness, and cognitive dullness.
Cranial nerve compression syndromes
Skull base meningiomas frequently compress cranial nerves due to their close anatomical relationships. Optic nerve involvement causes progressive visual loss and visual field defects. Trigeminal nerve compression produces facial pain or numbness. Vestibulocochlear nerve involvement leads to hearing loss, tinnitus, and imbalance. Lower cranial nerve compression results in swallowing difficulty, hoarseness of voice, and tongue deviation. These deficits significantly affect daily living and nutritional status. In Ayurvedic mapping this represents Vata disturbance in specific functional channels governing sensory and motor activities of the head and neck.
Rare but clinically significant associations
Radiation induced meningioma
These tumors develop years or even decades after exposure to therapeutic or environmental radiation. They are more common in individuals who received cranial irradiation during childhood. Radiation induced meningiomas tend to be multiple, atypical, and more aggressive than sporadic ones. Their latency period and distinct biological behavior make long term follow up essential in previously irradiated patients.
Malignant transformation
Although most meningiomas are benign, a small proportion may transform into atypical or anaplastic variants. These tumors show rapid growth, increased recurrence rate, and invasion into surrounding brain tissue. Patients may experience sudden worsening of neurological symptoms after a long stable period. Early detection of this change is crucial for timely intervention.
Extracranial metastasis
Metastasis outside the cranial cavity is extremely rare and usually occurs in high grade meningiomas. The lungs, liver, and bones are the most commonly reported sites. Its presence indicates aggressive tumor biology and significantly alters prognosis and treatment strategy.
Intratumoral hemorrhage
Bleeding within a meningioma is an uncommon but life threatening event. It can cause sudden severe headache, vomiting, rapid neurological deterioration, and loss of consciousness. Emergency neurosurgical management is required. The acute presentation contrasts with the typically slow growing nature of these tumors.
Paraneoplastic neurological syndromes
In rare situations, immune mediated neurological dysfunction may occur due to tumor related antigenic stimulation. Patients can develop unexplained neuropathy, cerebellar dysfunction, or encephalopathy without direct tumor compression. Recognition of this entity is important because symptoms may improve with treatment of the primary tumor.
Meningioma Ayurvedic Treatment by Grade

Meningioma Ayurvedic treatment is personalised according to the tumour’s WHO grade, anatomical location, growth pattern, neurological effects, previous treatment, molecular findings, and the patient’s digestive and functional strength. Grade helps estimate how actively the tumour may behave, how closely it should be monitored, how strongly the Brahma Rasayana Avaleha should be individualised, and how long the curative-intent programme may need to continue [4,23].
Meningioma grade is not the same as stage. Unlike many cancers, meningiomas are not routinely described through a stage 1 to stage 4 system. They are classified as WHO Grade 1, Grade 2, or Grade 3 according to microscopic appearance, mitotic activity, invasion, and selected molecular findings obtained from tumour tissue [23,24].
A tumour that appears slow-growing on MRI may still require histopathological examination before its grade can be confirmed. Similarly, a lesion described radiologically as “likely benign” should not automatically be presented as pathology-confirmed Grade 1 disease. Accurate classification helps the patient understand the expected behaviour of the tumour and provides a reliable baseline for evaluating the Ayurvedic response.
Grade 1 Meningioma
Grade 1 meningiomas are generally slower-growing and have a lower recurrence tendency than higher-grade tumours. They include several common histological patterns and account for most diagnosed meningiomas [4,23].
Some Grade 1 tumours are discovered incidentally during imaging for headache, injury, sinus symptoms, dizziness, or another unrelated reason. When they are small, stable, and not affecting neurological function, they may be followed through serial MRI while the personalised Rasayana programme is administered.
A Grade 1 tumour can still produce significant symptoms when it lies near the optic nerve, brainstem, pituitary region, venous sinus, spinal cord, or cranial nerves. The term “benign” therefore does not mean that the lesion is clinically unimportant. A small optic-pathway meningioma may threaten vision, while a larger frontal lesion may affect memory, judgement, or behaviour before producing severe pain.
The Brahma Rasayana Avaleha for Grade 1 disease is designed according to the tumour’s location and the functions affected. A patient with headache, visual pressure, dizziness, sleep disturbance, poor concentration, or fatigue may require a formulation combining lesion-directed herbs, Medhya Rasayana, Majja nourishment, digestive correction, oedema regulation, and Ojas support.
Treatment response is measured through symptom reduction, functional recovery, neurological stability, and comparative MRI. A favourable outcome may include tumour regression, reduction in oedema, decreased pressure on a nearby structure, or durable radiological stability accompanied by restored daily function.
The first 30-day cycle establishes medicine tolerance and early clinical direction. Continued treatment is then adjusted according to MRI findings, growth history, digestion, strength, and the functions that still require recovery.
Grade 2 Meningioma
Grade 2 meningiomas have a greater tendency to grow, recur, or invade adjacent tissue than Grade 1 tumours. Grade 2 classification may be based on increased mitotic activity, brain invasion, specific histological features, or recognised Grade 2 subtypes [23,24].
Patients may receive the Grade 2 diagnosis after surgery, biopsy, recurrence, or histopathological review. The pathology report should be examined for tumour subtype, mitotic activity, brain invasion, proliferation markers, surgical margins, molecular findings, and the extent of residual tumour.
A Grade 2 tumour requires a more intensive monitoring strategy because recurrence can occur even after apparently complete removal. Previous and current MRI studies should be compared for residual enhancement, new growth, oedema, mass effect, involvement of venous sinuses, and pressure on neurological structures [4].
The personalised Brahma Rasayana Avaleha for Grade 2 disease generally requires a stronger lesion-directed and tissue-regulating component while preserving neurological function and digestive tolerance. Haridra, Shallaki, Guduchi, Punarnava, Guggulu, Pippali, Manjistha, Kanchanara, Varuna, Medhya herbs, and physician-selected mineral Rasayana may be balanced according to the individual case.
The formulation must also address the effects of previous treatment. A postoperative patient may require stronger support for fatigue, appetite, cognition, sleep, limb strength, wound recovery, and functional rehabilitation. A patient who has undergone radiotherapy may require greater emphasis on Rakta balance, oxidative-stress regulation, neurological nourishment, tissue restoration, and Ojas.
Day 15 and Day 30 reviews remain important, but long-term assessment depends on serial MRI and neurological follow-up. A meaningful response includes sustained symptom recovery, stable or improving neurological function, reduction in residual disease where documented, and absence of progressive radiological change.
Grade 3 Meningioma
Grade 3 meningiomas are biologically more active and may grow, invade surrounding tissues, or recur more rapidly. Grade 3 classification can be based on marked mitotic activity, overtly malignant microscopic features, TERT-promoter mutation, or homozygous deletion of CDKN2A/B [23,24].
These molecular findings are important because a tumour may demonstrate high-risk biological behaviour even when every aggressive feature is not obvious on routine imaging. Pathology and molecular testing therefore provide information that cannot be obtained from symptoms, pulse examination, Prakriti, or MRI alone.
The Ayurvedic programme for Grade 3 disease is planned with an intensive curative objective. The formulation must address abnormal tissue activity, angiogenesis-related pathways, inflammatory signalling, neurological protection, metabolic resilience, strength, appetite, sleep, and the effects of previous surgery, radiation, or other treatment.
The Brahma Rasayana Avaleha may require a higher proportion of lesion-directed standardised extracts, Kapha-Meda-regulating medicines, Medhya Rasayana, deep-tissue restoration, and carefully selected mineral Rasayana. The final composition is determined by digestion, Bala, liver and kidney function, blood counts, current medicines, neurological findings, and the patient’s capacity to tolerate a concentrated formulation.
Clinical progress is assessed through headache, seizures, strength, cognition, speech, vision, balance, appetite, sleep, weight, energy, and independence. Imaging is reviewed for tumour dimensions, new lesions, residual disease, oedema, invasion, mass effect, and involvement of bone, nerves, blood vessels, or venous sinuses.
Shorter assessment intervals may be required because treatment decisions depend on how quickly the lesion is changing. The Rasayana formulation is modified according to each cycle’s clinical and radiological findings rather than being repeated unchanged.
Imaging Diagnosis and Tissue-Confirmed Grade
MRI can identify features strongly suggestive of meningioma, including a dural-based enhancing mass, surrounding oedema, bone involvement, compression of neighbouring structures, and characteristic relationships with the meninges. These findings help establish the probable diagnosis and guide the initial treatment plan [4].
MRI cannot reliably determine the complete microscopic grade in every patient. A lesion that appears smooth and slow-growing may still contain higher-risk histological or molecular features, while an irregular or oedematous lesion is not automatically Grade 2 or Grade 3.
Definitive grading usually depends on tissue obtained during surgery or biopsy. The neuropathologist evaluates cell pattern, mitotic activity, brain invasion, necrosis, architectural changes, and other microscopic characteristics. Molecular testing may add information about recurrence risk and biological behaviour [23,24].
Patients who have not undergone surgery should use the wording contained in the radiology report, such as “suspected meningioma,” “radiologically likely meningioma,” or “dural-based lesion consistent with meningioma.” This allows the oral Rasayana programme to begin from an accurate diagnostic foundation while future imaging clarifies the lesion’s behaviour.
Molecular Findings
Molecular testing can explain why meningiomas with similar size and appearance behave differently. Alterations involving NF2, TRAF7, KLF4, AKT1, PIK3CA, SMO, POLR2A, TERT, CDKN2A/B, BAP1, SMARCE1, or other genes may influence location, histological subtype, recurrence risk, and biological activity [23,24].
NF2 alteration or chromosome 22q loss is common in meningiomas arising along the convexity, falx, or posterior skull base. AKT1, TRAF7, KLF4, PIK3CA, and SMO alterations are more frequently associated with particular skull-base or midline locations.
TERT-promoter mutation and homozygous CDKN2A/B deletion are recognised molecular criteria for Grade 3 meningioma because they are associated with more aggressive behaviour. BAP1 loss may occur in rare rhabdoid or papillary tumours and can indicate an inherited tumour-predisposition syndrome in selected patients.
The cIMPACT-NOW update on meningioma grading also identified combined chromosome 1p loss with NF2 alteration or chromosome 22q loss as a higher-risk molecular pattern that may justify Grade 2 classification in selected morphologically lower-grade tumours [24].
Molecular results should be interpreted together with histology, tumour location, surgical findings, imaging, and clinical behaviour. No single molecular marker describes the entire patient or independently determines the Ayurvedic prescription.
Personalising Brahma Rasayana by Grade
The classical Rasayana foundation remains consistent across grades, but the therapeutic emphasis changes. Grade 1 disease may require greater focus on sustained lesion control, neurological restoration, digestion, cognition, and long-term tissue stability.
Grade 2 disease generally requires stronger attention to residual tumour, recurrence prevention, tissue regulation, oedema, neurological protection, and recovery from previous treatment. The formulation may be adjusted more frequently according to clinical and imaging changes.
Grade 3 disease requires the most intensive lesion-directed, restorative, and monitoring approach. The formulation must remain sufficiently potent while preserving Agni, Bala, blood formation, liver and kidney function, sleep, appetite, cognition, and daily strength.
The same mineral module is not used automatically for every grade. Swarna Bhasma, Heeraka Bhasma, Abhraka Bhasma, Rajata Bhasma, Lauha Bhasma, Mukta preparations, Rasa Sindura, Makaradhwaja, or other components are selected according to the complete case, laboratory findings, treatment history, and individual tolerance.
A higher tumour grade does not mean that every ingredient should simply be increased. Excessive concentration may weaken digestion or reduce treatment adherence. The strongest formulation is the one that combines adequate lesion-directed action with sustained absorption, neurological support, and uninterrupted administration.
Grade-Specific Follow-Up
Grade 1 meningioma is generally followed through periodic MRI, neurological assessment, and symptom review. The interval depends on tumour location, residual disease, previous growth, age, and treatment response [4].
Grade 2 disease requires closer imaging because recurrence and progression are more frequent. The comparison should include the surgical bed, residual enhancement, venous sinus involvement, oedema, and any new neurological change.
Grade 3 disease requires the closest monitoring of tumour dimensions, neurological function, treatment tolerance, blood reports, and functional capacity. Imaging intervals are determined by current behaviour and the response observed during each treatment phase.
For every grade, the response to Brahma Rasayana Avaleha is documented through the same four domains: clinical symptoms, neurological function, daily independence, and comparative imaging. This allows the curative-intent programme to remain aligned with the actual biology and behaviour of the individual meningioma.
How Fast Does Meningioma Grow?

Meningioma Ayurvedic treatment should begin with an assessment of the tumour’s growth pattern before Brahma Rasayana Avaleha is started. Many meningiomas enlarge slowly, some remain unchanged for years, some grow initially and then decelerate, and a smaller group continues to enlarge more rapidly. A single MRI shows the tumour’s present size, but only serial MRI comparison can establish how quickly that individual tumour is growing.
Average Meningioma Growth Rate
A 2024 serial volumetric study of 240 untreated intracranial meningiomas reported a median velocity of diametric expansion of 0.33 mm per year, with an interquartile range of 0.00–0.71 mm per year. This means that half of the tumours grew at approximately one-third of a millimetre per year or less, while individual tumours ranged from no measurable enlargement to substantially faster growth. PubMed
This figure should not be interpreted as a universal annual growth rate. It represents change in the tumour’s calculated mean diameter. A meningioma enlarges in three dimensions, so a small change in each diameter can produce a proportionally larger increase in total tumour volume.
A prospective cohort of 109 incidental asymptomatic meningiomas reported an average volume increase of 0.51 cm³ per year. Tumour growth was detected in 83.5% of lesions, but only 36.7% increased by more than 15%, neurological symptoms developed in 1.2% of patients, and 86.2% remained untreated during approximately four years of follow-up. This demonstrates that radiological enlargement and clinically important progression are not always the same event. PubMed
A separate five-year prospective study of incidental meningiomas found that 75% increased by more than 15% in volume, 20.3% remained unchanged, and 4.7% decreased by more than 15%. None of the patients developed tumour-related symptoms during the study period. The mean time until measurable growth was 2.2 years, with a range of six months to five years. PubMed
These studies report different growth figures because they used different patient populations, follow-up periods, MRI schedules, measurement methods, and definitions of progression. Some studies count any measurable increase, while others require a 15%, 20%, or 40% volume increase before classifying the tumour as progressive.
Linear Growth, Volume Growth, and Doubling Time
Meningioma growth can be expressed in several ways, and each method answers a different clinical question.
Linear growth is measured in millimetres per year. It usually represents change in one diameter or in a calculated mean diameter. It is simple to understand but may underestimate the growth of irregular, en-plaque, cavernous-sinus, parasellar, or optic-nerve-sheath meningiomas.
Absolute volume growth is measured in cubic centimetres per year. It shows how much total tumour volume is added during a defined period. If a tumour increases from 4.0 cm³ to 5.2 cm³ over two years, its approximate absolute growth rate is 0.6 cm³ per year.
Relative growth rate expresses annual growth as a percentage of the starting volume. In the same example, the tumour has increased by 30% over two years, corresponding to an approximate non-compounded relative growth rate of 15% per year.
Volume-doubling time estimates how long the tumour would take to double if it continued growing at the same exponential rate. A tumour increasing from 4.0 cm³ to 5.2 cm³ over two years would have an estimated doubling time of approximately 5.3 years. Doubling time becomes less reliable when growth decelerates, stops, or follows an irregular pattern.
A serial volumetric analysis of 240 tumours reported median volume-doubling times of approximately 185.7 months in the low-risk group, 100.1 months in the intermediate-risk group, and 51.7 months in the high-risk group. These correspond to approximately 15.5 years, 8.3 years, and 4.3 years, respectively. Only the high-risk group contained tumours with a doubling time of 12 months or less. PubMed
Why a Small Increase in Diameter Can Represent Significant Volume Growth
A tumour measured in three dimensions should not be described only by the largest diameter.
For example, a meningioma measuring 20 × 18 × 16 mm has an approximate ellipsoid volume of 3.0 cm³. If a later MRI measures it as 22 × 20 × 18 mm, the largest diameter has increased by only 2 mm, but the approximate volume has increased to 4.1 cm³. This represents an increase of approximately 37%, not merely “2 mm of growth.”
This is why volumetric segmentation is particularly valuable for irregular tumours and lesions that extend around nerves, blood vessels, the cavernous sinus, the optic canal, or the skull base. Manual or computer-assisted volumetric analysis can reveal meaningful growth that may not be evident from one diameter alone.
Meningioma Growth Patterns
Meningiomas do not always grow at a constant speed. Their behaviour may be linear, exponential, sigmoidal, parabolic, Gompertzian, continuously decreasing, or temporarily stable.
In the five-year prospective study, growth was quasi-exponential in 26% of tumours, linear in 17%, sigmoidal in 35%, parabolic in 17%, and continuously decreasing in 5%. More than 60% eventually displayed a self-limiting pattern in which growth slowed or reached a plateau. PubMed
A meta-analysis of 27 natural-history studies found that approximately half of untreated incidental meningiomas showed decelerating or no growth, while fewer than one-quarter demonstrated exponential growth. The proportion showing radiological progression generally approached a plateau after four to five years. PubMed
A volumetric study of 235 untreated meningiomas found that 59% grew, 27% remained stable, and 14% decreased in volume during a median five-year observation period. A Gompertzian curve best described the overall behaviour, meaning that growth tended to be more active during one phase and then gradually slowed. Only 5% of patients underwent surgery during the observation period. PubMed
Long-term prospective monitoring also shows that growth behaviour becomes clearer over time. In a prospective study extending to 12 years, growth decelerated on average after approximately 1.5 years and became statistically insignificant after eight years. Self-limiting growth occurred in 63.2% of tumours, while 29.4% continued without clear deceleration. Of the interventions performed during follow-up, 97.4% occurred within the first five years. PubMed
What Is Considered a Fast-Growing Meningioma?
There is no single universal number that defines fast growth in every meningioma. The clinical importance of growth depends on tumour volume, anatomical location, oedema, symptoms, neurological function, grade, and the interval between scans.
The natural-history meta-analysis found that an annual volume change of at least 2.1 cm³ per year was the strongest growth-related indicator of symptomatic progression. In the studies included in that analysis, no tumour growing below 2.1 cm³ per year became symptomatic, while tumours growing at or above that rate had a three-year clinical progression-free rate of 69.3%. PubMed
This threshold is useful for research and risk assessment, but a lower numerical growth rate can still be clinically important when the tumour lies near the optic nerve, optic chiasm, brainstem, pituitary region, spinal cord, cavernous sinus, venous sinus, or a major artery.
For example, a 1–2 mm increase in an optic-canal meningioma may reduce the space available for the optic nerve and affect vision. The same increase in a convexity meningioma surrounded by more available space may not immediately impair neurological function.
A fast-growing meningioma is therefore identified through the combined pattern of persistent enlargement, increasing volume, shorter doubling time, greater oedema, increasing mass effect, and new or progressive neurological symptoms.
MRI Features Associated With Faster Growth
The strongest practical imaging predictors are the tumour’s T2-weighted MRI signal and the presence or absence of calcification.
In the 2024 study, tumours that were T2 isointense or hyperintense and lacked calcification formed the highest-risk radiological group. Their median diametric growth was approximately 0.49 mm per year, compared with approximately 0.35 mm per year in the intermediate-risk group and 0.05 mm per year in the low-risk group. Exponential growth occurred more frequently in the high- and intermediate-risk categories than in the low-risk category. PubMed
The earlier 240-tumour analysis found that the presence of calcification was associated with a lower probability of growth, while T2 isointensity or hyperintensity was associated with a greater probability of growth. Older age showed a small negative association with growth in that cohort. PubMed
The EANO meningioma guideline also identifies larger baseline size, absence of calcification, peritumoral oedema, and T2 isointensity or hyperintensity as features associated with increased growth risk during observation. PubMed
Calcification is generally associated with slower growth, but it does not establish that a tumour will remain unchanged permanently. A calcified tumour still requires comparison imaging when it is newly diagnosed, close to a critical structure, or associated with changing symptoms.
Does Age Affect Meningioma Growth?
The relationship between age and growth is not identical across studies.
In the five-year prospective study, average volume growth increased across age groups: approximately 0.10 cm³ per year in patients younger than 55, 0.24 cm³ per year in patients aged 55–75, and 0.85 cm³ per year in patients older than 75. Larger baseline tumour volume was also associated with faster absolute growth. PubMed
However, another 240-tumour study found that older age slightly reduced the probability of measurable growth, while the Gompertzian growth study found no significant independent association between age and future growth. PubMed
These apparently different findings arise partly because older patients may have larger tumours at diagnosis, producing a greater absolute volume increase even when the percentage growth rate is not faster. Age should therefore be interpreted together with starting volume, MRI characteristics, symptoms, comorbidities, and expected duration of follow-up.
Growth Rate by Tumour Location
Location affects both the measured growth rate and the clinical consequences of growth.
A study of 313 convexity, parasagittal, and falx meningiomas reported a median relative growth rate of 6.1% per year and a median absolute volume change of 0.20 cm³ per year. In the extremely high-growth group, the median relative growth rate was 17.5% per year and the median absolute increase was 1.05 cm³ per year. In the high-growth group, the corresponding figures were 8.2% and 0.33 cm³ per year. In the low-growth group, they were 3.4% and 0.04 cm³ per year. PubMed
The extremely high-growth group showed a typical 2.24-fold increase, or an additional 5.24 cm³ of volume, over five years. Low-growth tumours showed little volumetric change over the same period. PubMed
Long-term prospective data also found that larger tumours involving venous sinuses grew more aggressively than smaller lesions without venous-sinus involvement. PubMed
Location must therefore be considered together with growth speed. A slowly growing tumour near the optic pathway may require closer functional monitoring than a faster-growing lesion in a less sensitive location.
Growth Rate by WHO Grade
Grade 1 meningiomas generally have more favourable biological behaviour, while Grade 2 and Grade 3 tumours have greater risks of recurrence and progression. However, growth rate on MRI cannot independently establish WHO grade.
In the 2024 growth-velocity study, the measured diametric growth was 1.30 mm per year for WHO Grade 1 tumours and 4.01 mm per year for WHO Grade 2 tumours, but the difference was not statistically significant. The investigators concluded that rapid enlargement does not, by itself, indicate a higher WHO grade. PubMed
Definitive grading generally requires histopathological examination of tumour tissue, including assessment of mitotic activity, brain invasion, microscopic architecture, and relevant molecular findings. MRI defines anatomical behaviour, while pathology defines the biological grade.
A radiologically suspected meningioma that has not been biopsied should therefore be described according to its imaging appearance and observed growth pattern rather than being assigned an assumed Grade 1, Grade 2, or Grade 3 classification.
Growth of Residual Meningioma After Surgery
A residual meningioma can continue to grow after partial removal, but the rate varies considerably between patients.
A volumetric study of 236 postoperative residual meningiomas reported an average absolute growth rate of 0.11 cm³ per year and a relative growth rate of 4.3% per year during a median follow-up of 5.3 years. Fifty-six percent reached the study’s radiological progression definition of a 40% volume increase, but only 5.5% developed clinical progression. PubMed
Skull-base location increased the risk of radiological progression, and a higher Ki-67 proliferation index was also associated with progression. These findings show why the postoperative pathology report, residual volume, tumour location, Ki-67 index, MRI pattern, and neurological condition should be reviewed together before the next treatment cycle is planned. PubMed
A residual tumour that increases slowly without neurological change requires a different follow-up strategy from a residual lesion showing accelerating growth, increasing oedema, visual decline, seizures, or progressive weakness.
Calculating Growth From Two MRI Scans
The most reliable calculation uses the exact dates and tumour volumes from two comparable MRI examinations.
Absolute annual volume change can be calculated by subtracting the earlier volume from the later volume and dividing by the number of years between the scans.
If a tumour increases from 4.0 cm³ to 5.2 cm³ over two years, the absolute volume increase is 1.2 cm³, giving an average annual volume change of 0.6 cm³ per year.
The approximate relative increase is calculated by dividing the volume change by the original volume. In this example, 1.2 cm³ divided by 4.0 cm³ equals a 30% increase over two years.
The estimated exponential doubling time is calculated from the volume ratio and the interval between scans. For this example, the estimated doubling time is approximately 5.3 years.
These calculations are most reliable when MRI examinations use comparable contrast-enhanced sequences, similar slice thickness, similar anatomical planes, and consistent tumour-contouring methods. Computer-assisted volumetric segmentation is preferable for irregular lesions.
When only linear dimensions are available, all three dimensions should be recorded. The radiologist may estimate ellipsoid volume by multiplying the anteroposterior, transverse, and craniocaudal measurements and applying the ellipsoid correction factor. Direct segmentation remains more accurate for complex skull-base or en-plaque tumours.
Growth During Brahma Rasayana Avaleha Treatment
Before Brahma Rasayana Avaleha begins, the available MRI studies should be arranged chronologically to establish whether the meningioma was previously stable, slowly enlarging, accelerating, or already decelerating.
The pretreatment record should include tumour dimensions or volume, enhancement, calcification, T2 signal, oedema, mass effect, compression of adjacent structures, venous-sinus or vascular involvement, and the symptoms present at each imaging date.
Day 15 and Day 30 reviews assess early clinical response through headache frequency, eye pressure, dizziness, seizures, sleep, appetite, bowel function, energy, concentration, vision, balance, strength, walking, work capacity, and medicine tolerance.
Follow-up MRI assesses the structural response. The tumour may continue to enlarge, enlarge more slowly, become stable, reduce in volume, show less oedema, or exert less pressure on adjacent neurological structures. These findings are interpreted together with the patient’s clinical and functional recovery.
For example, if a tumour increased from 3.5 cm³ to 4.4 cm³ during the year before treatment and remains approximately 4.4 cm³ on a later comparable scan, the record shows a transition from documented pretreatment growth to interval stability.
If the tumour had already remained approximately 4.4 cm³ for several years before treatment, a further stable scan confirms continued stability. Longer serial follow-up is then used to determine whether its established natural pattern has changed.
The strongest evidence of a structural response is a consistent change demonstrated across comparable scans, such as reduced volume, reduced oedema, decreased mass effect, increased space around a compressed nerve, or a sustained reduction in the previously documented growth rate.
MRI Follow-Up According to Risk and Grade
The EANO guideline recommends annual MRI for suspected meningiomas and WHO Grade 1 meningiomas during the first five years, followed by imaging every two years when appropriate. WHO Grade 2 tumours are generally monitored every six months for five years and annually thereafter. WHO Grade 3 tumours require MRI at least every three to six months, adjusted according to their behaviour and treatment course. PubMed
These intervals are adapted when the tumour is close to the optic pathway, brainstem, spinal cord, pituitary region, cavernous sinus, venous sinus, or a major vessel. New or progressive visual loss, seizures, weakness, speech change, cognitive decline, balance disturbance, or bladder and bowel dysfunction may justify earlier imaging.
Recent risk models can also improve monitoring decisions. An international external validation of the IMPACT prognostic tool included 1,248 patients and reported progression risks of 3.9% in the low-risk group, 24.2% in the medium-risk group, and 51.6% in the high-risk group. The model combines patient factors, comorbidity, performance status, and MRI characteristics to support more individualised follow-up. PubMed
The growth rate therefore guides the intensity of Brahma Rasayana treatment, the timing of repeat imaging, and the interpretation of response. It should always be considered together with tumour location, grade, oedema, neurological function, disease duration, age, associated disorders, previous treatment, and the patient’s ability to continue the prescribed programme.
Diagnostic Evaluation

Accurate diagnosis of meningioma requires a combination of advanced imaging, histopathological confirmation, and assessment of surrounding structural involvement. The objective is not only to confirm the presence of a tumor but also to understand its biological behavior, vascularity, and impact on brain function. From an Ayurvedic perspective, this diagnostic process parallels the evaluation of doshic imbalance, tissue degeneration, and srotas obstruction within the cranial system [3, 4, 10, 14].
Magnetic Resonance Imaging (MRI)
Magnetic resonance imaging with gadolinium contrast enhancement remains the gold standard for diagnosing meningioma [1, 9, 42]. MRI provides exceptional soft tissue contrast and enables visualization of the tumor’s origin, shape, and relationship to nearby brain structures. Typical imaging features include an extra-axial mass with a broad dural attachment, often demonstrating a “dural tail” sign, which is characteristic of meningioma [42, 43].
MRI can differentiate between benign, atypical, and anaplastic variants by revealing differences in contrast enhancement, edema, and invasion of adjacent tissue. Modern advancements such as MR spectroscopy and diffusion tensor imaging further allow metabolic assessment and mapping of white matter tracts for surgical planning [43].
Ayurvedically, MRI corresponds to a modern form of Roga Pariksha (disease examination) that allows direct visualization of Srotas obstruction and Majja Dhatu pathology. The enhanced contrast image symbolizes the concentration of Aama and deranged Kapha within affected regions [3, 10, 14].
Computed Tomography (CT) Scan
CT scan plays a supplementary role, especially in evaluating calcification, bone invasion, and hyperostosis associated with skull base meningiomas [42, 44]. It provides detailed bony architecture useful for preoperative assessment in complex cranial or spinal lesions. CT also assists in identifying hyperdense lesions with well-defined margins, particularly when MRI is contraindicated.
From an Ayurvedic interpretive lens, CT imaging corresponds to examination of Ashti and Majja Dhatus (bone and marrow tissues), revealing structural distortion caused by long-standing Vata–Kapha aggravation and tissue stagnation [3, 10].
Angiography
Cerebral angiography, though less frequently performed today, remains valuable in preoperative planning, especially for large or highly vascular meningiomas [25, 26, 44]. It delineates feeding arteries, venous drainage, and collateral circulation, allowing interventional embolization to minimize intraoperative bleeding. Tumors with a dominant supply from branches of the external carotid artery may be safely embolized preoperatively.
Ayurveda explains this stage as the mapping of Rakta Vaha Srotas (channels of blood circulation) and Sira Srotas, whose obstruction or excessive proliferation parallels the concept of increased vascularity described as Raktavriddhi [3, 4, 14].
Histopathology and Immunohistochemistry
Histopathological analysis is the definitive step in diagnosis, providing information about the tumor’s grade and subtype. Classical Grade I meningiomas exhibit spindle-shaped meningothelial cells arranged in whorls and psammoma bodies. In contrast, atypical (Grade II) and anaplastic (Grade III) meningiomas show increased mitotic activity, necrosis, and cellular atypia [1, 20, 43]. Immunohistochemical staining plays a crucial role in confirming meningioma lineage: cells typically express epithelial membrane antigen (EMA) and vimentin, with occasional positivity for progesterone receptor [42, 45].
These molecular markers also help differentiate meningiomas from other extra-axial lesions such as hemangiopericytoma or metastases. Modern laboratories now integrate genetic profiling of NF2, TRAF7, KLF4, and AKT1 mutations to refine prognosis and guide targeted therapy [20, 23, 45].
In Ayurvedic pathology, histological variation mirrors the degree of doshic imbalance and dhatu degeneration. A benign meningioma corresponds to a Granthi-like structure (encapsulated swelling), whereas atypical and anaplastic variants represent the full development of Arbuda with profound Agnimandya and loss of tissue intelligence (Dhatu Agni) [3, 4, 10, 14].
Integrative Diagnostic Approach
While modern diagnostic tools provide structural precision, Ayurveda emphasizes functional and energetic assessment. A thorough examination of Nadi (pulse), Drishti (eyes), Jihva (tongue), and Sharira Bala (physical strength) reveals the internal status of doshas, dhatus, and Ojas, forming a complete clinical picture beyond imaging data [3, 10]. Combining MRI and histopathology with Ayurvedic diagnostic techniques allows for a deeper understanding of the patient’s internal terrain, helping design personalized management strategies that go beyond tumor resection and focus on systemic balance and recurrence prevention [5, 29].
Latest Meningioma Ayurvedic Treatment Research

Meningioma Ayurvedic treatment can now be planned and monitored with greater precision because molecular testing, receptor-based imaging, volumetric MRI, and biomarker-selected clinical trials provide more detailed information about tumour biology. These developments help identify whether a lesion is relatively slow-growing or biologically active, distinguish residual or recurrent tumour from treatment-related tissue change, and define objective measurements for evaluating the response to personalised Brahma Rasayana Avaleha.
Molecular Testing for Individualised Treatment
Modern meningioma assessment increasingly combines histopathology with molecular findings. Alterations involving NF2, CDKN2A/B, CDK4/6, AKT1, PIK3CA, SMO, TERT, BAP1, SMARCE1, TRAF7, KLF4, SSTR2A, VEGF-related pathways, and DNA-methylation patterns can provide information about tumour behaviour, recurrence risk, and eligibility for biomarker-directed research [32].
Molecular testing is most useful after surgery or biopsy because it requires tumour tissue. A patient whose diagnosis is based only on MRI may begin a personalised oral Rasayana programme according to the radiological findings, symptoms, growth pattern, and Ayurvedic assessment, while molecular information can be incorporated later if tissue becomes available.
The European Association of Neuro-Oncology molecular-testing guideline found that several pathways are suitable for research-guided treatment selection, particularly NF2, CDK4/6, mTOR, AKT, SMO, SSTR2A, VEGF, and immune-related markers. The guideline supports using molecular results to improve classification and clinical-trial selection rather than assuming that all meningiomas share the same biological pathway [32].
For the Brahma Rasayana Avaleha programme, molecular findings help determine the intensity of monitoring and the balance between lesion-directed, anti-inflammatory, neurological, metabolic, and restorative components. A tumour with higher-risk molecular features requires closer imaging and a stronger long-term follow-up plan than a stable lesion without recognised aggressive markers.
CDK-Pathway Treatment Research
A 2026 phase 2 study evaluated abemaciclib in recurrent or progressive Grade 2 and Grade 3 meningiomas containing NF2 mutations or alterations in the CDK pathway. Ninety-six patients were screened, and 36 received treatment. Among the first 24 eligible patients assessed for the primary endpoint, 14 remained progression-free at six months, producing a six-month progression-free survival rate of 58% [33].
Stable disease was the best recorded response in 16 of the 24 primary-evaluable patients. The findings indicate that identifying the molecular pathway before selecting treatment can provide more useful results than giving the same medicine to an unselected group of meningioma patients [33].
This research is relevant to Ayurvedic treatment planning because it confirms that meningioma is not one biologically uniform disease. A patient with an NF2-altered tumour may have a different growth pathway from a patient with an AKT1-, SMO-, PIK3CA-, or TRAF7-associated lesion. The personalised Rasayana formulation therefore remains based on the individual tumour, affected neurological functions, digestive capacity, strength, previous treatment, and available molecular findings.
The response to Brahma Rasayana Avaleha should be measured through the same objective principles used in contemporary meningioma research. Baseline tumour dimensions, previous growth rate, oedema, mass effect, neurological findings, and functional capacity should be documented before treatment so that stability or regression can be interpreted accurately.
Immune-Pathway Research
Meningiomas can create an immune microenvironment that allows abnormal cells to persist despite the presence of immune cells. PD-1 and PD-L1 signalling has therefore been studied as a possible therapeutic pathway, particularly in recurrent or progressive disease.
A 2025 phase 2 study evaluated the PD-1 inhibitor sintilimab in 40 patients with recurrent or progressive meningioma. The study included nine Grade 1, eighteen Grade 2, and thirteen Grade 3 tumours. The six-month progression-free survival rate was 67% among patients with Grade 1 disease and 42% among those with Grade 2 or Grade 3 disease [34].
Stable disease was the best recorded response in the study. The results also indicated that tumour mutational burden, tumour-infiltrating immune cells, and treatment-related immune changes may help identify which patients are more likely to benefit from immune-directed approaches [34].
Within the Ayurvedic model, immune regulation is not assessed through one laboratory marker alone. Guduchi, Amalaki, Haridra, Tulsi, Ashwagandha, Brahma Rasayana, Ojas-supporting treatment, digestion, sleep, nutritional status, and treatment tolerance are considered together. Molecular and immune findings can add measurable biological information to this broader patient-specific assessment.
SSTR-PET Imaging
Most meningiomas express somatostatin receptor type 2, known as SSTR2. This receptor can be detected through PET imaging using radiolabelled somatostatin-receptor ligands such as DOTATATE or DOTATOC.
Joint international practice standards report that SSTR-PET can provide clinically relevant information beyond ordinary MRI or CT in selected patients. It may help define the true extent of meningioma tissue, identify bone involvement, detect small or complex skull-base components, and distinguish recurrent tumour from scar tissue or radiation-related change [35].
This is particularly useful when a lesion surrounds the optic nerve, extends into the cavernous sinus, involves the skull base, enters bone, or has been treated previously. MRI remains essential for anatomical comparison, while SSTR-PET can show whether tissue within an uncertain area retains the receptor pattern associated with meningioma.
SSTR-PET can also help establish a more accurate baseline before beginning or continuing Brahma Rasayana Avaleha. When the boundaries of the lesion are more clearly defined, later changes in MRI, receptor activity, symptoms, vision, neurological function, and daily capacity can be interpreted with greater confidence.
A reduction in tracer uptake may indicate a biological change, but PET findings should be interpreted together with MRI rather than used alone. Tumour dimensions, oedema, mass effect, neurological symptoms, visual function, and functional recovery remain part of the complete assessment [35].
SSTR-Targeted Radioligand Research
The same SSTR2 receptor used for PET imaging can also be used to deliver targeted radionuclide treatment. This approach is known as peptide receptor radionuclide therapy. Radiolabelled somatostatin analogues bind to receptor-positive meningioma cells and deliver radiation directly to the tumour tissue.
The LUMEN-1 trial is the first prospective randomised phase 2 study designed to compare lutetium-177 DOTATATE with locally selected standard care in recurrent SSTR-positive meningioma. The trial plans to enrol 136 patients with Grade 1, Grade 2, or Grade 3 disease across 35 centres in 10 European countries. Participants must have measurable progressive disease, previous surgery and radiotherapy, and sufficient SSTR uptake on PET imaging [36].
A 2026 pilot study evaluated combined or sequential actinium-225 and lutetium-177 DOTATATE in seven patients with advanced, refractory, receptor-positive meningioma. Six of the seven patients remained progression-free at six months. One patient achieved complete clinical remission, two achieved partial remission, and three had stable disease [37].
The study also compared MRI and PET findings across individual lesions. Some lesions within the same patient responded differently, showing that a person with multiple meningiomas may have biological variation between tumour sites. This reinforces the need to assess every measurable lesion rather than describing the whole patient through one general response [37].
A larger French multicentre cohort published in October 2026 evaluated lutetium-177 DOTATATE in 69 patients with refractory meningioma treated across 18 centres. Most patients had previously undergone surgery or radiotherapy. Six-month progression-free survival was 70%, median progression-free survival was 14.6 months, and median overall survival was 27.6 months [38].
These receptor-directed developments provide additional options for patients with progressive SSTR-positive disease and also improve tumour mapping. They do not alter the need for a personalised Ayurvedic assessment. A patient receiving or being considered for receptor-targeted therapy may still require support for appetite, digestion, fatigue, blood-cell recovery, sleep, neurological function, cognitive endurance, and tissue restoration through an individually planned Rasayana programme.
Integrating New Research With Brahma Rasayana
The latest research strengthens four parts of the Brahma Rasayana treatment pathway: patient selection, baseline definition, response measurement, and long-term follow-up.
Molecular testing helps identify the dominant biological pathway and the risk of recurrence or progression. SSTR-PET helps define tumour extent and receptor expression. Volumetric MRI measures structural change. Neurological, visual, endocrine, and functional testing determines whether the anatomical response is producing meaningful recovery for the patient.
These findings are incorporated into the Ayurvedic assessment of Dosha, Agni, Aama, Srotas, Dhatu, Bala, and Ojas. A patient with high-grade or molecularly active disease may require a stronger lesion-directed formulation and closer imaging. A patient with marked oedema may require greater emphasis on Punarnava, Shallaki, Guduchi, Manjistha, and fluid-regulating treatment. A patient with cognitive or visual dysfunction may require greater Medhya, Majja, and Pitta-Rakta support.
Brahma Rasayana Avaleha remains the continuous oral foundation for suitable patients because it allows lesion-directed herbs, neurological Rasayana, metabolic correction, tissue nourishment, and physician-selected mineral preparations to be administered together. Modern molecular and imaging developments provide additional tools for determining whether the individual treatment objective is being achieved.
The complete response is assessed through tumour dimensions, oedema, mass effect, receptor activity where tested, visual or neurological function, seizure burden, cognition, energy, digestion, sleep, and return to normal activity. This integrated approach allows the treatment programme to remain directed toward measurable tumour control and whole-patient recovery.
Modern Treatment Side Effects

Modern management of meningioma includes observation, surgical removal, radiotherapy, and in selected cases systemic drug therapy. These interventions are often essential for tumor control and survival, yet many patients in the USA, UK, Canada, and Australia report long term neurological, cognitive, and hormonal effects after treatment. The intensity of these effects depends on tumor size, location, duration of compression, and the type of therapy used.
Side effects of meningioma surgery
Surgical resection relieves pressure on the brain immediately, but the healing phase can involve several physical and functional changes. In the early postoperative period, patients commonly experience headache, scalp numbness, fatigue, and temporary brain swelling. As the brain adapts to the decompressed state, concentration difficulties and short term memory disturbances may appear.
When tumors are located near eloquent areas of the brain, surgery can affect specific neurological functions. Weakness of the limbs, speech difficulty, visual field defects, imbalance, and seizures may occur. In frontal lobe meningiomas, personality changes, emotional instability, and reduced decision making ability are sometimes observed, which can be more distressing than physical symptoms for both patients and caregivers. Even after complete removal, long term MRI surveillance is required because recurrence can occur if microscopic tumor tissue remains.
Side effects of radiotherapy and radiosurgery
Radiotherapy and stereotactic radiosurgery are widely used for residual or inoperable meningiomas. Although they avoid open surgery, their biological effects on surrounding healthy tissue may develop gradually. Early reactions usually include fatigue, localized scalp irritation, and hair loss at the treatment site.
Delayed effects are more significant and are related to vascular and white matter changes in the brain. Patients may develop memory decline, reduced processing speed, difficulty with multitasking, and a persistent sense of mental fog. When the radiation field involves the skull base or pituitary region, hormonal imbalance and metabolic changes may appear months or years later. A small number of patients are at risk of radiation induced secondary tumors, which is why long term follow up is essential.
Side effects of systemic therapy
Systemic therapy has a limited role in most meningiomas, but it may be used in aggressive or recurrent cases. In such situations, patients can experience generalized side effects including nausea, appetite loss, liver enzyme elevation, bone marrow suppression, reduced immunity, and chronic fatigue. These effects influence overall vitality and delay neurological recovery.
Long term quality of life after treatment
Even when imaging confirms tumor control, many individuals report persistent symptoms that affect daily life. Chronic fatigue, sleep disturbance, anxiety about recurrence, sensory sensitivity, and reduced professional productivity are commonly described in survivorship clinics across Western countries. Long term use of anti seizure medication may further contribute to cognitive slowing and reduced alertness.
Ayurvedic understanding of post treatment effects
From an Ayurvedic perspective, these long term complications reflect depletion of Majja Dhatu and aggravation of Vata due to surgical intervention, radiation exposure, and tissue loss. Reduced Ojas manifests as fatigue, impaired cognition, emotional instability, and low stress tolerance. Therefore, the therapeutic goal is not only local tumor control but restoration of systemic balance and neural regeneration.
Integrative recovery approach
In an integrative care model, modern treatment addresses the structural component of the disease by removing or controlling the tumor, while Ayurvedic Rasayana therapy focuses on rebuilding Majja Dhatu, stabilizing Vata, improving cognitive function, supporting hormonal equilibrium, and enhancing immunity. This combined strategy directly responds to the most common patient concern in the USA, UK, Canada, and Australia, which is how to regain normal brain function and prevent recurrence after meningioma treatment.
Diet for Meningioma Ayurvedic Treatment

Diet for meningioma Ayurvedic treatment is not one fixed menu for every patient. Food choices vary according to Prakriti, the person’s natural constitutional pattern; Vikriti, the present imbalance created by illness, medicines, surgery, radiation, stress, or altered lifestyle; Agni, the current digestive and metabolic capacity; Satmya, the foods naturally adapted to the person; body weight, nutritional status, blood sugar, bowel function, neurological symptoms, and the way the patient responds to Brahma Rasayana Avaleha.
A Vata-predominant patient with constipation, poor sleep, weakness, and weight loss requires a different diet from a Kapha-predominant patient with heaviness, fluid retention, slow digestion, and weight gain. A Pitta-predominant patient with acidity, burning eye discomfort, irritability, and disturbed sleep requires different food preparation and spices from a patient with coldness, bloating, and reduced appetite. The diet must therefore change according to the patient rather than forcing every person with meningioma to follow the same restrictions.
Classical Ayurvedic assessment examines Prakriti, Vikriti, tissue strength, body build, accustomed foods, psychological strength, digestive capacity, exercise capacity, and age before finalising treatment and diet. This multidimensional examination is described in Charaka Samhita, Vimana Sthana, Chapter 8, Rogabhishagjitiya Vimana [39].
Complete Your Prakriti Analysis
Patients can begin by completing the Prakriti Analysis Questionnaire. The questions should be answered according to the characteristics that were usual for most of adult life, before meningioma symptoms, major weight changes, corticosteroids, antiseizure medicines, surgery, prolonged stress, sleep deprivation, or hormonal treatment changed the body’s natural pattern.
The questionnaire helps identify whether Vata, Pitta, Kapha, or a dual-Dosha constitution is more prominent. The result is then interpreted together with the current Vikriti, because the diet required during treatment may differ from the patient’s natural constitution.
A Vata-predominant person may currently have strong Pitta symptoms such as acidity, burning discomfort, heat intolerance, and irritability. Such a patient cannot be given only warming and heavily spiced Vata food. The diet must nourish Vata while simultaneously calming the active Pitta disturbance.
A Kapha-predominant person may become dry, constipated, weak, and underweight after surgery, radiotherapy, prolonged illness, or loss of appetite. A highly restrictive Kapha diet would not meet that patient’s current need for tissue restoration. The immediate diet must address the present depletion while avoiding excessive heaviness.
A Pitta-predominant person may develop Vata aggravation through insomnia, anxiety, constipation, weight loss, or neurological symptoms. Cooling foods alone may not be sufficient; warm cooked meals, regular timing, healthy fats, and bowel support may be required.
The online Prakriti result therefore provides the constitutional starting point. The final food plan is prepared after comparing it with current symptoms, digestion, weight, laboratory findings, medicines, treatment history, and the patient’s response during the first treatment cycle.
Diet Changes According to Agni
Agni determines how much food the patient can digest, how well Brahma Rasayana Avaleha is tolerated, and whether nourishment reaches the tissues without producing heaviness or Aama. Aama refers to incompletely transformed metabolic material associated with poor digestion, coating of the tongue, bloating, post-meal fatigue, nausea, heaviness, irregular bowel movements, and reduced appetite.
A patient with strong and regular Agni may tolerate a wider variety of grains, legumes, vegetables, proteins, healthy fats, and the full prescribed Avaleha dose. A patient with weak Agni may initially require smaller meals, softer textures, cooked foods, lighter proteins, digestive spices, and more gradual introduction of concentrated nourishment.
Irregular Agni is common when Vata is aggravated. The patient may feel very hungry at one time and unable to eat at another. Regular meal timing, warm cooked food, moderate healthy fats, and avoidance of prolonged fasting help stabilise this pattern.
Sharp Agni may present through intense hunger, acidity, burning, irritability when meals are delayed, loose stools, or heat intolerance. Meals should be regular and sufficiently nourishing, while excessive chilli, vinegar, alcohol, deep-fried food, and highly acidic combinations are reduced.
Slow Agni may present through prolonged heaviness, low hunger, lethargy, thick tongue coating, bloating, and weight gain. Lighter meals, smaller evening portions, cooked vegetables, appropriate spices, and reduced refined sugar and heavy dairy may be required.
The patient’s diet can therefore change during treatment. Food that was appropriate in the first week may be modified after digestion, appetite, bowel function, strength, and neurological symptoms begin to improve.
Vata-Predominant Diet
Vata-predominant patients commonly experience variable appetite, gas, bloating, constipation, dry skin, light sleep, anxiety, fatigue, dizziness, weakness, irregular pain, sensory disturbance, or difficulty maintaining weight. Their diet should be warm, moist, freshly prepared, regular, and adequately nourishing.
Suitable meals may include oatmeal, rice porridge, quinoa porridge, soft wheat preparations, vegetable poha, khichadi, mung dal, red lentils, soups, stews, cooked root vegetables, pumpkin, squash, courgette, carrots, beetroot, green beans, asparagus, and moderate quantities of ghee or another suitable healthy fat.
Protein may come from mung dal, red lentils, well-cooked legumes, paneer, eggs, fish, poultry, yogurt, or other tolerated foods according to dietary preference and medical requirements. The protein source should be prepared in a soft, warm, digestible form rather than dry, fried, or heavily processed.
Stewed apples, pears, soaked raisins, prunes, or dates may be used according to blood sugar and bowel requirements. Warm fluids and cooked vegetables support bowel regularity and help the patient tolerate the concentrated Avaleha.
Cold smoothies, iced drinks, dry crackers, frequent raw salads, skipped meals, prolonged fasting, and large quantities of dry roasted foods may increase Vata symptoms. These restrictions are relaxed or strengthened according to digestion, body weight, climate, season, and the patient’s response.
When Vata-predominant patients also have Pitta symptoms, the food remains warm and nourishing but uses milder spices. When Vata occurs with Kapha heaviness, the meal remains cooked and regular but contains less oil, less sweetness, and smaller portions.
Pitta-Predominant Diet
Pitta-predominant patients may experience strong hunger, acidity, burning sensations, loose stools, heat intolerance, inflammatory eye discomfort, irritability, disturbed sleep, thirst, or sensitivity to pungent foods and concentrated medicines. Their diet should maintain good nutrition while avoiding excessive heat.
Suitable grains may include basmati rice, oats, quinoa, barley where tolerated, and soft wheat preparations. Mung dal, red lentils, moderate dairy where suitable, eggs, fish, poultry, or other proteins may be selected according to digestion and nutritional needs.
Vegetables may include courgette, asparagus, green beans, broccoli, cauliflower, leafy greens, pumpkin, cucumber when tolerated, and other mildly prepared seasonal vegetables. Fruits may include pears, apples, berries, pomegranate, melons, and other sweet or mildly astringent fruits according to blood sugar and digestion.
Coriander, fennel, cardamom, small quantities of cumin, fresh herbs, and mild turmeric may support digestion without excessive heating. Food should remain freshly cooked and comfortably warm rather than being continuously refrigerated or ice-cold.
Large quantities of chilli, hot sauce, strong pickles, vinegar, alcohol, energy drinks, excessively sour food, heavily fried meals, and repeated coffee may aggravate acidity, heat, sleep disturbance, or visual irritation. The degree of restriction depends on whether these symptoms are actually present.
A Pitta-predominant patient with weight loss and weakness still requires adequate calories, protein, and healthy fats. Pitta balancing should not become a low-calorie or excessively restrictive diet.
When Pitta occurs with Vata constipation or insomnia, warm cooked food and moderate ghee may be increased. When Pitta occurs with Kapha heaviness, portions of sweets, oils, refined flour, and heavy dairy are reduced while maintaining cooling vegetables and regular meals.
Kapha-Predominant Diet
Kapha-predominant patients may experience low appetite, slow digestion, heaviness after meals, lethargy, fluid retention, excessive sleep, metabolic sluggishness, weight gain, congestion, or reduced motivation. Their diet should be lighter, well cooked, appropriately spiced, and proportionate to activity and metabolic needs.
Suitable grains may include barley, millet, buckwheat, quinoa, and moderate amounts of rice. Protein may come from mung dal, red lentils, lighter bean preparations, eggs, fish, poultry, low-fat paneer, or another suitable source according to digestion and dietary preference.
Cooked leafy vegetables, cabbage, broccoli, cauliflower, green beans, asparagus, bitter greens, and vegetable soups may support lighter digestion. Ginger, cumin, coriander, turmeric, black pepper, mustard seed, and fenugreek may be used in moderate quantities when Pitta and current medicines permit.
Heavy cheese, cream, excess butter, deep-fried food, refined flour, sugary drinks, frequent desserts, oversized portions, and large late-night meals are reduced. The aim is to improve digestion and metabolic regulation without depriving the patient of protein or micronutrients needed for neurological recovery.
A Kapha-predominant patient who has lost weight, appetite, or muscle after surgery or prolonged illness requires more nourishment than a Kapha patient with obesity and fluid retention. The constitution remains the same, but the current treatment diet changes according to Vikriti and Bala.
When Kapha is combined with Vata, meals should remain lighter but warm and moist rather than dry. When Kapha is combined with Pitta, excessive chilli and very heating spices are avoided even though metabolic stimulation is required.
Dual-Dosha and Mixed Patterns
Many patients do not fit into a single-Dosha pattern. Vata-Pitta, Pitta-Kapha, and Vata-Kapha constitutions require blended dietary planning.
A Vata-Pitta patient may need warm, moist, regular meals without excessive chilli, sourness, or heating spices. Rice, oats, quinoa, mung dal, soups, cooked vegetables, moderate ghee, pears, apples, and pomegranate may suit this pattern when digestion allows.
A Pitta-Kapha patient may benefit from lighter meals, moderate grains, cooked vegetables, sufficient protein, and minimal refined sugar, while also avoiding excessive heat, chilli, fried food, and sour fermented products.
A Vata-Kapha patient may require warm, light, digestible meals with moderate oil. Dry foods can aggravate Vata, while heavy sweet foods can aggravate Kapha. Soups, khichadi, cooked vegetables, mung dal, mild spices, and regular meal timing often provide a balanced foundation.
The dominant treatment diet is decided by the active Vikriti rather than constitution alone. The same Vata-Kapha patient may require more Vata nourishment during weight loss and more Kapha regulation after appetite and strength return.
Diet With Brahma Rasayana Avaleha
The prescribed dose of Brahma Rasayana Avaleha is 15 g twice daily after meals for the 30-day course. Breakfast and the evening meal should provide enough nourishment to support the dose without producing excessive fullness.
The morning meal may consist of warm porridge, cooked grains, vegetable poha, mung dal pancakes, eggs with cooked vegetables, or another constitution-appropriate meal. The morning dose is taken after breakfast with the prescribed Anupana.
Lunch is generally the principal meal and may contain a grain, a suitable protein, and cooked vegetables. The proportions vary according to constitution, activity, body weight, blood sugar, digestion, and treatment stage.
The evening meal is lighter than lunch and is completed early enough for comfortable digestion before sleep. Vegetable soup, mung soup, khichadi, quinoa with cooked vegetables, light lentils, fish with cooked vegetables, or another suitable meal may be used.
The evening Avaleha dose is taken after the meal. The interval, Anupana, and meal quantity are modified when the patient develops heaviness, acidity, reduced appetite, loose stools, constipation, or disturbed sleep.
The Anupana may vary according to the individual. Warm water may suit Kapha or slow digestion. Milk or a suitable alternative may be selected for Vata-related depletion where digestion permits. Ghee may be used in selected neurological and Vata-Pitta patterns. The Anupana is not automatically the same for every patient.
Diet During Weight Loss or Weakness
Patients with reduced appetite, muscle loss, fatigue, postoperative weakness, or difficulty maintaining weight require calorie-dense but digestible meals. Smaller meals may be given more frequently when large portions are uncomfortable.
Protein should be distributed across the day through lentils, dairy where suitable, eggs, fish, poultry, legumes, quinoa, or patient-specific alternatives. Healthy fats may be increased in measured quantities according to Agni, liver function, gallbladder tolerance, and constitution.
Soups, stews, khichadi, soft rice, porridges, cooked fruits, smoothies at room temperature, and other nutrient-dense preparations may improve intake. The diet should rebuild Bala without producing heaviness or interfering with the Avaleha.
A Kapha constitution does not prevent the use of nourishing foods when the patient is depleted. The quantity, preparation, and digestive support are adjusted so that nourishment reaches the tissues without aggravating Kapha-Meda accumulation.
Diet During Fluid Retention or Oedema
Patients with oedema, steroid-related swelling, high blood pressure, kidney disease, or fluid imbalance require individual adjustment of sodium, fluids, and packaged foods.
Commercial sauces, instant soups, crisps, processed meats, salted snacks, pickles, and frequent restaurant meals may increase sodium exposure. Freshly prepared meals allow better control of salt and fluid intake.
Punarnava and other fluid-regulating ingredients may be present in the Brahma Rasayana formulation, while diet supports the same objective through appropriate sodium intake, hydration, protein, and kidney-conscious planning.
Fluid advice varies according to kidney function, blood pressure, medications, thirst, urine output, and oedema. A universal instruction to drink excessive water is not appropriate for every patient.
Diet With Diabetes or Corticosteroid Use
The traditional Avaleha base contains a sweet medium, ghee, and honey. Patients with diabetes, insulin resistance, obesity, or steroid-induced hyperglycaemia require an individually modified base, measured carbohydrate intake, and blood-glucose monitoring.
The total daily carbohydrate burden is reviewed across the medicine and meals. Sugary drinks, desserts, biscuits, refined bread, sweetened breakfast cereals, and frequent sweet snacks are reduced so that the prescribed Avaleha can be incorporated more effectively.
Protein, cooked vegetables, suitable whole grains, and consistent meal timing support better metabolic control. The dose, Avaleha base, Anupana, and meal plan may be adjusted after reviewing fasting glucose, post-meal glucose, HbA1c, steroid dose, appetite, and weight.
Corticosteroids may also increase appetite, fluid retention, acidity, insomnia, and muscle weakness. The diet is therefore adjusted for sodium, protein, meal timing, and refined carbohydrate intake according to the individual response.
Diet With Antiseizure Medicines
Patients taking antiseizure medicines benefit from regular meal timing, adequate sleep, hydration appropriate to their condition, and consistent medicine administration. Food should support stable energy and minimise long periods without eating when these worsen weakness or neurological symptoms.
The complete medicine list is reviewed before adding concentrated herbs, mineral preparations, or major dietary changes. The Brahma Rasayana dose and food plan are adjusted according to sedation, appetite, bowel function, liver tests, weight, and seizure pattern.
Alcohol is avoided where seizures, balance problems, liver dysfunction, or sedating medicines are present. Caffeine is reduced when it worsens insomnia, palpitations, anxiety, headache, tremor, or neurological irritability.
Diet After Surgery or Radiotherapy
After surgery, the diet emphasises protein, wound recovery, bowel regularity, strength, cognition, and gradual return to activity. Food texture and meal size are adjusted according to appetite, swallowing, nausea, constipation, pain medicines, and mobility.
After radiotherapy, patients may experience fatigue, taste changes, nausea, dryness, reduced appetite, or altered digestion. Meals are simplified around the foods that remain nourishing and well tolerated.
The Brahma Rasayana programme may support systemic recovery, blood-cell resilience, and oxidative-stress regulation during intensive treatment [3]. Diet works with the formulation by providing the calories, protein, micronutrients, hydration, and digestive stability required for continued treatment.
Day 15 and Day 30 Diet Changes
The Day 15 review records appetite, food tolerance, bloating, acidity, nausea, bowel regularity, sleep, energy, body weight, blood sugar where relevant, and the patient’s ability to take both daily doses comfortably.
The diet is then modified according to the actual response. A Vata patient whose constipation has improved may tolerate more variety. A Pitta patient whose acidity persists may require milder spices and a different Anupana. A Kapha patient with continuing heaviness may need lighter evening meals and reduced sweet or dairy intake.
The Day 30 review compares digestion, weight, strength, neurological function, sleep, and daily activity with the pretreatment baseline. The next month’s food plan is adjusted together with the next Brahma Rasayana batch.
Prakriti remains the constitutional foundation, but the active diet continues to change with Vikriti, Agni, treatment stage, season, climate, medicines, body weight, laboratory findings, and clinical response. This allows the patient to receive a diet that supports the current curative-intent programme rather than following a static body-type menu throughout the entire course.
Meningioma Ayurvedic Treatment Duration

Meningioma Ayurvedic treatment is administered in structured 30-day cycles so that the patient receives continuous Brahma Rasayana Avaleha while symptoms, neurological function, digestion, strength, and imaging findings are reviewed at defined intervals. The prescribed dose of 15 g twice daily requires 900 g of finished Avaleha for each 30-day cycle.
The first month establishes how the patient digests and responds to the formulation. Subsequent cycles are planned according to the tumour’s location, size, grade where confirmed, previous growth pattern, neurological involvement, earlier surgery or radiotherapy, constitutional assessment, and the response recorded during treatment. The total duration therefore varies between patients even when the diagnosis is the same.
A small, slow-growing meningioma under MRI surveillance may require a different duration and formulation intensity from a recurrent Grade 2 tumour, a postoperative residual lesion, or a meningioma affecting the optic nerve, brainstem, cavernous sinus, venous sinus, or spinal cord. Treatment continues toward the defined curative objective while each cycle provides new clinical and radiological information.
The First 30-Day Cycle
Before the first dose, the physician records the patient’s latest MRI findings, symptoms, neurological status, visual function where relevant, current medicines, digestion, sleep, appetite, bowel pattern, energy, and ability to perform normal activities.
The first Brahma Rasayana Avaleha batch is prepared according to this baseline. The core classical Rasayana foundation remains consistent, while lesion-directed herbs, Medhya medicines, digestive support, oedema-regulating ingredients, nourishing substances, and physician-selected mineral components are adjusted to the individual case.
The Day 15 review examines the early response. For example, a patient who experienced headache on seven days each week may report that it now occurs on three days. A patient with pressure behind one eye may report longer reading tolerance and fewer pain episodes. A patient with postoperative fatigue may be able to walk farther, remain awake through the day, and complete more daily activities.
The same review examines whether the patient is digesting the full dose comfortably. Reduced appetite, heaviness, acidity, constipation, loose stools, excessive sleepiness, or disturbed sleep may require a change in dose, meal timing, Anupana, or the digestive component of the formulation.
The Day 30 review determines whether the early response has become sustained. The physician compares headache, vision, seizures, dizziness, strength, cognition, sleep, appetite, bowel function, energy, walking capacity, work or study tolerance, and rescue-medicine use with the pretreatment baseline.
The next batch is then prepared from the updated findings. Treatment does not depend on repeating an identical formulation every month. The Brahma Rasayana base continues, while the proportions and additions evolve according to the patient’s progress.
Treatment Beyond the First Month
The second and subsequent treatment cycles are directed toward deeper and more stable recovery. Early symptom improvement may occur during the first month, while restoration of neurological function, reduction of oedema, recovery from prolonged weakness, and measurable change in the lesion may require continued treatment.
A patient with a radiologically stable Grade 1 lesion and improving symptoms may continue the same core formulation with smaller adjustments. A patient with persistent oedema or pressure symptoms may require greater emphasis on Punarnava, Shallaki, Guduchi, Manjistha, and other fluid- and inflammation-regulating ingredients.
A patient whose digestion has improved may be able to tolerate a stronger lesion-directed or mineral Rasayana component during the next cycle. A patient who remains weak after surgery or radiotherapy may require greater Brimhana, Ojas, blood-forming, and Majja-supportive emphasis before the formulation is intensified.
For example, a patient may begin treatment with poor appetite, constipation, four hours of interrupted sleep, daily headache, and limited walking. The first cycle may focus strongly on Agni, bowel regulation, sleep, pain, and medicine tolerance. Once these improve, the second batch can place greater emphasis on lesion-directed Rasayana, neurological restoration, and long-term tissue stability.
Another patient may begin with good digestion but progressive visual discomfort from an optic-pathway lesion. The formulation can emphasise Medhya Rasayana, Pitta-Rakta balance, microcirculation, Majja nourishment, inflammatory regulation, and visual support from the beginning, while visual acuity, fields, OCT, and MRI are followed locally.
Duration According to Tumour Grade
Grade 1 meningiomas are generally slower-growing, but their location can still make them clinically important. A Grade 1 lesion affecting vision, seizures, limb strength, cognition, or the spinal cord requires a more intensive treatment and monitoring schedule than an incidental asymptomatic lesion.
The duration of Grade 1 treatment depends on whether the objective is tumour regression, control of documented growth, reduction of oedema, restoration of neurological function, or long-term recurrence prevention after surgery. Treatment may continue through successive 30-day cycles until the clinical and imaging objectives have been achieved and consolidated.
Grade 2 meningiomas require a stronger long-term strategy because they have a higher tendency to recur or progress. Treatment planning includes the pathology report, extent of removal, residual tumour, brain invasion, mitotic activity, molecular findings, previous radiotherapy, and the interval since surgery.
A patient with residual Grade 2 disease may continue Brahma Rasayana Avaleha through multiple cycles while MRI, neurological function, strength, sleep, digestion, and treatment tolerance are followed more closely. Each new scan is compared with the baseline and the most recent previous study [4].
Grade 3 meningiomas require the most intensive and closely monitored programme. The formulation may place greater emphasis on lesion-directed extracts, angiogenesis-related pathways, metabolic regulation, Majja protection, Ojas, appetite, blood formation, and recovery from previous treatment. Treatment cycles are adjusted according to shorter clinical and imaging review intervals [4].
A higher grade does not automatically mean that every ingredient is increased. A potent formulation must remain digestible and sustainable. The strongest programme is one that the patient can absorb, tolerate, and continue without avoidable interruption.
Duration According to Tumour Location
Tumour location often influences treatment duration as much as size or grade. Lesions near the optic nerve, optic chiasm, pituitary region, brainstem, cavernous sinus, major blood vessels, venous sinuses, or spinal cord require close functional monitoring because small anatomical changes can affect important structures.
An optic-nerve-sheath meningioma may require repeated comparison of visual acuity, colour vision, visual fields, optic-disc findings, OCT, and MRI. Treatment may continue even after eye pressure or headache improves because preservation and restoration of visual function remain central objectives.
A frontal meningioma may require longer cognitive follow-up. Headache may improve early, while memory, judgement, concentration, emotional stability, and work capacity recover more gradually. Caregiver observations can help identify changes that the patient may not recognise.
A parasagittal lesion associated with seizures or limb weakness requires continued seizure recording, strength assessment, gait monitoring, and MRI comparison. A spinal meningioma requires repeated evaluation of walking, sensation, pain, limb strength, and bladder or bowel function.
The treatment duration is therefore based on the affected function as well as the scan. A lesion may appear stable while the patient continues to regain vision, cognition, strength, coordination, or independence.
MRI and Follow-Up Timing
The first 15-day and 30-day reviews focus primarily on clinical response, medicine tolerance, digestion, neurological stability, and daily function. MRI timing is selected according to the tumour’s location, grade, previous growth, current symptoms, and treatment history.
A patient with a stable lesion already under scheduled surveillance may complete imaging according to the existing monitoring interval. A patient with changing vision, new seizures, progressive weakness, or altered cognition may require earlier reassessment.
Comparative imaging should evaluate tumour dimensions, volume where available, enhancement, oedema, mass effect, compression of neighbouring structures, venous sinus involvement, bone changes, and any new lesion. The baseline and follow-up scans should be compared directly rather than interpreting each report separately [4].
For example, a patient may show a reduction in headache from daily to occasional episodes during the first month. This is a meaningful clinical response. The deeper tumour response is assessed when follow-up imaging shows whether the lesion, oedema, or mass effect has changed.
Another patient may show stable tumour dimensions with reduced oedema, fewer seizures, improved limb strength, and greater independence. These combined findings provide a more complete treatment outcome than one measurement considered alone.
Continuing, Modifying, or Consolidating Treatment
Treatment is continued when symptoms, neurological function, digestion, strength, or imaging are moving in the intended direction. The same core formula may be retained when the response is steady and well tolerated.
The formulation is modified when a particular problem remains active. Persistent headache may require stronger oedema, Pitta-Rakta, or Vata support. Ongoing cognitive fatigue may require greater Medhya Rasayana. Poor appetite or heaviness may require stronger Agni correction. Continued weakness may require additional Brimhana, Majja, and Ojas support.
When the major clinical and imaging objectives have been achieved, treatment enters a consolidation phase. The formulation may gradually shift from intensive lesion-directed treatment toward neurological restoration, Ojas, metabolic stability, recurrence prevention, and long-term Rasayana.
Consolidation is important because symptom improvement alone does not represent the complete therapeutic objective. The response should remain stable during continued follow-up, with preserved neurological function and no evidence of renewed progression on serial imaging.
Medicine Preparation and Continuity
Each personalised batch requires approximately seven to ten days for ingredient authentication, preparation, Avaleha processing, mineral incorporation where prescribed, quality assessment, and packing.
International delivery commonly requires additional transit time, and customs procedures may extend the total delivery period. Patients should request the next cycle before the current supply is exhausted so that daily treatment remains continuous.
For patients living overseas, two consecutive monthly batches may be prepared and shipped together when the physician determines that the formulation is unlikely to require major immediate changes. Follow-up still occurs after the first month, and the second batch can be adjusted when sufficient preparation and delivery time is available.
When significant changes occur during the first cycle, the next formulation is revised before preparation. Examples include improved digestion allowing stronger Rasayana, new blood reports requiring dose adjustment, changes in visual findings, reduction in oedema, improved seizure control, or continuing weakness that requires additional restoration.
Remote Treatment Reviews
Patients do not need to travel for every treatment cycle. Day 15, Day 30, and later consultations can be completed through video review while blood tests, MRI, visual testing, neurological examinations, or rehabilitation assessments are performed locally.
Before each review, the patient submits current symptoms, medicine adherence, appetite, digestion, bowel pattern, sleep, energy, weight, neurological changes, and any new reports. Patients with visual involvement also submit visual-acuity, visual-field, OCT, or ophthalmology findings when available.
The physician compares the new information with the pretreatment baseline and previous reviews. This determines the next Brahma Rasayana composition, dosage, Anupana, diet, monitoring schedule, and imaging objective.
The duration of meningioma Ayurvedic treatment is therefore determined through progressive evidence from each treatment cycle. Clinical recovery, neurological restoration, imaging response, digestion, strength, and long-term stability guide how treatment is continued and when the programme moves from active tumour-directed therapy into consolidation and Rasayana maintenance.
Modern Management vs Ayurvedic Root-Cause Approach

Treatment goal
Modern management focuses on removing or controlling the tumor through surgery or radiation.
Ayurveda aims to correct the internal environment that allows abnormal growth, targeting Dosha balance, Agni restoration, and Majja Dhatu regeneration.
View of the disease
Modern medicine treats meningioma as a localized structural lesion.
Ayurveda understands it as Arbuda, a systemic disorder caused by Vata–Kapha imbalance, Aama accumulation, and Srotorodha.
Approach to small and asymptomatic tumors
Modern care often follows a watch-and-wait protocol with periodic MRI.
Ayurveda begins early intervention to improve metabolism, clear microchannel obstruction, and prevent further growth.
Method of tumor control
Surgery provides immediate decompression and removal of the mass.
Shodhana and Rasayana therapies gradually reduce pathological tissue activity and normalize cellular function.
Effect on surrounding brain tissue
Surgery and radiotherapy may affect nearby healthy structures depending on tumor location.
Ayurvedic medicines are selected to nourish Majja Dhatu, support neuronal repair, and improve cognitive function.
Recurrence prevention
Modern follow-up relies on imaging and repeat intervention if regrowth occurs.
Ayurveda focuses on long-term terrain correction, Ojas enhancement, and hormonal and metabolic balance to reduce recurrence tendency.
Recovery phase
Post-surgical rehabilitation is mainly symptomatic and supportive.
Rasayana therapy is used to rebuild strength, memory, sleep quality, emotional stability, and overall vitality.
Systemic impact
Modern treatment is primarily local, targeting the tumor site.
Ayurveda works at a whole-body level, improving digestion, immunity, circulation, and neuroendocrine harmony.
Long-term outcome vision
Modern management defines success as tumor control or stable imaging.
Ayurveda defines success as restoration of function, prevention of new pathology, and return to a balanced physiological state.
| Aspect | Modern Management | Ayurvedic Root-Cause Approach |
|---|---|---|
| Core goal | Tumor removal or size control | Correction of Dosha, Agni, and tissue metabolism |
| Disease view | Localized structural lesion | Systemic disorder (Arbuda) involving Majja Dhatu and Srotas |
| Strategy for small tumors | Observation with periodic MRI | Early metabolic correction to prevent progression |
| Primary intervention | Surgery and radiotherapy | Shodhana and Rasayana therapy |
| Effect on brain tissue | Risk of functional impact depending on location | Neuro-nourishment and cognitive support |
| Recurrence prevention | Imaging surveillance and re-intervention | Ojas restoration and terrain correction |
| Recovery phase | Symptom-based rehabilitation | Regeneration of strength, memory, and vitality |
| Systemic impact | Mostly local treatment | Whole-body metabolic and immune balance |
| Long-term vision | Stable scan or tumor control | Functional recovery and prevention of new pathology |
Who Is the Ideal Candidate for Ayurvedic Treatment?
Ayurvedic management of meningioma is most beneficial when the therapy is selected according to tumor status, systemic strength, and the stage of neurological involvement. The goal is not only structural control but correction of the internal terrain that supports abnormal growth.
Patients with small or asymptomatic meningioma
Individuals diagnosed incidentally on MRI, with minimal or no neurological deficit, are considered ideal candidates. At this stage, Dosha imbalance, Aama accumulation, and early Majja Dhatu involvement can be addressed through Agni correction, Shodhana where appropriate, and Rasayana therapy to prevent progression.
Patients under observation (watch-and-wait protocol)
Many patients in the USA, UK, Canada, and Australia are advised periodic imaging without immediate surgery. This phase provides a therapeutic window in which Ayurveda can work to stabilize metabolism, improve microcirculation in Sira Srotas, and reduce the biological activity of the tumor.
Post-surgical recovery phase
After craniotomy, patients frequently experience fatigue, cognitive slowing, sleep disturbance, anxiety, and reduced vitality. Ayurvedic Rasayana therapy is particularly suitable here for Majja Dhatu regeneration, Vata pacification, restoration of Ojas, and improvement in memory and neuromuscular coordination.
Patients after radiotherapy or radiosurgery
Radiation may lead to long term cognitive decline, hormonal imbalance, and tissue depletion. Ayurvedic treatment supports neuronal repair, enhances adaptive immunity, and helps restore neuroendocrine balance while reducing chronic fatigue and mental fog.
Patients with recurrent meningioma
When tumors regrow after surgery or radiation, repeated local interventions are often advised. Ayurveda offers a systemic approach by correcting the underlying metabolic and doshic environment that contributes to recurrence.
Patients with strong digestive capacity and treatment compliance
Successful Rasayana therapy requires functional Agni, the ability to follow Pathya Ahara (dietary discipline), regular medicine intake, and long term follow up. Patients who can maintain these are the best responders.
Patients seeking integrative care
Those who do not want to choose between modern and traditional systems but prefer a combined strategy for long term neurological recovery, immune strengthening, and quality of life improvement are ideal candidates.
Patients who may need a modified or delayed approach
Individuals with severe raised intracranial pressure, rapidly progressing neurological deficit, or emergency neurosurgical indication require immediate modern medical intervention first. Ayurvedic therapy becomes supportive after stabilization.
Online Meningioma Ayurvedic Treatment
Meningioma Ayurvedic treatment can be started from the patient’s home through a structured online consultation, personalised Brahma Rasayana Avaleha, scheduled 15-day and 30-day reviews, and locally completed investigations. Patients living in the United States, United Kingdom, Canada, Australia, Europe, the Middle East, Africa, or another part of India can receive the complete oral Rasayana programme without routinely travelling to Bangalore.
The consultation is used to understand the tumour, the functions it is affecting, the patient’s constitutional and metabolic condition, previous treatment, current medicines, and the measurable outcome expected from the first treatment cycle. The final prescription is prepared only after these factors have been reviewed together.
Reports Required Before Consultation
The latest contrast-enhanced MRI or CT report should be submitted with the original scan images whenever available. Previous scans are equally important because they show whether the lesion has remained stable, enlarged slowly, or changed more rapidly over time.
Patients who have undergone surgery or biopsy should provide the histopathology report, WHO grade, molecular findings where available, operation notes, discharge summary, and the most recent postoperative imaging. Patients who have received radiotherapy should provide the treatment dates, radiation type, treated area, and follow-up reports.
A complete medicine list should include prescription medicines, antiseizure treatment, corticosteroids, hormonal medicines, anticoagulants, supplements, and any Ayurvedic or herbal products already being used. The exact name, dose, and frequency help the physician personalise the formulation and administration schedule.
Patients with visual involvement should submit visual acuity, visual-field testing, optical coherence tomography, optic-disc findings, colour-vision testing, and neuro-ophthalmology reports where available. Patients with seizures should provide the number, pattern, duration, and date of recent episodes.
The symptom history should explain when the problem began and how it affects daily life. Headache frequency, eye pressure, dizziness, sleep, memory, concentration, speech, walking, limb strength, appetite, bowel function, energy, work capacity, and study tolerance should be recorded before consultation.
For example, “headache is present on six days each week, eye pressure occurs twice daily, sleep is limited to five hours, and comfortable reading is possible for thirty minutes” provides a measurable baseline for Day 15 and Day 30 comparison.
What Is Assessed During Consultation
The physician reviews the tumour’s location, dimensions, oedema, mass effect, compression of nearby structures, previous growth, pathology where available, and the neurological functions affected. These findings establish the clinical priorities of the Rasayana programme [4].
The Ayurvedic assessment examines Prakriti, Vikriti, Agni, Aama, bowel function, appetite, sleep, Bala, Ojas, Vata-related neurological symptoms, Kapha-Meda accumulation, Pitta-Rakta involvement, and the patient’s tolerance of previous treatment.
Prakriti represents the patient’s constitutional pattern, while Vikriti represents the current imbalance. A Vata-predominant patient with constipation, insomnia, weakness, and dizziness requires a different formulation and diet from a Kapha-predominant patient with heaviness, fluid retention, slow digestion, and fatigue.
The consultation also determines whether the full prescribed dose of 15 g twice daily can begin immediately or whether a short introductory period is needed. The Anupana, meal timing, dietary plan, and review schedule are selected according to digestion, strength, blood sugar, body weight, neurological condition, and current medicines.
The physician then defines the first-month treatment objectives. These may include reducing headache frequency, improving eye comfort, supporting visual function, reducing seizure burden, improving cognition, restoring appetite and sleep, increasing walking capacity, or improving daily independence.
Personalised Brahma Rasayana Preparation
After consultation, the Brahma Rasayana Avaleha is prepared as a patient-specific 30-day batch. The standard finished quantity is approximately 900 g, providing 60 doses of 15 g.
The classical Rasayana foundation remains central, while lesion-directed herbs, Medhya medicines, digestive support, oedema-regulating ingredients, restorative herbs, premium extracts, and physician-selected mineral Rasayana are adjusted according to the individual case.
A patient with optic-pathway involvement may receive greater emphasis on Medhya Rasayana, Pitta-Rakta balance, visual comfort, microcirculation, and Majja nourishment. A patient with seizures and limb weakness may require greater Vata regulation, neurological stability, strength, and oedema support.
A patient recovering after surgery may require stronger Brimhana, Ojas, appetite, sleep, cognitive, and physical-rehabilitation support. A patient with heaviness, obesity, slow digestion, and fluid retention may require stronger Agni, Kapha-Meda, Lekhana, and Srotas-regulating components.
The final formula, dose, Anupana, and diet are documented for that individual treatment cycle. The same combination is not automatically supplied to every patient with meningioma.
Medicine Preparation Time
Personalised Brahma Rasayana Avaleha generally requires approximately seven to ten working days for ingredient selection, authentication, decoction preparation, Avaleha processing, uniform incorporation of fine powders and prescribed mineral components, quality review, and packing.
The medicine is not prepared as a ready-made commercial product because the quantities and therapeutic emphasis vary according to the patient’s MRI, symptoms, digestion, Prakriti, current medicines, previous treatment, and first-month objectives.
The completed course may be packed in two 450 g containers. Dividing the batch reduces repeated exposure of the complete medicine to air and moisture and makes administration easier during the 30-day treatment period.
Each dose should be measured with a standardised 15 g spoon. The patient takes one dose after breakfast and one dose after the evening meal with the prescribed Anupana.
International Medicine Delivery
After preparation, international courier delivery commonly requires approximately five to seven working days. Customs clearance may occasionally extend the delivery period by approximately fifteen to twenty days depending on the destination country, import procedures, local holidays, and requests for additional documentation.
Patients should therefore arrange the next treatment cycle before the current medicine is exhausted. Continuous daily administration allows the Rasayana programme to progress without avoidable gaps.
Where the physician expects the core formulation to remain stable, two consecutive monthly courses may be prepared and dispatched together. This can reduce repeated courier expenses and lower the risk of customs-related interruption.
The Day 15 and Day 30 reviews still take place as scheduled. When a clinically important change requires modification, the subsequent batch can be revised according to the updated symptoms, digestion, blood reports, visual findings, neurological status, or MRI response.
For example, the second cycle may contain stronger Medhya and Majja support when cognition and sleep are improving but neurological fatigue remains. It may contain greater Agni and Kapha-Meda regulation when heaviness and slow digestion continue despite improvement in headache.
Day 15 Online Review
The first review is performed after approximately 15 days of treatment. The patient submits the same measurements recorded before starting the medicine.
Headache days, pain intensity, eye pressure, dizziness, sleep duration, appetite, bowel function, energy, concentration, visual comfort, seizure frequency, walking capacity, and rescue-medicine use are compared with baseline.
Medicine tolerance is also assessed. The physician reviews whether the full dose is being digested comfortably and whether the patient has developed heaviness, acidity, constipation, loose stools, reduced appetite, sleep disturbance, or excessive tiredness.
The dose, timing, Anupana, diet, or supporting medicines can be adjusted during this review. The purpose is to strengthen the response while maintaining comfortable digestion and continuous treatment.
Day 30 Online Review
The Day 30 review compares the patient’s condition with both baseline and Day 15. The physician determines whether early improvement has become stable and which therapeutic objectives should receive greater emphasis during the next cycle.
For example, a patient whose headache has reduced from daily occurrence to twice weekly may continue the same lesion-directed core. If visual comfort has improved but reading remains limited, the next formulation may place greater emphasis on Medhya, Majja, Pitta-Rakta, and visual-supportive Rasayana.
A patient whose digestion and appetite have improved may be able to tolerate a stronger tumour-directed or mineral component during the next month. A patient who remains depleted may require additional Brimhana, Bala, and Ojas support before the formulation is intensified.
The next batch is therefore prepared from the current clinical response rather than automatically repeating the first prescription.
Local Testing and Remote Monitoring
MRI, CT, blood tests, visual testing, neurological examinations, and rehabilitation assessments can be completed near the patient’s home. The reports and scan images are then submitted digitally for comparison.
Comparative MRI assesses tumour dimensions, estimated volume where available, enhancement, oedema, mass effect, compression of nearby structures, venous-sinus involvement, bone changes, and any new lesion [4].
Patients with optic-pathway involvement submit visual acuity, fields, colour vision, OCT, and optic-disc findings. Patients with seizures submit an updated seizure record. Patients with weakness or balance problems may provide physiotherapy findings, walking measurements, or dated gait videos.
This arrangement allows the patient to receive continuous Brahma Rasayana Avaleha from home while objective clinical and radiological evidence guides each treatment cycle.
Consultation Fee and Treatment Cost
The international initial video consultation fee is USD 73. The consultation includes review of available medical reports, current symptoms, medicines, Ayurvedic constitutional factors, formulation planning, diet guidance, and the first follow-up strategy.
The medicine cost is calculated separately because the final formulation depends on the ingredients, premium extracts, Bhasmas, total batch quantity, treatment intensity, and the patient’s specific clinical requirements.
Tax, courier charges, local investigations, and repeat imaging are calculated separately where applicable. The patient receives the treatment quotation after the reports and formulation requirements have been reviewed.
Starting the Consultation
The patient should submit the latest MRI or CT report, original scan images where available, previous comparative scans, pathology report, operation or radiotherapy records, current medicine list, visual or neurological reports, symptom history, age, country, city, and time zone.
The consultation then establishes the personalised Brahma Rasayana Avaleha, dose of 15 g twice daily, Anupana, Prakriti-based diet, first 30-day objectives, Day 15 review, Day 30 review, imaging schedule, preparation time, treatment cost, and international delivery plan.
Frequently Asked Questions (FAQs)
Can Ayurveda Cure Meningioma?
Ayurveda can be planned with curative intent in selected meningioma patients. Treatment aims to influence the underlying tumour process, reduce oedema and pressure effects, protect neurological function, and achieve measurable clinical and radiological improvement. The outcome depends on tumour location, grade, previous growth, symptoms, treatment history, digestion, strength, adherence, and the patient-specific Brahma Rasayana Avaleha programme.
Can Meningioma Be Treated Without Surgery?
Meningioma treatment without surgery may be considered when the patient is medically stable and suitable for monitored oral treatment. The decision depends on tumour location, growth rate, oedema, neurological symptoms, vision, seizures, confirmed grade where available, and previous treatment. A personalised Brahma Rasayana programme can be administered from home with structured clinical reviews and comparative imaging.
How Can Meningioma Be Shrunk Naturally?
A natural meningioma treatment requires more than one herb or supplement. The programme combines personalised Brahma Rasayana Avaleha, correction of digestion and metabolism, Prakriti-based diet, neurological support, regular follow-up, and comparative MRI. The treatment is designed to address abnormal tissue accumulation, inflammation, oedema, neurological function, strength, and the individual disease pathway identified during consultation.
What Is Brahma Rasayana Avaleha for Meningioma?
Brahma Rasayana Avaleha is a personalised semi-solid Ayurvedic formulation used as the principal oral treatment. It combines classical Rasayana herbs with Medhya medicines, lesion-directed botanicals, digestive support, standardised extracts, nourishing ingredients, and physician-selected mineral preparations. The formulation is customised according to MRI findings, tumour location, symptoms, Prakriti, Agni, strength, previous treatment, and current medicines.
Is Panchakarma Necessary for Meningioma Treatment?
Panchakarma is not compulsory for every meningioma patient. Virechana, Nasya, or another procedure is selected only when the patient’s strength, digestive capacity, Dosha pattern, symptoms, and treatment requirements justify it. Medically stable patients may receive a complete home-based Brahma Rasayana Avaleha programme without routine hospital admission, inpatient Panchakarma, or repeated travel to India.
What Improvement May Occur After 15 and 30 Days?
The Day 15 review assesses early changes in headache, eye pressure, dizziness, sleep, appetite, bowel function, energy, concentration, visual comfort, seizures, walking, and medicine tolerance. The Day 30 review determines whether these improvements have become sustained and whether daily function has increased. The next Brahma Rasayana batch is then adjusted according to the patient’s measured response.
How Is Meningioma Treatment Response Measured?
Treatment response is measured through symptoms, neurological function, daily independence, visual testing where relevant, and comparative MRI or CT. Imaging evaluates tumour dimensions, volume, enhancement, surrounding oedema, mass effect, and pressure on nearby structures. Clinical improvement and radiological change are documented separately so that headache relief, better sleep, improved vision, or increased strength are not confused with tumour shrinkage.
How Long Does Meningioma Ayurvedic Treatment Take?
Meningioma Ayurvedic treatment is administered in personalised 30-day cycles. The total duration depends on tumour size, location, grade, previous growth, neurological involvement, surgery or radiotherapy history, digestion, strength, and imaging response. Treatment continues through active tumour-directed care, neurological restoration, and consolidation until the intended clinical and radiological objectives have been achieved and maintained.
Can Brahma Rasayana Be Taken After Surgery or Radiotherapy?
Brahma Rasayana Avaleha can be personalised after surgery or radiotherapy. Treatment may address residual tumour, recurrence prevention, fatigue, poor appetite, sleep disturbance, cognitive changes, weakness, bowel problems, neurological recovery, and tissue restoration. The postoperative MRI, pathology, WHO grade, extent of removal, radiation history, current medicines, blood reports, and present symptoms guide the formulation.
Which Reports Are Required Before an Online Consultation?
Patients should submit the latest MRI or CT report, original scan images where available, previous comparison scans, pathology report, operation records, radiotherapy details, current medicine list, visual or neurological reports, and a dated symptom history. Age, weight, country, Prakriti information, digestion, sleep, appetite, bowel function, energy, seizures, vision, walking capacity, and daily limitations are also required.
Start Meningioma Ayurvedic Treatment

Meningioma Ayurvedic treatment begins with a detailed review of the patient’s MRI, symptoms, previous treatment, current medicines, digestion, strength, Prakriti, and daily functional limitations. The consultation determines whether a personalised home-based Brahma Rasayana Avaleha programme is suitable and establishes measurable objectives for the first 30 days.
Patients do not routinely need to travel to Bangalore for the initial assessment or oral Rasayana treatment. Reports can be reviewed through a video consultation, the personalised medicine can be prepared and delivered, and follow-up investigations can be completed in the patient’s own city or country.
Reports to Send Before Consultation
The latest contrast-enhanced MRI or CT report should be submitted together with the original scan images whenever available. Previous imaging is important because it shows whether the meningioma has remained stable, grown gradually, changed rapidly, or developed new oedema or pressure effects.
Patients who have undergone surgery should provide the histopathology report, WHO grade, operation notes, discharge summary, extent of tumour removal, molecular findings where available, and the latest postoperative MRI. Patients who have received radiotherapy should include the treatment dates, radiation type, number of sessions, treated area, and subsequent imaging.
The current medicine list should include antiseizure medicines, corticosteroids, blood thinners, blood-pressure tablets, diabetes medicines, thyroid treatment, hormonal medicines, pain medicines, supplements, and any Ayurvedic products. The exact dose and timing help the physician design the Rasayana schedule appropriately.
Patients with visual involvement should provide visual acuity, automated visual fields, colour-vision testing, optical coherence tomography, optic-disc examination, and neuro-ophthalmology reports where available. Patients with seizures should submit a dated record of seizure frequency, duration, pattern, warning symptoms, and recovery time.
A short symptom history should explain when the problem began and how it affects ordinary life. For example, “headache occurs six days each week, pressure behind the left eye occurs twice daily, sleep is limited to five hours, and comfortable reading is possible for only thirty minutes” provides a measurable baseline for the Day 15 and Day 30 reviews.
What the Consultation Assesses
The consultation reviews the tumour’s location, available dimensions, oedema, mass effect, previous growth, neurological effects, visual involvement, confirmed grade where available, and previous treatment.
The Ayurvedic assessment examines Prakriti, current Dosha disturbance, Agni, Aama, bowel function, appetite, sleep, energy, Bala, Ojas, neurological symptoms, tissue depletion, Kapha-Meda accumulation, and Pitta-Rakta involvement.
The patient’s main treatment priorities are then defined. One patient may require greater emphasis on headache, eye pressure, sleep, and vision. Another may require closer attention to seizures, weakness, balance, memory, speech, appetite, or recovery after surgery or radiotherapy.
The first-month objectives are written in measurable terms. These may include reducing headache from daily occurrence to fewer days each week, increasing comfortable reading time, improving sleep duration, restoring appetite, reducing dizziness, improving walking distance, or supporting stable neurological function.
Personalised Brahma Rasayana Avaleha
After the consultation, the Brahma Rasayana Avaleha is prepared according to the patient’s complete clinical profile. The classical Rasayana foundation is combined with patient-specific Medhya herbs, lesion-directed botanicals, metabolic support, oedema-regulating ingredients, restorative medicines, standardised extracts, and selected mineral Rasayana where indicated.
The standard 30-day course contains approximately 900 g of finished Avaleha. The prescribed dosage is 15 g twice daily after meals, providing 60 individual doses over 30 days.
The exact formulation varies between patients. A patient with optic-pathway involvement may require greater emphasis on visual comfort, Medhya Rasayana, Majja nourishment, Pitta-Rakta balance, microcirculation, and oedema support.
A patient with seizures and limb weakness may require stronger Vata regulation, neurological stability, Majja support, sleep regulation, strength, and lesion-directed ingredients.
A patient recovering after surgery may require greater Brimhana, appetite support, bowel regulation, cognition, sleep, muscle strength, Ojas, and recurrence-focused Rasayana.
A patient with slow digestion, heaviness, fluid retention, and weight gain may require stronger Agni, Kapha-Meda, Lekhana, and Srotas-regulating components before the formulation is intensified.
Treatment From Home
The patient begins the prescribed programme from home after receiving the medicine, dosage instructions, Anupana, diet plan, and monitoring schedule. Routine hospital admission, inpatient Panchakarma, Virechana, Nasya, or repeated travel is not required when the physician selects the oral Rasayana pathway.
The morning dose is taken after breakfast, and the evening dose is taken after the evening meal. The prescribed Anupana varies according to Prakriti, Agni, neurological symptoms, blood sugar, strength, and treatment goals.
The patient records headache, eye pressure, dizziness, vision, seizures, sleep, appetite, bowel function, energy, concentration, walking, work or study capacity, and medicine tolerance during the first month.
For example, a patient may record headache intensity on a zero-to-ten scale, the number of headache days per week, comfortable reading hours, nightly sleep duration, and rescue-medicine use. The same measurements are repeated during follow-up so that improvement can be assessed accurately.
Day 15 Review
The Day 15 consultation evaluates early symptom improvement, neurological stability, digestion, bowel response, sleep, appetite, energy, and medicine tolerance.
The dose, timing, Anupana, diet, or supporting components may be modified when the patient develops heaviness, acidity, constipation, loose stools, excessive sleepiness, reduced appetite, disturbed sleep, or persistent symptoms.
A patient whose headache has reduced from seven days per week to three days may continue the same lesion-directed core. A patient whose sleep has improved but digestion remains heavy may require adjustment of the Avaleha timing, meal size, Anupana, or digestive support.
Day 30 Review
The Day 30 review compares the patient’s condition with both baseline and Day 15. It determines whether early improvement has become sustained and which therapeutic priorities should guide the next 30-day cycle.
Clinical changes may include fewer headache episodes, reduced eye pressure, improved sleep, better appetite, regular bowel movements, increased energy, improved concentration, greater walking capacity, fewer seizures, or improved ability to work, study, read, or manage household activities.
The next Brahma Rasayana batch is prepared from these findings. The formulation may retain the original core when the response is steady, strengthen lesion-directed components when digestion and strength permit, or increase Medhya, Majja, Brimhana, Agni, Ojas, or oedema support according to the remaining symptoms.
MRI and Local Follow-Up
MRI, visual testing, neurological examinations, blood investigations, and rehabilitation assessments can be completed near the patient’s home. The reports and scan images are submitted digitally for comparison.
Comparative imaging is reviewed for tumour dimensions, estimated volume, enhancement, oedema, mass effect, compression of nearby structures, venous-sinus involvement, bone changes, and any new lesion.
Patients with optic-pathway disease submit visual acuity, visual fields, colour vision, OCT, and optic-disc findings. Patients with seizures provide an updated seizure record. Patients with weakness or balance problems may submit strength measurements, physiotherapy findings, walking distance, or dated gait videos.
Clinical improvement and radiological response are recorded separately. Reduced headache, improved sleep, better appetite, or increased energy demonstrates functional recovery, while tumour regression, reduced oedema, decreased mass effect, or durable stability is established through comparative imaging.
Consultation and Medicine Preparation
The initial international video consultation fee is USD 73. The consultation includes report review, Ayurvedic assessment, treatment suitability, formulation planning, Prakriti-based diet, first-month objectives, and the Day 15 and Day 30 follow-up strategy.
Medicine cost is calculated separately because the final price depends on the selected herbs, standardised extracts, Bhasmas, premium Rasayana ingredients, and total batch requirements. Tax and courier charges are added according to the patient’s location.
Personalised medicine preparation generally requires seven to ten working days. International courier delivery commonly requires an additional five to seven working days, while customs procedures may occasionally extend delivery by approximately fifteen to twenty days.
The patient should arrange the next treatment cycle before the current medicine is exhausted. Continuous daily administration allows the Brahma Rasayana programme to proceed without avoidable interruption.
Treatment begins after the latest reports, scan images, current medicine list, symptom history, age, weight, country, city, and time zone have been reviewed and the personalised first-month programme has been finalised.
References
[1] Kajaria, D., & Wasnik, K. S. (2022). Parasellar massive meningioma cured with therapeutic purgation (Virechana) and nasal instillation (Nasya). Journal of Integrative Medicine and Public Health, 1(2), 71–77. Publication record
Brief: Describes a one-month Ayurvedic case involving a large left parasellar meningioma, Virechana, Nasya and contrast-enhanced CT assessment. The reported outcome concerns the combined procedural treatment described in the case.
[2] Singh, R. H., Sodhi, J. S., & Dixit, U. (2020). Rasayana Chikitsa Adhyaya. In Charak Samhita New Edition: Chikitsa Sthana, Chapter 1, Abhayamalakiya Rasayana Pada. Charak Samhita Research, Training and Skill Development Centre. Classical text
Brief: Classical source for the first Brahma Rasayana in Charaka Samhita, Chikitsa Sthana 1.1.41–57, and the second preparation in 1.1.58–61. Covers ingredients, preparation and Rasayana objectives.
[3] Joseph, C. D., Praveenkumar, V., Kuttan, G., & Kuttan, R. (1999). Myeloprotective effect of a non-toxic indigenous preparation Rasayana in cancer patients receiving chemotherapy and radiation therapy: A pilot study. Journal of Experimental & Clinical Cancer Research, 18(3), 325–329. PubMed
Brief: Reports blood-cell recovery and oxidative-stress findings with Brahma Rasayana during chemotherapy and radiotherapy. Outcomes included leukocyte recovery and duration of leukopenia and neutropenia.
[4] Goldbrunner, R., Stavrinou, P., Jenkinson, M. D., Sahm, F., Mawrin, C., Weber, D. C., Preusser, M., Minniti, G., Lund-Johansen, M., Lefranc, F., Houdart, E., Sallabanda, K., Le Rhun, E., Nieuwenhuizen, D., Tabatabai, G., Soffietti, R., & Weller, M. (2021). EANO guideline on the diagnosis and management of meningiomas. Neuro-Oncology, 23(11), 1821–1834. PubMed
Brief: Covers imaging, histopathological diagnosis, WHO grading, surveillance, surgery, radiosurgery, fractionated radiotherapy and follow-up.
[5] Suśruta. (n.d.). Granthyapacyarbudagalagandanidāna. In Suśruta Saṃhitā, Nidāna Sthāna (Chapter 11, verses 13–21; V. Dwarampudi, Trans. & commentary). Ayana Ayurveda. Classical text
Brief: Describes Arbuda, including its attachment, growth pattern and Dosha and tissue involvement. Provides classical context for an Ayurvedic assessment of persistent masses.
[6] Ayurvedic Pharmacopoeia Committee. (2003). The Ayurvedic Formulary of India: Part I (2nd rev. ed., Formulation 3:20, Brāhma Rasāyana). Controller of Publications, Government of India. Bibliographic record
Brief: Provides the official formulation framework and source attribution for Brahma Rasayana. The supplied reference identifies Aṣṭāṅga Hṛdaya, Uttara Sthāna 39, as its classical source.
[7] Thangapazham, R. L., Sharma, A., Gaddipati, J. P., Singh, A. K., & Maheshwari, R. K. (2006). Inhibition of tumor angiogenesis by Brahma Rasayana. Journal of Experimental Therapeutics & Oncology, 6(1), 13–21. PubMed
Brief: Reports preclinical findings involving Brahma Rasayana, experimental tumour growth, angiogenesis, VEGF and matrix metalloproteinases in prostate-cancer models.
[8] Curic, S., Wu, Y., Shan, B., Schaaf, C., Utpadel, D., Lange, M., Kuhlen, D., Perone, M. J., Arzt, E., Stalla, G. K., & Renner, U. (2013). Curcumin acts anti-proliferative and pro-apoptotic in human meningiomas. Journal of Neuro-Oncology, 113(3), 385–396. PubMed
Brief: Examines curcumin in a meningioma cell line and primary human meningioma cultures. Reports growth inhibition, cell-cycle arrest and apoptosis.
[9] Chen, X., Tian, F., Lun, P., & Feng, Y. (2021). Curcumin inhibits HGF-induced epithelial–mesenchymal transition by regulating c-MET-dependent PI3K/Akt/mTOR signalling pathways in meningioma. Evidence-Based Complementary and Alternative Medicine, 2021, Article 5574555. PubMed
Brief: Reports experimental findings involving curcumin, meningioma-cell growth, migration, invasion and c-MET-dependent signalling pathways.
[10] Park, Y. S., Lee, J. H., Bondar, J., Harwalkar, J. A., Safayhi, H., & Golubic, M. (2002). Cytotoxic action of acetyl-11-keto-β-boswellic acid on meningioma cells. Planta Medica, 68(5), 397–401. PubMed
Brief: Reports cytotoxic activity of acetyl-11-keto-β-boswellic acid in primary human meningioma cultures, including effects on ERK1/2 phosphorylation.
[11] Kirste, S., Treier, M., Wehrle, S. J., Becker, G., Abdel-Tawab, M., Gerbeth, K., Hug, M. J., Lubrich, B., Grosu, A. L., & Momm, F. (2011). Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors: A prospective, randomized, placebo-controlled, double-blind pilot trial. Cancer, 117(16), 3788–3795. PubMed
Brief: Evaluates Boswellia for MRI-measured cerebral oedema during radiotherapy for brain tumours. The clinical outcome examined was oedema reduction.
[12] Naewwan, N., Talabnin, K., Trasaktaweesakul, T., et al. (2025). Piperlongumine induces meningioma cell death via ROS-mediated endoplasmic-reticulum stress and alteration of the ubiquitin–proteasome system. Journal of Neuro-Oncology, 175(3), 1091–1102. PubMed
Brief: Reports preclinical findings in benign and malignant meningioma cells, including growth inhibition, oxidative stress, cell-cycle arrest and apoptosis.
[13] Leyon, P. V., & Kuttan, G. (2004). Effect of Tinospora cordifolia on the cytokine profile of angiogenesis-induced animals. International Immunopharmacology, 4(13), 1569–1575. PubMed
Brief: Examines Guduchi-related effects on experimental angiogenesis, VEGF, inflammatory cytokines and microvessel outgrowth.
[14] Saraswati, S., Alhaider, A. A., & Agrawal, S. S. (2013). Punarnavine, an alkaloid from Boerhaavia diffusa, exhibits anti-angiogenic activity via downregulation of VEGF in vitro and in vivo. Chemico-Biological Interactions, 206(2), 204–213. PubMed
Brief: Reports experimental effects of punarnavine on endothelial migration, capillary formation, VEGF, matrix metalloproteinases and tumour growth.
[15] Xu, H.-B., Chen, X.-Z., Yu, Z.-L., & Xue, F. (2023). Guggulsterone from Commiphora mukul potentiates the anti-glioblastoma efficacy of temozolomide via downregulating EGFR/PI3K/Akt signalling and NF-κB activation. Journal of Ethnopharmacology, 301, Article 115855. PubMed
Brief: Investigates guggulsterone combined with temozolomide in experimental glioblastoma models, including effects on signalling and apoptosis.
[16] Shah, N., Kataria, H., Kaul, S. C., Ishii, T., Kaur, G., & Wadhwa, R. (2009). Effect of the alcoholic extract of Ashwagandha leaves and its components on proliferation, migration, and differentiation of glioblastoma cells. Cancer Science, 100(9), 1740–1747. PubMed
Brief: Reports laboratory findings involving Ashwagandha leaf extract, glioblastoma-cell proliferation, migration and differentiation.
[17] Mishra, S. R., Behera, B. P., Singh, V. K., Mahapatra, K. K., Mundkinajeddu, D., Bhat, D., Minz, A. M., Sethi, G., Efferth, T., Das, S., & Bhutia, S. K. (2024). Anticancer activity of Bacopa monnieri through apoptosis induction and mitophagy-dependent NLRP3 inflammasome inhibition in oral squamous-cell carcinoma. Phytomedicine, 123, Article 155157. PubMed
Brief: Examines Brahmi in preclinical oral squamous-cell carcinoma models, including apoptosis, mitophagy and NLRP3 inflammasome regulation.
[18] Ngamkitidechakul, C., Jaijoy, K., Hansakul, P., Soonthornchareonnon, N., & Sireeratawong, S. (2010). Antitumour effects of Phyllanthus emblica: Induction of cancer-cell apoptosis and inhibition of in vivo tumour promotion and in vitro invasion. Phytotherapy Research, 24(9), 1405–1413. PubMed
Brief: Reports preclinical Amalaki findings involving cancer-cell growth, apoptosis, invasion and experimental tumour promotion.
[19] Kumar, N., Gangappa, D., Gupta, G., & Karnati, R. (2014). Chebulagic acid from Terminalia chebula causes G1 arrest, inhibits NF-κB, and induces apoptosis in retinoblastoma cells. BMC Complementary and Alternative Medicine, 14, Article 319. PubMed
Brief: Examines chebulagic acid in retinoblastoma cells, reporting cell-cycle arrest, NF-κB inhibition and apoptosis.
[20] Roland, N., Kolla, E., Baricault, B., Dayani, P., Duranteau, L., Froelich, S., Zureik, M., & Weill, A. (2025). Oral contraceptives with progestogens desogestrel or levonorgestrel and risk of intracranial meningioma: National case-control study. BMJ, 389, Article e083981. PubMed
Brief: Examines meningioma risk associated with oral contraceptive exposure, including duration-dependent associations with desogestrel and findings for the levonorgestrel formulations studied.
[21] Roland, N., Neumann, A., Hoisnard, L., Duranteau, L., Froelich, S., Zureik, M., & Weill, A. (2024). Use of progestogens and the risk of intracranial meningioma: National case-control study. BMJ, 384, Article e078078. PubMed
Brief: Reports associations between meningioma and prolonged exposure to selected progestogens, including injectable medroxyprogesterone acetate, medrogestone and promegestone.
[22] Lundstrøm, N. H., Knudgaard, M. H., Pedersen, M. S., Christiansen, M. L. S., & Skovlund, C. W. (2026). Contraceptive progestogens and incident meningioma. JAMA Network Open, 9(7), Article e2622603. PubMed
Brief: Examines meningioma incidence in relation to contraceptive progestogens, including product, dose and route of administration.
[23] Wang, J. Z., Landry, A. P., Raleigh, D. R., et al. (2024). Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients. Neuro-Oncology, 26(10), 1742–1780. PubMed
Brief: Reviews meningioma epidemiology, molecular pathways, inherited susceptibility, diagnosis, treatment, recurrence and emerging therapies.
[24] Sahm, F., Aldape, K. D., Brastianos, P. K., et al. (2025). cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas. Neuro-Oncology, 27(2), 319–330. PubMed
Brief: Clarifies molecular risk assessment and grading, including TERT-promoter mutations, CDKN2A/B deletion, brain invasion and selected chromosomal alterations.
[25] Almeida, N. D., Sinha, S., Fang, M., Sullivan, D., Rupp, J., Cheruvu, H., Shekher, R., Goulenko, V., Madhugiri, V., Schrand, T. V., Milano, M. T., & Prasad, D. (2026). Radiation-induced meningiomas: A systematic review and meta-analysis of 927 meningiomas. Surgical Neurology International, 17, Article 35. PubMed
Brief: Reviews radiation-induced meningiomas, including latency, tumour behaviour, multiplicity, recurrence and surveillance after exposure.
[26] Mahjari, A., Alyazidi, A., El-Sayed, K., et al. (2026). Traumatic brain injury and risk of intracranial meningioma: A systematic review and meta-analysis. Journal of Korean Neurosurgical Society, 69(5), 695–703. PubMed
Brief: Evaluates the reported association between traumatic brain injury and meningioma. Discusses inconsistent findings and methodological limitations affecting causal interpretation.
[27] Xu, C., Shao, C., Wang, J., Ding, X., & Wu, N. (2025). Association between anthropometric factors and meningioma risk: A systematic review and meta-analysis. PLOS ONE, 20(5), Article e0323461. PubMed
Brief: Examines associations involving body mass index, abdominal measurements, height and meningioma risk.
[28] Veiga, L. H. S., et al. (2022). Pooled analysis of meningioma risk following treatment for childhood cancer. JAMA Oncology, 8(12), 1756–1764. PubMed
Brief: Reports a dose-dependent association between childhood cranial radiation and later meningioma, with elevated risk persisting for decades.
[29] Goh, C. Q., Kaur, R., Ayeni, F. E., Eslick, G. D., & Edirimanne, S. (2024). Bidirectional association between breast cancer and meningioma: A systematic review and meta-analysis. ANZ Journal of Surgery, 94(5), 811–818. PubMed
Brief: Examines the epidemiological association between breast cancer and meningioma. The mechanisms underlying the association remain uncertain.
[30] Byadgi, P. S., & Saini, N. (2020). Maharoga Adhyaya. In Charak Samhita New Edition: Sutra Sthana, Chapter 20. Charak Samhita Research, Training and Skill Development Centre. Classical text
Brief: Provides the classical framework for internally arising and externally originating disease and the interaction between external factors and internal disturbance.
[31] Gehlot, S., Singh, B. M., & Gujarathi, J. (2020). Mahatigarbhavakranti Sharira. In Charak Samhita New Edition: Sharira Sthana, Chapter 4, verses 30–32. Charak Samhita Research, Training and Skill Development Centre. Classical text
Brief: Discusses Bija, Bija-bhaga and Bija-bhaga-avayava in the classical account of hereditary susceptibility.
[32] Sahm, F., Bertero, L., Brandner, S., Capper, D., Goldbrunner, R., Jenkinson, M. D., et al. (2025). European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection. Neuro-Oncology, 27(4), 869–883. PubMed
Brief: Reviews molecular testing and the evidence supporting biomarker-directed treatment selection, including NF2, AKT1, SMO, CDKN2A/B and other pathways.
[33] Brastianos, P. K., Dooley, K., Geyer, S., et al. (2026). Abemaciclib in meningiomas with somatic NF2 or CDK-pathway alterations: The phase 2 Alliance A071401 trial. Nature Medicine, 32(2), 717–724. PubMed
Brief: Evaluates abemaciclib in molecularly selected recurrent meningioma. The supplied study summary reports 58% six-month progression-free survival, with stable disease the most frequent best response.
[34] Wang, Y., Wang, C., Yin, S., Yu, C., Li, X., Kang, X., Yang, S., Xie, W., Lin, Y., Wu, Z., Li, W., & Chen, F. (2025). Phase 2 trial of PD-1 inhibitor sintilimab in recurrent or progressive meningioma. CNS Neuroscience & Therapeutics, 31(12), Article e70659. PubMed
Brief: Evaluates sintilimab in recurrent or progressive meningioma. Reports disease-control and biomarker findings, with the trial failing to meet its progression-free-survival objective.
[35] Albert, N. L., Preusser, M., Traub-Weidinger, T., et al. (2024). Joint EANM/EANO/RANO/SNMMI practice guideline for diagnostics and therapy of meningiomas using radiolabelled somatostatin-receptor ligands: Version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 51(12), 3662–3679. PubMed
Brief: Covers somatostatin-receptor imaging for tumour delineation, bone involvement and recurrence assessment. Also discusses receptor-directed radionuclide therapy.
[36] Albert, N. L., Tabouret, E., Le Rhun, E., Sahm, F., Furtner, J., Tonn, J.-C., et al. (2026). [177Lu]Lu-DOTATATE for recurrent meningioma: Study protocol for the randomized phase II LUMEN-1 trial. Journal of Nuclear Medicine, 67(1), 23–30. PubMed
Brief: Describes a randomised phase II trial of receptor-targeted radionuclide therapy in progressive, somatostatin-receptor-positive meningioma after previous treatment.
[37] Nemati, R., Juweid, M. E., Jafari, E., Jokar, N., Peer-Firozjaei, M., Rekabpour, S. J., Mottaghy, F. M., & Assadi, M. (2026). Preliminary evaluation of 225Ac/177Lu-DOTATATE PRRT in progressive meningiomas: Efficacy, dosimetry, and imaging insights. Clinical Nuclear Medicine, 51(10), e865–e876. PubMed
Brief: Describes a seven-patient pilot study assessing radionuclide therapy, imaging response, dosimetry and preliminary safety in progressive meningioma.
[38] Garabedian, N., Zaragori, T., Tabouret, E., et al. (2026). Radiopharmaceutical therapy with [177Lu]Lu-DOTATATE in refractory meningiomas: Results from the French multicentre MELUTE cohort. Journal of Nuclear Medicine. Advance online publication. PubMed
Brief: Reports outcomes from a 69-patient cohort. The supplied summary identifies 70% six-month progression-free survival, median progression-free survival of 14.6 months and median overall survival of 27.6 months.
[39] Dubey, S. D., Singh, A. N., Samant, A., & Deole, Y. S. (2020). Rogabhishagjitiya Vimana. In Charak Samhita New Edition: Vimana Sthana, Chapter 8, verse 94. Charak Samhita Research, Training and Skill Development Centre. Classical text
Brief: Describes tenfold patient examination, including constitution, disease disturbance, tissue quality, build, measurements, suitability, psychological strength, food capacity, exercise capacity and age.
[40] Thippeswamy, G., Sheela, M. L., & Salimath, B. P. (2008). Octacosanol isolated from Tinospora cordifolia downregulates VEGF gene expression by inhibiting nuclear translocation of NF-κB and its DNA-binding activity. European Journal of Pharmacology, 588(2–3), 141–150. PubMed
Brief: Reports experimental findings on Guduchi-derived octacosanol, VEGF expression, NF-κB activity and angiogenesis. This reference maps specifically to the octacosanol mechanism.
[41] European Medicines Agency. (2024, December 16). Medroxyprogesterone-containing medicines: Risk of meningioma and measures to minimise this risk. EMA safety communication
Brief: Provides European regulatory recommendations concerning meningioma risk with injectable and high-dose oral medroxyprogesterone acetate, including symptom monitoring and treatment reassessment.